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Abstract 
Severe asthma is an airways disease that causes restriction of airflow to the 
lung leading to difficulty breathing, where even high doses of medication does 
not alleviate the symptoms. There are studies that have demonstrated 
differentially expressed genes in both CD8+ T-cells and the bronchial 
epithelium of severe asthmatics, however the causes of the changes in  gene 
expression have not been elucidated.  Histones, proteins which store DNA, 
can be acetylated or methylated which changes their binding of DNA allowing 
for modified transcription. I hypothesise that modifying the histone 
modification of Bronchial Epithelium and CD8+ T-cells would be able to limit 
the inflammatory effects of severe asthma, that measuring changes in histone 
modifications would show differences between severe and non-serere 
asthmatics and that by using modern analysis of gene expression and histone 
modifications it would be possible to discover novel genes and pathways 
involved in asthma. 
 
The Bromodomain and Extra terminal domain mimic JQ1 was able to 
suppress release of Interleukin-6 and Interleukin-8 and SGC-CBP30 the 
CBP/p300 inhibitor limited proliferation in bronchial epithelium. CD8+ T-cells 
from a small group of severe and non-severe asthmatics had gene arrays 
carried out and were analysed by weighted geneome coexpression network 
analysis which found modules containing genes involved in intracellular 
motility and vesicle formation that linked strongly to % predicted Forced 
Expiratory volume in one second. CD8+ ChIP-Seq studies of T-cell histone 
modifications were attempted, but not successful. 
 
A pilot test on Severe asthmatics CD8+ T-cells treated with SGC-CBP30 
showed a reduction in the release of the inflammatory mediator MIP1α and 
suggested that this was without affecting its mRNA production or cell viability, 
however higher numbers of patients would be needed to confirm this.  
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1.1 Asthma 
1.1.1 Definition 
Asthma is a chronic airways disease marked by repeated incidences of 
difficulty in breathing including wheezing, breathlessness, chest tightness and 
coughing. In asthma these ‘attacks’ results in a reversible limited expiratory 
flow after which breathing returns to normal. (Global Initiative for Asthma 
2016, http://ginasthma.org/). 
1.1.2 Prevalence 
Asthma poses a huge healthcare burden on society.  Approximately 5.4 
million people in the UK are treated for asthma and worldwide it is estimated 
that >300 million people suffer from asthma, nearly 5% of the world’s 
population (Masoli et al. 2004). There are 65,000 hospital admissions for 
asthma per annum in the UK with 25,000 of these admissions for under 14s 
(Levy et al. 2014). Treating asthma costs the NHS £1 billion a year (Levy et al. 
2014). Most of these costs are associated with patients with severe asthma, 
patients who do not respond to the primary treatment of inhaled 
corticosteroids (ICS).  Accordini and colleagues estimated that severe asthma 
costs the EU more than €20bn per annum (Accordini et al. 2013). 
 
1.1.3 Mechanism of asthma 
Many asthmatics have allergic asthma or atopic asthma, around 54% of 
adults (Pearce et al. 1999) and have a tendency towards having an allergic 
response to airborne factors that would not affect a healthy subject (Platts-
Mills 2001).  Initial exposure to an allergen in atopic asthmatics occurs when 
allergens enter the airways and are sensed and phagocytosed by dendritic 
cells, macrophages or neutrophils (antigen presenting cells, APCs).  APCs 
present the allergen to CD4+ naïve T-cells.  These naïve T-cells cells are 
induced to differentiate into TH2 Cells when their antigen specific T-cell 
receptor binds the major histocompatibility complex 2 (MHCII) on the APC 
which presents the antigen, the T-cell is co-activated by CD28 (Huang et al. 
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2002). Activated TH2 cells release Th2 cytokines defined as IL-4 (Swain et al. 
1990), IL-5 (Kraft et al. 2002) and IL-13 (McKenzie et al. 1993). IL-4 induces 
differentiation of naïve T-Cells to TH2 cells and proliferation of T-cells 
propagating in a feed-forward manner but also induces B cell priming (Swain, 
Weinberg, English, et al. 1990; Le Gros et al. 1990).  B cells release 
immunoglobulins when their B-cell receptors detect antigens. B-cell receptors 
are upregulated in the cell membrane by IL-4 and both IL-4 and IL-13 causes 
Ig switching to IgE and B-cell proliferation (Noelle et al. 1984; Punnonen et al. 
1993).  The released antibodies subsequently bind to mast cells via their Fc 
region interacting with the FcεRI receptor (Mallamacis et al. 1993). 
 
Once atopy in asthma is induced repeated stimulation with the antigen will 
activate two processes, an early phase response and a late stage response. 
The early phase response is activated when mast cell bound antibodies bind 
their antigen causing the FcεRI receptors to cross link and initiate mast cell  
degranulation (Metzger et al. 1986). This happens in minutes and may last for 
up to two hours (Janeway 2001). Degranulating mast cells release histamine, 
leukotrienes, serotonin and serine proteases, after this initial release mast 
cells will also release prostaglanidins, leukotrienes, GM-CSF, TNFα, IL-8, IL-
14 and Il-4. Histamine and serotonin both cause bronchospasm (Leff 1982; 
Beretta et al. 1965). See Figure 1.1 for a full over view of the mechanisms of 
action of atopic asthma. 
TH2 cells will be activated by APCs presenting antigens and this second 
allergic challenge will cause them to release IL-5.  IL-5 induces eosinophil 
migration and as eosinophils migrate through the basement membrane and 
pass through the epithelium they release major basic protein and eosinophil 
peroxidase which damages the epithelia and causes bronchospasm (Gleich et 
al. 1979; Gundel et al. 1991; Flavahan et al. 1988).  This process is known as 
the Late Asthmatic Response (LAR) and occurs between 3-8 hours after 
allergen challenge when high levels of eosinophilia are evoked (Demonchy et 
al. 1985; Cartier et al. 1982). Eosinophils also release leukotrienes such as 
LTC4 which is a highly potent bronchoconstrictor (Shaw et al. 1985; Adelroth 
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et al. 1986).   Early studies using an anti-IL-5 monoclonal antibody 
(Mepolizumab, GSK) given to mild-moderate asthmatics who were not 
stratified according to having high sputum or blood eosinophils were able to 
limit eosinophilia without inhibiting the late airways response demonstrating 
our understanding of asthma is still not complete (Leckie et al. 2000).  In 
patients with high levels of sputum and/or blood eosinophils, anti-IL-5 
monoclonal Abs are very effective at reducing asthma exacerbations although 
the effect on lung function, airways hyperresponsiveness (AHR) and asthma 
symptoms are less pronounced (Pavord et al. 2012; Bel et al. 2014; Ortega et 
al. 2014). 
 
Figure 1.1 Mechanisms of Atopic Asthma 
 
Not all asthmatics are atopic, but non-atopic patients still suffer AHR in 
response to indirect stimuli such as cold air, exercise or hyperventilation or to 
direct stimuli such as histamine and methacholine (often used as a challenge 
to measure AHR) (Billen & Dupont 2008).  Although atopy is absent in many 
patients with asthma, there is evidence that airways hyperresponsiveness, the 
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late airways response and eosinophilia are IgE-dependent (Kirby et al. 1986; 
Cockcroft et al. 1977; Flint et al. 1985; Demonchy et al. 1985; Cockcroft & 
Murdock 1987; Booij-Noord et al. 1971). Omalizumab  a FCεRI Binding 
domain antibody suppressed early and late phase response and limited 
allergen activation by limiting IgE binding to mast cells (Fahy et al. 1997). In a 
longer study Omalizumab decreased asthma exacerbations, but not totally, 
showing that the role of T-cell and B-cell receptors and PAMPs on non-
immune cells can trigger some reactions (Busse et al. 2001).  
Innate Lymphoid Cells (ILCs) which are a lymphoid cell, similar in lineage to 
T-cells and B-cells (Walker et al. 2013) but without antigen receptors, can be 
categorised in a similar manner to T-cells with Group 1 ILCs producing type 1 
cytokines such as IFN-γ (Fuchs et al. 2013; Bernink et al. 2013; Klose et al. 
2014) and Group 2  producing type 2 cytokines (Fort et al. 2001) such as IL-4, 
IL-5 and IL-13 with expression of GATA-3 (Moro et al. 2010; Price et al. 2010; 
Neill et al. 2010; Mjösberg et al. 2012). ILC3s resemble Th17 cells releasing 
IL-17A and IL-22 (Spits et al. 2013). A GWAS study suggested 
polymorphisms in IL-33, an activator of ILC2 cells and IL-1RL1, the IL-33 
receptor, are linked to the development of asthma (Tamari et al. 2013; 
Grotenboer et al. 2013). Despite the fact these two receptors are on different 
chromosomes they are reproducibly identified in asthma GWAS studies and 
implicated in asthma pathogenesis (Oboki et al. 2010). IL-33 has also been 
shown to be released by bronchial epithelium in response to allergens (Oh et 
al. 2013). IL-33 and ILC2 cells have also been found to be increased in the 
lung lavage of asthmatics (Christianson et al. 2015). The Thymic Stromal 
Lymphopoietin (TSLP) receptor is found on ILCs and it’s activation enhances 
Type two responses by enhancing GATA3 expression in human ILC2 
(Mjösberg et al. 2012). Recent data in a human allergen challenge model 
demonstrated positive effects of an anti-TSLP antibody (Gauvreau et al. 
2014). 
 
 
1.2 Treatments 
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Asthma in most patients is well controlled by treatment with bronchodilators, 
relievers and Inhaled Corticosteroids (ICS) controllers.  Step 1 of the British 
Thoracic Society guidelines suggest mild intermittent asthma should be 
treated with short acting bronchodilator such as inhaled short-acting β2 
agonists or inhaled ipratropium bromide, a muscarinic inhibitor to relieve 
symptoms as they occur (British Thoracic Society 2014).  Step 2, for more 
moderate asthma (using β2 agonists three times a week), the suggested 
treatment is a preventative ICS which will act on the underlying inflammation 
rather than just the bronchoconstriction symptoms.  The doses are titrated to 
the minimum effective dose taken twice daily.  Other preventer therapies 
include leukotriene receptor antagonists which are useful for children under 
five years old who can’t use an inhaler and sodium cromoglycate, a mast cell 
stabiliser, with some benefit in a few adults (Chauhan & Ducharme 2012).  If 
adults are taking high doses of ICS and still suffering from nocturnal 
awakenings or have no relief from asthma attacks then there are further add-
on therapies to consider under Step 3 of the guidelines (British Thoracic 
Society 2014).  These include inhaled long acting β2 agonists (LABA) in 
combination with ICS, leukotriene receptor antagonists, theophylline (an anti-
inflammatory xanthine) and slow release β2 agonist tablets. Combination 
ICS/LABA inhalers can help combat poor compliance in taking inhaled 
steroids and often improves outcomes (Murphy & Bender 2009). 
After this selection of treatments, if control is still inadequate, Step 4 begins 
with addition of a long acting muscarinic receptor antagonist such as 
tiotropium along with an ICS/LABA being of benefit (Peters et al. 2010).  If the 
long acting muscarinic antagonist does not improve asthma symptoms or 
exacerbations then higher dose inhaled steroids are recommended. Finally at 
Step 5, if the increased inhaled steroid makes no improvement the use of 
continuous or frequent oral corticosteroids is recommended.  Prolonged 
treatment with high dose oral steroids is an unsatisfactory situation as there 
are many side effects including glaucoma, striae, buffalo hump, high blood 
pressure, diabetes mellitus, hyperlipidaemia, decreased bone density, 
cataracts in children and steroid psychosis (Stanbury & Graham 1998). 
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However, it is often a balancing act between controlling asthma and these 
side effects. 
 
A selection of monoclonal Ab treatments are now available which are able to 
improve outcomes in small sub-sets of asthmatic patients.  Most of these are 
against Th2 asthma and it is important to have a specific predictive marker so 
that the thereapy is used in the patients most likely to respond to the 
treatment. 
The anti-IgE, Omalizumab, has significantly reduced the number of 
exacerbations and improved lung function in severe and moderate patients 
(Busse et al. 2001). Anti IL-5s such as Reslizumab and Mepolizumab show 
significant reductions in exacerbations and improvements in lung function in 
severe asthmatics with high blood eosinophilia (Ortega et al. 2014; Castro et 
al. 2015) with similar effects for Anti-Il-5-receptor (Bleecker et al. 2016a; 
Castro et al. 2014; FitzGerald et al. 2016) 
 
Anti-IL-13 Lebrikizumab demonstrated an improvement in lung function in 
patients with poorly controlled asthma by ICS. The increase in FEV1 following 
Lebrikizumab treatment was 8.2% in patients with high periostin levels (a 
marker for Th2 asthma) compared with a 1.6% improvement in subjects with 
low periostin levels (Corren et al. 2011). Tralokinumab also shows 
Statistically significant reduction in exacerbations and improvements in 
lung function in patients with high periostin and dipeptidyl peptidase 4 
(Brightling et al. 2015) However, due probably to problems with periostin as 
a predictive biomarker, the Phase 3 studies showed less efficacy (Noonan et 
al. 2013; Hanania et al. 2016). Periostin is a ligand for integrins and could be 
involved in other disease pathways, especially infection and also increases 
eosinophil binding (Bentley et al. 2014). Currently, high blood eosinophils are 
being used to predict Th2 asthma subjects suitable for mAb treatment – it is 
likely that more selective biomarkers will improve the responder:non-
responder ratio. Anti-Il-4 has also reduced exacerbation and improved lung 
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function in moderate to severe patients with eosinic inflammation whilst 
tapering ICS therapy (Wenzel et al. 2013). 
 
1.3 Severe Asthma 
Though asthma is generally well controlled, severe asthma is a subset of 
asthma which has been defined since 2014 as ‘asthma that requires 
treatment with high dose ICS plus a second controller and/or systemic 
corticosteroids (CS) to prevent it from becoming "uncontrolled" or that it 
remains "uncontrolled" despite this therapy’ by the ERS/ATS guidelines 
(Chung et al. 2014).  
 
Severe asthmatics have on average 2.5 exacerbations in 12 months as 
opposed to 0.4 in well-controlled mild-moderate asthmatics and these patients 
have higher levels of anxiety and depression (Shaw et al. 2015). As severe 
asthmatics have poorly controlled asthma they are more likely to become 
hospitalised with considerably higher healthcare and societal costs. In the 
Europe it has been shown that the mean costs for a patient with controlled 
asthma was €509 and for uncontrolled asthma was €2281 (Accordini et al. 
2013). In 1992 in the US health care system annual cost for a mild patient 
was $1336, a moderate asthmatic $2407 and a severe asthmatic $6393 
demonstrating the higher associated costs with severity of asthma and the 
indirect costs for all patients  were double the cost of treatment (Serra-Batlles 
et al. 1998). Similar studies in the UK have shown that the cost of treating 
severe asthma accounts for 80% of the healthcare cost of asthma despite 
severe asthmatics only representing around 10% of asthmatics (Godard et al. 
2002; Masoli et al. 2004).  
 
Severe asthmatics are difficult to differentiate from asthmatics with poor 
compliance as they present with similar symptoms. Reported rates of non-
adherence ranges from 30 to 70 percent (Global Initiative for Asthma 2016; 
Rand & Wise 1994; Bender & Bender 2005). In a study of Dutch asthmatics 
which selected patients based on compliance (chosen by selecting patients 
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who had 80% or greater prescription filling of ICS) only 3.6% of patients had 
severe asthma as opposed to “difficult to control asthma” which made up 
17.4% of the total asthma population. Only 20% of the ‘difficult to control 
asthma’ population were adherent and had correct inhalation technique 
(Hekking et al. 2015). Despite this challenge for research several studies have 
begun to identify the mechanism of severe asthma. A 2013 paper has 
demonstrated it is possible to measure compliance of ICS usage using 
fractional exhaled Nitric Oxide measurements (FeNO) and may allow future 
studies and clinicians simpler ways of testing compliance (McNicholl et al. 
2012). 
 
1.3.1 Mechanisms and subtypes of Severe Asthma 
There are a large variety of mechanisms that have been proposed to cause 
severe asthma and this underpins the concept of severe asthma being 
heterogeneous and not a single disease. There are two clear severe asthma 
phenotypes, type-2 inflammation and non-type-2 inflammation.  Type-2 
inflammatory cytokines include IL-4, IL-5 and IL-13 and these are released 
from Type-2 T-helper cells, ILCs and Mast Cells among others.  About 40-
50% of severe asthmatics have Th2 asthma based on blood, lung and airway 
eosinophilia and mast cell counts (Wenzel et al. 1999; Adelroth et al. 1986).  
Mild Th2 asthma is associated with allergy and IgE-mediated inflammation 
whereas the Th2 type inflammation in severe asthma is more complex as 
there is an increase in eosinophilic inflammation without necessarily a 
concomitant increase in serum IgE (Miranda et al. 2004). T Helper cells have 
been shown to be elevated in severe asthmatics with high eosinophilia 
(Wenzel et al. 1999) although as a group there appears little difference in the 
number of infiltrating cells within bronchial biopsies of severe asthmatics from 
the U-BIOPRED study compared to non-severe asthmatics or healthy controls 
(Wilson et al. 2016). 
 
Type-2 associated severe asthma can also be divided into several 
phenotypes (Wenzel 2016).  These include a severe early onset phenotype 
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linked to atopic conditions and high IgE, but without eosinophilia and a later 
onset, less atopic disease with systemic and airways eosinophilia (Miranda et 
al. 2004; Haldar et al. 2009).  Both of these phenotypes have some degree of 
eosinophilia in the lung but it seems that the pathway of activation may be 
different.  Recent studies have provided further evidence for this (Kuo et al. 
2017).  Studies in severe asthmatic patients treated with high dose ICS and/or 
OCS with high sputum and/or blood eosinophils clearly demonstrate a key 
role for eosinophils in severe asthma.  Treatment with anti-IL-5 and anti-IL-5 
receptor monoclonal antibodies decreased asthma exacerbations by nearly 
50% with much less effect on lung function (Pavord et al. 2012; Haldar et al. 
2009; Castro et al. 2011; Laviolette et al. 2013). Benralizumab a monocolonal 
antibody against the IL-5 receptor α has also shown to increase FEV1 pre-
bronchodilator (Bleecker et al. 2016b). 
 
Non-type-2 patients are often found in clusters linked to neutrophilic 
inflammation using cluster analysis.  The pathways involved have not yet 
been elucidated although comorbidities such as obesity and smoking are 
often observed (Baines et al. 2011; Moore et al. 2014; Moore et al. 2010; 
Haldar et al. 2008). There is a suggestion that IL-6, a biomarker of 
inflammation, metabolic dysfunction and asthma severity may be associated 
with this subset (Peters et al. 2016).   A subset of patients with increased 
airway neutrophilia tend to have similar blood eosinophilia and IgE levels to 
non-severe asthmatics (The ENFUMOSA Study 2003; Moore et al. 2007). 
There is also suggestion that Th17 phenotype of asthma may drive 
neutrophilic inflammation as IL-4 neutralisation increases IL-17 along with 
neutrophilia in mice.  In contrast,  when IL-13 and IL-17 are neutralised the 
mice are protected from eosinophilia and neutrophilic inflammation is ablated 
(Choy et al. 2015). 
 
There are indications that some non-type-2 asthma could be driven by type-1 
inflammation led by the canonical cytokine IFN-γ.  Severe asthmatics as a 
group have increased IFN-γ expression in the airways compared to healthy or 
 30 
mildly asthmatic subjects (Shannon et al. 2008; Voraphani et al. 2014).  It has 
also been shown SNPs in the Th1/IL-12 genes (IL12A, IL12RB1, STAT4 and 
IRF) are significantly associated with both FEV1 % predicted and asthma 
severity (X. Li et al. 2013).  
 
Th17 Cells, a distinct population of IL-17A, IL-17E, IL-17F and IL-22 
producing cells can mediate neutrophil migration in severe asthmatics by an 
IL-8-driven mechanism (Roussel et al. 2010).  This is important as neutrophilic 
SA has been shown as a subgroup of severe asthmatics who are less 
responsive to CS (Wenzel et al. 1997; Green et al. 2002; Choy et al. 2015).  
These neutrophilic patients tended to also be low in airway eosinophilia 
suggesting another potential mechanism of action for severe asthma (Wenzel 
et al. 1997).  TNF-α has been proposed as playing a role in neutrophil rich 
severe asthma as it increases AHR, mucus production and expression of 
adhesion molecules and in a synergistic manner with IL-17 it can enhance 
neutrophil recruitment (Green et al. 2002; Baines et al. 2011). A breakdown of 
the subtype markers is shown in Table 1.1.  However, monoclonal Abs 
against both IL-17 (Brodalumab) and against TNFα (etanercept and 
infliximab) have either failed in asthma or produced deleterious side-effects 
(Busse et al. 2013; Holgate et al. 2011; Erin et al. 2006). 
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Phenotype 
Inflammation 
Type-2 
Non-Type 2 
Early Onset Late Onset 
IgE High Present Blood 
Eosinophilia None Airway and Blood Blood 
Neutrophilia None None Airway 
Atopy High Present Present 
Smoking Not correlated Not correlated Correlated 
Obesity Not correlated Not correlated Correlated 
Table 1.1. Breakdown of Severe asthma phenotypes 
 
Large asthma cohort studies such as the U-BIOPRED study in Europe and 
the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) 
study in the USA have been used to corroborate each other (Loza et al., 2016; 
Lefadeau et al., JACI 2016).  These studies have shown, using eight easy to 
measure clinical variables and cluster analysis that there are four clear groups 
of asthma.  Cluster 1 patients are mild asthmatics not treated with ICS, well 
controlled, normal lung function and low airways inflammation. Cluster 2 
subjects are partially-controlled, have mild airflow obstruction and severe 
airway hyperresponsiveness and a Th2 type phenotype.  Subjects in cluster 3 
are partially-controlled with mild airflow obstruction and reduced vital capacity, 
less bronchodilator reversibility and a non-Th2 phenotype with neutrophilia.  
Cluster 4 subjects are poorly controlled with high airflow obstruction and 
notable bronchodilator reversibility and a mixed inflammatory phenotype.  In 
the ADEPT study these phenotypes were maintained for at least 12 months 
(Loza et al. 2016).  These clusters are similar to those determined by Severe 
Asthma Research Program (Cohen et al. 2007; Moore et al. 2010; Moore et 
al. 2014). 
When studying gene set variation analysis (GSVA) signatures from the 
transcriptomics of bronchial biopsies and airway epithelial brushings 9 
described signatures demonstrated two distinct asthma signatures associated 
with tissue eosinophilia, high Th2 type cytokines and a lack of CS response 
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(Kuo et al. 2016). The two non-steroid responsive groups were a group with 
high sub-mucosal eosinophilia with high exhaled nitric oxide, high 
exacerbations and high oral (CS) use.  The other group had high BMI and the 
highest levels of eosinophilia of all groups determined. In contrast to these CS 
non-responders, the other groups had a much greater chance of having non-
eosinophilic inflammation (Kuo et al. 2016). 
 
1.4 Bronchial Epithelial Cells 
A large number of cell types have been implicated in asthma pathogenesis.  
For the purposes of this thesis, I will focus on epithelial cells and T-cells only.  
The bronchial epithelium is frontline between environment and the body; it is 
both a physical barrier and possesses immunological functions (Folkerts & 
Nijkamp 1998).  In most cases of asthma there are a variety of structural 
changes to the airways.  Airway remodelling can consist of increased smooth 
muscle mass, thickening of the basement membrane, an increase of goblet 
cells and a breach in the integrity of the epithelium.  
 
One of the key roles of epithelium is to form a physical barrier seperating 
microorganisms, gases and allergens from the body by creating tight and 
adherent junctions.  This, combined with their ability to perform mucocillary 
clearance, allows epithelial cells to not only stop the transfer of foreign bodies 
into the body but to also actively remove them (Poynter 2012).  When this 
boundary is broken allergens are more easily able to enter the body to trigger 
allergic responses, in addition intra-epithelial sensory nerves can be 
stimulated by the inhaled foreign bodies and carry out reflex 
bronchoconstriction (Folkerts & Nijkamp 1998).  E-cadherin is an important 
molecule in the adherens junctions between epithelial cells and its expression 
is reduced in biopsies taken from asthmatics, suggesting a reduced boundary 
function in asthmatic patients (de Boer et al. 2008).  
 
Airway epithelial cells also possess important immune and inflammatory 
functions.  Epithelial cells have a pattern recognition receptors (PRR) on their 
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surface which can trigger the release of cytokines, chemokines and 
antimicrobial peptides such as interleukin 6 (IL-6) and thymic stromal 
lymphopoietin  and β-defensins in response to cellular stress, bacterial 
infection or tissue damage (Ge et al. 2010; Soumelis et al. 2002; Duits et al. 
2003). Epithelial cell activation is key to the recruitment of dendritic cells (DC) 
one of the APCs that proceed to activate the immune responses (Lambrecht & 
Hammad 2012).  DCs are able to cross the epithelial boundary to sample the 
air entering the lung whilst maintaining the integrity of the boundary (Sung et 
al. 2006).  
 
A common PRR that is found on epithelial cells is TLR-4 which along with 
being activated by LPS, a sugar structure associated with bacteria,  can be 
activated by the allergens Der p2 and p7 from house dust mite or Fel D1 from 
cats demonstrating the epithelia’s direct sensitivity to allergens (Trompette et 
al. 2009).  PRRs activate nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) which controls the expression of inflammatory 
genes.  Constitutive activation of NF-κB in epithelial cells is enough for 
epithelial cells to activate DCs and to promote sensitisation to immunologically 
neutral allergens such as ovalbumin (OVA).  Importantly, in mouse models of 
asthma inhibition of NF-κB reduces TH2 cell recruitment (Ather et al. 2011; 
Broide et al. 2005).  Several NF-κB-regulated cytokines including CXCL8, 
RANTES and IL-6 are released from human airway epithelial cells in response 
to rhinoviral infection and to allergens such as the house dust mite proteases 
Der p1 and Der p9 (King et al. 1998; Chun et al. 2013). 
 
The epithelium is able to attract DCs and monocytes by releasing chemokines 
including CCL2, CCL20 and IL-12p40 which also prime DCs to promote a TH2 
type inflammation including TSLP (Walter et al. 2001; Nathan et al. 2009; 
Hammad et al. 2009; Ito et al. 2005).  The release of TSLP in human 
bronchial epithelium from asthmatics is higher than from healthy subjects 
suggesting an epithelial-driven phenotype in asthma (Ying et al. 2005). Finally 
it is important to note that the epithelium isn’t exclusively inflammatory, it is 
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also able to supress DC reactivity and smooth muscle tone by releasing 
prostaglandin E2 (PGE2) (Nagarkar et al. 2012; Hartney et al. 2006).  
 
Thymic Stromal Lymphopoetin (TSLP) has a key role in asthma is mainly 
created by the epithelium and stromal cells in the skin, gut and lungs(Kashyap 
et al. 2011; Redhu & Gounni 2012). It was shown to be vital to mice in 
developing allergic inflammation when TSLP receptors were knocked out  and 
wild-type CD4+ T-cell transfer was able to restore allergic responses to OVA 
showing TSLPs role directly on T-cells (Al-Shami et al. 2005; Zhou et al. 
2005).   
IL-33 is quickly released after epithelial damage and recruits a variety of Th2 
type cells and will influence CD4+ differentiation (Komai-Koma et al. 
2007)(Cohn et al. 1997). Mouse models of inflammation have been shown to 
IL-33 dependant in murine models of Ova induced allergy (Coyle et al. 1999; 
Townsend et al. 2000). IL-33 is able to activate mast cells to release IL-8, IL-
5, IL-13, IL-6, TNFα and GM-CSF (Allakhverdi et al. 2007; Moulin et al. 2007; 
Iikura et al. 2007). It has been posited that the detection of alleregen, virus or 
bacterial infection could begin the the asthmatic response to some extent by 
activating mast cells and eosinophils (Borish & Steinke 2011). 
 
In summary, the epithelium plays a key role in the induction of allergic asthma 
via recognition of allergens and other damaging proteins and the release of 
important inflammatory mediators.  It is also a very accessible target for 
specific drug delivery when using inhalers and may present a possibility for 
new treatments which should be investigated. 
 
1.5 T-Cells 
T-cells are lymphocytes that express T-cell receptors (TCR) which are 
capable of specific antigen binding and along with CD4 or CD8 receptors 
which stabilise the binding of the TCR to MHCII and MHCI respectively, 
activate the T-Cells leading to induction of the innate and adaptive immune 
responses.  TCRs are always co-activated by either CD4 or CD8; T helper 
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cells which have a CD4 cell marker come in multiple forms, T helper 1 (Th1), 
T helper 2 (Th2), T helper 17 (Th17) and regulatory T-cells (Tregs) whereas  
 cytotoxic T-cells have a CD8+ marker. An overview of these cell types 
activation, key transcription factors and cytokines that induce them can be 
seen in Table 1.2. 
Cell	 Inducing	 Transcription	 Cytokines	 Inhibitory	
Type	 Cytokine	 Factors	 Produced	 Cytokines	
Th1	 IL-12,	IL-18,	IFN-γ	 T-Bet,	STAT1	 IFNgamma	 IL-4,	IL-10	and	TGF-β	
Th2	 IL-2,	IL-4,	IL-5,	IL-13	 GATA3,	STAT6	 IL-4	 IFN-gamma,	TGF-β	
Th17	 IL-6,	TGF-β	 RoRγt,	STAT3	 IL-17A	 IL-4,	IL-2,	IL-27,	IFN-γ	
Treg	 IL-2,	TGF-β	 FOXP3,	STAT5	 TGF-Beta	 IL-17,	I-23,	IL-6	
 
Table 1.2 T-cell Subtype Breakdown 
1.5.1 T helper 1 cells 
The role of the Th1 cells is to combat bacterial and protozoa infection.  Th1 
cells do this by release of IFN-γ which will cause macrophage chemotaxis, 
activation and phagocytosis of bacteria and IgG switching in B Cells.  Th1 
cells can be activated by IL-2 which promotes TCR activation and cell 
proliferation, these effects are mediated by STAT4 and T-bet transcription 
factors. IL-12 is produced by dentritic cells and macrophages and also 
activates the STAT4 pathway via Tyk2 and JAK2 (Sugimoto et al. 2003) 
 
STAT1 is induced by IFN-γ and induces T-box transcription factor TBX21 (T-
bet) during Th1 differentiation (Afkarian et al. 2002; Lighvani et al. 2001) 
which can amplify the Th1 response by subsequently up-regulating IFN-γ in a 
positive feedback loop.  However, in toxoplasmosis-infected Stat1 knock-out 
(KO) mice, IFN-γ-producing CD4 cells are still found, demonstrating that 
STAT1 has an element of redundancy (Lieberman et al. 2003). STAT2 forms 
a heterodimer with STAT1 in response to type I IFNs (Au-Yeung et al. 2013).  
 
T-bet, induced by STAT1, is vital in for inducing Th1 reactions and IFN-γ 
production (Szabo et al. 2000).  T-bet overexpression/activation can increase 
IFN-γ production whilst inhibiting IL-4 production in Th2 cells demonstrating 
the plasticity of Th cells.  It does this by up-regulating IL-12Rβ2 expression 
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which promotes Th1 cell expansion and IFN-γ production. T-bet-expressing 
CD4+ T-cells are dramatically reduced in human asthma and may account for 
increased viral exacerbations alongside dysfunctional CD8+ T-cells (Finotto et 
al. 2002). Knockouts of the T-bet gene, Tbx21, result in major defects in Th1 
responses in vivo and vitro (Szabo et al. 2002; Mullen et al. 2002; Mullen et 
al. 2001).  
 
Similarly, in mouse models Tbx21 KO mice spontaneously develop AHS 
(Finotto et al. 2002). As Tbx KO cells can produce normal quantities of IFN-γ 
under IL-4 low conditions it maybe that the main role of T-bet is to inhibit 
GATA3 (Usui et al. 2006).  However some studies have shown that T-bet 
alone may not supress GATA3 (Afkarian et al. 2002).  
 
Knockout studies have shown that T-bet acts through enhancers to allow 
recruitment of P-TEFb and Mediator, the super elongation complex, to inhibit 
the release of Th1 target genes. STAT4 is activated by IL-12 and IFN-γ and is 
important in Th1 responses.  STAT4 activation can be downregulated by the 
Th2 drivers IL-4 and GATA3 (Frucht et al. 2000; Thierfelder et al. 1996; 
Kaplan et al. 1996; Usui et al. 2003). 
 
1.5.2 T helper 2 cells 
Th2 cells are effectors against parasites and helminths. They are triggered by 
IL-4, IL-5 and IL-13, which they also produce (described above) to drive the  
recruitment of eosinophils, basophils, mast cells and B cells creating a 
cytotoxic environment that destroys parasites.  The Th2 environment also 
causes bronchoconstriction and cough to speed the exhalation of helminths or 
parasites during infection. The intracellular processes involved in activating 
Th2 cells include enhanced DNA binding by the transcription factors STAT6 
and GATA3 (Wan 2014).   
 
GATA3 is the Th2 master regulator (Zhang et al. 1997; Zheng & Flavell 1997) 
and vital for development of CD4+ T-cells.  GATA3 is expressed by naïve 
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cells and is upregulated to enable Th2 differentiation and downregulated for 
Th1 cell development (Ouyang et al. 1998; Zhang et al. 1997; Usui et al. 
2006).  This was demonstrated using a dominant negative form of GATA3 
which reduced Th2 cytokine expression and blocked airway hypersensitivity 
(Zhang et al. 1999). 
 
STAT6 is the signal transducer for IL-4-mediated Th2 differentiation and 
expansion (Kaplan et al. 1996).  STAT6 mediates it’s function by increasing 
expression of GATA3 (Zhu et al. 2001; Kurata et al. 1999; Ouyang et al. 
1998). STAT5 has two isoforms a & b and blocking either causes major 
defects in Th2 cell differentiation (Kagami et al. 2000; Kagami et al. 2001; Zhu 
et al. 2003; Cote-Sierra et al. 2004; Moriggl et al. 1999).  Low levels of STAT5 
signalling are needed for proliferation and survival, however, for full Th2 
differentiation strong STAT5 signalling is required (Zhu et al. 2003; Cote-
Sierra et al. 2004).  STAT5 activation is induced by IL-2 and is important for 
the further production of IL-2 and of IL4 (Burchill et al. 2008; Burchill et al. 
2007; Davidson et al. 2007).   
 
1.5.3 T helper 17 Cells 
Th17 cells are able to promote neutrophil infiltration and activation, potentially 
for the clearance of fungal and bacterial infections, however may also 
contribute to inflammatory diseases, including asthma. They release IL-17A, 
IL-17F, TNFα which causes the epithelial cells to release IL-6 and IL-8 which 
can recruit neutrophils (Chung et al. 2001). Th17 have been shown to be 
increased in the blood and airways tissue of severe asthmatics (Al-Ramli et al. 
2009). 
 
STAT3 is activated by IL-6, IL-21 and IL-23 and controls Th17 cell 
differentiation, amplification and maintenance.  STAT3 induction by IL-6 also 
causes the downregulation of Treg cells (Veldhoen et al. 2006; Zhou et al. 
2007; Nurieva et al. 2007; Korn et al. 2007; Bettelli et al. 2006; Mangan et al. 
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2006; Yang et al. 2007; Xu et al. 2007a; Yang et al. 2008). STAT 3 also 
increases RAR-related orphan receptor gamma t (RORγt) expression, a DNA 
binding transcription factor which directs the differentiation of Th17 cells (Wei 
et al. 2007; Zhou et al. 2007a; Ivanov et al. 2006)  
 
1.5.4 Regulatory T-Cells 
Treg cells also have a CD4+ marker on their membrane but their role is 
limiting any deleterious T-cell activity (Sakaguchi et al. 2007).  The primary 
function of Treg cells is to maintain self-tolerance towards other T-cells 
staving off autoimmune attacks (Sakaguchi et al. 1995).  They are now 
known, however, to have many other functions including the suppression of 
asthma and allergy (Zuany-Amorim et al. 2002; Akbari et al. 2002; Curotto de 
Lafaille et al. 2001), inducing maternal tolerance to the foetus (Aluvihare et al. 
2004) and supressing T-cell activation triggered by weak stimuli (Baecher-
Allan et al. 2002).  There have been questions raised about how to identify 
Treg cells as they have many markers which are not exclusive to themselves 
such as CD25 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). 
FOXP3 which is generally considered to be the most reliable marker (Read et 
al. 2000; S Read et al. 2000; McNeill et al. 2007; Fontenot et al. 2005; Khattri 
et al. 2003; Fontenot et al. 2003; Hori et al. 2003; Sakaguchi et al. 1995) 
although FOXP3 can be found in some CD8+ T-cells (Fontenot et al. 2005).  
Tregs supress asthmatic responses; in a 2001 study, the high IgE response 
and AHR seen in mice sensitised and challenged with ovalbumin (OVA) was 
completely ablated by adoptive transfer of CD25+ and CD25- CD4+ Treg cells 
from unstimulated mice (Curotto de Lafaille et al. 2001).  The results show 
that regulatory T-cells do not prevent hyper IgE production by turning naive 
OVA-specific T-cells to IFN-γ producing Th1 cells as both Th1 and Th2 
responses were decreased when Tregs are infused into the mice.   
 
Tregs work in an epitope specific manner to limit eosinophilia (Zuany-Amorim 
et al. 2002). It was also hypothesised that presentation of bacteria in early life 
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could protect against future asthma by class switching - turning Th2 cells to 
Th1 cells.  Studies showed that in response to certain mycobacterial strains 
there was a shift from Th1 to Th2 inflammation in mice (Gajewski & Fitch 
1988; Herz et al. 1998; Erb et al. 1998).  It was finally shown that 
Mycobacterium vaccae gave rise to allergen-specific Treg cells showing that 
Tregs also have antibacterial properties which limit Th1 and Th2 inflammation 
in an epitope-specific manner which limited eosinophilia (Zuany-Amorim et al. 
2002).  The inhibitory abilities of Treg cells was attenuated by anti-IL-10 and 
anti-ICOS-ligand providing a mechanism for this effector function (Akbari et al. 
2002). 
Mast cells can induce immunotolerance in allografts and limit host rejection. 
They are recruited by Tregs and release IL-9 which is essential for 
immunotolerance and is demonstrated in mast cell KO mice where this is not 
seen (Lu et al. 2006).   
 
Patients and mice that are FOXP3 deficient lack Treg cells (Wildin et al. 2001; 
Patel 2001; Brunkow et al. 2001) and continuous expression of FOXP3 is vital 
for the continued suppressive effects of Tregs (Williams & Rudensky 2007).  It 
has been suggested that rather than FOXP3 being a master regulator it may 
simply amplify and fix features of Treg cells (Gavin et al. 2007).  
 
STAT5, which is vital for Th2 differentiation, is also vital for Treg differentiation 
and may bind to the Foxp3 promoter to enable Foxp3 induction (Davidson et 
al. 2007; Yao et al. 2007). 
1.5.5 Cytotoxic T-Cells 
Cytotoxic T (Tc) cells have a CD8 marker on their surface and as the name 
suggest they are cytotoxic against aberrant self-expressing cells which have 
either viral or cancer cell markers on their surface.  The TCR on Tc cells are 
only able to recognise antigens bound to the major histocompatibility complex 
I (MHCI) which is expressed by all non-professional antigen presenting cells, 
unlike Th cells, which can only recognise MHCII from APCs.  To fully activate 
CD8+ T-cells a co-stimulatory signal is needed alongside the TCR.  This 
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signal can be detected by CD28 receptor which is activated by either CD80 or 
CD86, both of which are found on the surface of the presenting cell.  Once 
activated the T-cells can undergo clonal expansion in response to IL-2 
(Sakaguchi et al. 2007).  The activation of CD8+ T-cells causes a release of 
stored perforins, granzymes and granulysin which can puncture holes in the 
targeted cells causing cell death.  However, they may also induce apoptosis 
by expressing the Fas ligand which can bind the Fas receptor on the affected 
cell.  
 
Signal transducer and activator of transcription (STAT) proteins are vital for Tc 
fate determination. STAT activation is not controlled by large changes in gene 
expression but by cytokine-controlled post-translational modifications such as 
phosphorylation (Levy & Darnell  Jr. 2002). 
 
T-bet is important in the early stages of CD8+ cell development (Cruz-Guilloty 
et al. 2009) however, T-bet is not as important in developed CD8+ cells in so 
far as IFN-γ production is concerned.  IFN-γ production remains normal in T-
bet KO mice suggesting that T-bet is not the only mediator involved in CD8+ 
T-cell differentiation  (Szabo et al. 2002).  
Eomes is another T-box transcription factor which is expressed in activated 
CD8+ cells.  Double knockouts of T-bet and Eomes in CD8+ cells do largely 
limit IFN-γ production and these mice fail to control certain viral infections 
(Pearce et al. 2003; Owen et al. 2013; Nurse et al. 2000).  
 
CD8+ T-cells activate GATA3 when their TCR is stimulated alongside 
cytokine stimulation much like when the combination of these stimuli activate 
Th2 cells.  The importance of GATA3 in CD8+ T-cell function was 
demonstrated in GATA3 KO CD8+ T-cells which had defective responses  to 
viral infections (Yunqi Wang et al. 2013). 
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1.5.6 The Role of Cytotoxic T-Cells in Asthma 
Though CD8+ T-cells were originally designated with an anti-cancer and anti-
viral function there is growing evidence that they have a role in allergy and 
asthma.  CD8 cells have Th1-like and Th2-like differentiation, Cytotoxic T-cell 
type 1 (Tc1) and Cytotoxic T-cell type 2 (Tc2), as well there being regulatory 
Tc reg and naïve Tc0 cells.  Between 80-90% of circulating Tc in the blood 
are Tc1 and these have been defined in culture as expressing IFN-γ and no 
detectable IL-4, the remaining circulating cells produce both IL-4 and IFN-γ 
(Vukmanovic-Stejic et al. 2000).  A Tc2 profile can be induced by stimulating 
Tc cells with IL-2 and IL-4 which evoked no IFN-γ.  Tc2 cells are also induced 
to produce IL-13 by the presence of IL-4 producing CD4+ Th2 cells (Koya et 
al. 2007). 
 
A key piece of evidence to suggest cytotoxic T-cells have a role in asthma is a 
study of bronchial biopsies comparing lung function decline with CD4+ and 
CD8+ T-cell counts over 14 years (den Otter et al. 2016).  This study showed 
a weak correlation between the rate of lung function decline and the CD4+ cell 
count at the start of the study and a strong correlation between lung function 
decline and CD8+ T-cell counts, both at the start and end of the study.  
Although the lung function decline in the asthma population is generally 
similar to that of the healthy population, asthmatics with chronic airflow 
limitation have a decline in FEV1 of around 50ml a year, similar to that seen in 
patients with chronic obstructive pulmonary disease (COPD) (Contoli et al. 
2010).  This confirmed a previous study which showed a link between asthma 
severity as measured by hyperresponsiveness to histamine and sputum CD8+ 
cells in atopic asthmatics (Cho et al. 2005). 
 
The phenotype of the CD8+ T-cells in the lung was not investigated in the den 
Otter study, but it can be speculated based upon previous studies and on 
other information in the study by den Otter and colleagues (den Otter et al. 
2016). These authors demonstrated enhanced levels of granzyme B in the 
patients with greatest fall in lung function and interestingly, levels of granzyme 
 42 
B were also increased in fatal asthma (Annoni et al. 2015) which suggests a 
classic Tc1 anti-viral response, implicating a key role for viral infection in the 
decline in lung function in asthmatics. Natural Killer cells also produce this 
and are activated by IgE via the FcγRIII receptor (Arase et al. 2003).   
Asthmatics have a more severe clinical response to viral (RV16) infection than 
non-asthmatic subjects which may reflect the fact that Tc cells remain in the 
asthmatic airway longer than in normal subjects (Hogan et al. 2001).  These 
cells may be Tc1-type effector-memory cells which remain active and patrol 
the airways (Contoli et al. 2006; Bedoui et al. 2016; Hogan et al. 2001). 
Wheezing episodes in young children caused by RSV infections are also 
associated with the development of asthma (Jackson et al. 2008). 
 
In mice this persistent CD8+ activation can cause lung damage and in 
humans persistent CD8+ activation may be associated with epithelial damage 
and greater immigration of immune cells (Cannon et al. 1988).  Some studies, 
but not all, have reported that epithelial cells from asthmatic subjects produce 
lower levels of IFNβ and λ than healthy subjects and are more likely to have 
unfavourable reactions to normally mild airway viral infections.  The lower 
production of IFN implies that the Tc1 type antiviral CD8+ T-cells which 
produce IFN-γ could have an important antiviral role in asthmatic airways 
(Baraldo et al. 2012).  
It is of note that bacterial infections may also be more persistent in the 
airways. It has also been demonstrated that macrophages cultured from 
sputum of severe asthmatics have impaired phagocytic function of bacteria 
which may lead to increased exacerbations due to higher levels of 
colonisation of the airways and more persistent inflammation (Liang et al. 
2014).  
 
Leukotriene B4 acting through BLT1 receptors on Tc2 cells may induce IL-13 
and the production of Th2 cells both of which cell types are correlated with 
asthma (Dakhama et al. 2013).  IgE-mediated mast cell release of LTB4 
recruits CD8+ T-cells into the lung which then release IL-13 (Taube et al. 
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2004; N. Miyahara et al. 2005; Nobuaki Miyahara et al. 2005; Taube et al. 
2006; Gelfand & Dakhama 2006). Tc2 type cells can also be modulated by 
vitamin D which has been implicated in limiting asthmatic inflammation by 
inhibiting IL-4-induced IL-13 production and thus limiting IgE class switching 
and B cell proliferation (Hejazi et al. 2016; Schedel et al. 2016). 
 
CD8+ cells release macrophage inflammatory protein 1α (MIP1α) also known 
as chemokine (C-C motif) ligand 3 (CCL3) when activated (Cocchi et al. 
1995).  MIP1α has been shown to be strongly chemotactic for murine 
eosinophils and macrophages suggesting that it is able to evoke both Th1- 
and Th2-type responses (Oliveira et al. 2002; Reichel et al. 2009). 
A study has shown strong links between the mediator of Treg cells, FOXP3, 
and serum MIP1α.  Low concentrations of MIP1α increase the stability of 
FOXP3 and thus the activation of Treg immunosuppression, however high 
concentrations lead to instability of FOXP3 which would limit Treg function 
(Chen et al. 2013).  This suggests a mechanism by which Treg cells may limit 
low levels of inflammation whilst allowing high levels. If in asthma there was 
an incorrect ‘cut off’ for high inflammation this could explain some effects of 
the disease.  This disease model may apply in the lungs as well as the skin 
where there are high levels of CD8+ T-cells in asthma. 
 
Circulating CD8+ T-cells have been shown to have highly differentially 
expressed genes in severe asthmatics. Despite the fact that there are no 
differences in CD4+ or CD8+ cell numbers in peripheral blood when 
comparing healthy, severe and non-severe asthmatic subjects (Tsitsiou et al. 
2012).  However, the CD8+ T-cells in severe asthmatic blood demonstrated 
1359 genes upregulated by more than 1.5-fold and 207 downregulated by this 
amount compared to genes expressed in CD8+ cells from healthy subjects.  
In contrast with only 40 genes were upregulated and no genes were 
downregulated genes in CD4+ T-cells from severe asthmatics blood 
compared to healthy patients.  Pathway analysis indicated that CD8+ T-cells 
had several activated pathways including CD28 T-cell stimulation, T-cell 
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adhesion, JAK-STAT, IL-4 and IL-9 signalling.  A selection of miRNAs 
including key mIRs for T-cell differentiation and proliferation such as miR-146a 
and miR-146b (Lu et al. 2006), which were also significantly reduced in 
severe asthmatic CD4+ and CD8+ cells.   
 
1.6 Genetics of Asthma 
Asthma twin studies and polygenic heritability estimates show a heritable 
component to the disease (Thomsen et al. 2010; McGeachie et al. 2013).  As 
such genome wide association studies look for specific single nucleotide 
polymorphisms (SNPs) which may account for differently functioning genes 
and proteins.  However, limited genetic links to asthma have been found. The 
largest study of this type was reported in 2010 with 10,365 asthmatics and 
16,110 unaffected controls.  Significant asthma-associated SNPs were for 
genes encoding IL1Rl1/IL18R1, HLA-DQ, IL-33 and ORMDL3. /GSDMB.  
Only ORMDL3/GSDMB was associated with early onset asthma (Moffatt et al. 
2010).  Asthma is however a heterogeneous disease and it would have been 
surprising to find one polymorphism which causes asthma since the definition 
of asthma used in these genetic studies does not enable sub-phenotyping.  In 
addition, although these SNPs and putative disease-associated genes are 
significant on a population scale they are by no means predictive of disease in 
an individual.  Furthermore, gene expression may be regulated at different 
levels beyond the DNA sequence alone.  
 
Despite the lack of SNPs associated with asthma it is possible to see clear 
differences in gene expression.  For example, a genome-wide profiling study 
of epithelial cells comparing 42 asthmatics with healthy volunteers showed 
that the expression of genes coding for chloride channel, calcium-activated, 
family member (CLCA1), periostin and serine peptidase inhibitor, clade B 
(ovalbumin), member 2 (serpinB2) were up-regulated in asthma and that CS 
decreased their expression.  However, despite CS upregulating the 
expression of FKBP51, a high basal expression of FKBP51 was linked with a 
poor response to CS and could potentially indicate severe asthmatics 
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(Woodruff et al. 2007).  Similarly, as discussed in the section on the role of 
cytotoxic T-cells in asthma above, there are large changes in gene expression 
in CD8+ T-cells and some changes in CD4+ T-cells which demonstrate 
differences in the control of gene expression in asthma.  This control of gene 
expression could be via a variety of epigenetic mechanisms. 
 
1.7 Epigenetics 
Epigenetic factors hereitably alter the expression of genes without changing 
the DNA sequence.  These modifications can be controlled by the 
environment and the genome.  Examples of these factors are DNA 
methylation, the methylation of cytosine residues on DNA which generally 
inhibits local gene expression (Rastogi et al. 2013), and histone modifications 
which alter the affinity of histones for DNA, act as tags for the recruitment of 
transcriptional co-factors/repressors and alter the ability of DNA to interact 
with RNA polymerase II enabling changes in gene transcription. Histone 
modifications can both increase (methylation on specific lysine residues) or 
decrease (acetylation) their affinity for DNA, alter the local chromatin structure 
and change the accessibility of binding sites for other transcription factors 
resulting in either gene repression or activation (Schones & Zhao 2008).  
 
1.8 Histones Modification 
A nucleosome is an octomeric complex of histones molecules which binds a 
146 base pairs of DNA (Luger et al. 1997).  The octomeric complex is made 
up of 2 pairs of the histones H2A and H2B and two pairs of H3 and H4, the 
nucleosomes being tethered by a histone H1 molecule (Ransom et al. 2010).  
The primary function of histones is the safe storage of DNA, allowing the long 
DNA chains to be organised into a more condensed space (Ransom et al. 
2010).  Histones bind tightly to DNA to create a structure which may limit 
transcription  (Huisinga et al. 2006).  Relaxing the interaction of histones with 
DNA results in a more ‘open’ chromatin state. The control of histone’s affinity 
for DNA and for transcription factors is controlled by posttranslational 
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modifications of the histone tails.  Most data is focussed on modifications of 
histones H3 and H4, where methylation, acetylation, phosphorylation and 
ubiquitination of lysine and arginine residues regulates transcriptional activity 
(Tessarz & Kouzarides 2014).  These modifications alter the molecular charge 
of the histone tails, since DNA is negatively charged an increase in the 
positive charge of the histone tail will increase the affinity between DNA and 
histones to produce heterochromatin (Dumuis-Kervabon et al. 1986).  It is 
evident that other modifications on H2A and H2B may also play a role in the 
regulation of specific cellular functions although these will not be discussed 
here (Tessarz & Kouzarides 2014).   
1.8.1 Histone Acetylation 
Acetylation increases the negative charge of the histones and causes 
repulsion of DNA from the histone creating a looser chromatin structure and 
allows increased DNA accessibility (Dumuis-Kervabon et al. 1986; Xu et al. 
2007b).  The acetylated histone tags also provide binding sites for 
bromodomain-containing proteins that transduce the acetylation signal to the 
basal transcriptional complex (Yang et al. 2005).   Acetylation of multiple 
lysines on a tail of a histone can increase acetylation such as both the histone 
3 lysine 9 (H3K9) and lysine 27 (H3K27) (Dumuis-Kervabon et al. 1986; Xu et 
al. 2007b). 
 
Histone acetylation is controlled by histone acetyltransferases (HATs) and 
histone deacetylases (HDACs) and the effects of this modification are further 
transduced by acetyl readers (bromodomain-containing proteins) which 
integrate the downstream effects on basal transcription factor recruitment and 
activity and subsequent gene expression.  HAT activity has been shown to be 
increased in cross-sectional studies in asthmatic biopsies in adults and 
children and the HAT/HDAC ratio alters with asthma severity (Ito et al. 2002; 
Su et al. 2008).  
 
H3K27ac is associated with the enhancer regions of actively expressed genes 
(Creyghton et al. 2010).  When combined with GWAS studies epigenetic 
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surveys can demonstrate which SNPs might be most important in disease 
(Gerasimova et al. 2013).  For example, H3K27ac along with H3K4me1 has 
been shown to be enriched in non-coding SNPs of asthmatic CD4+ T-cells 
(Gerasimova et al. 2013).  
 
It is also key to note that even with the siRNA depletion of HATs in drosophila 
cells histone acetylation was often constant and sometimes higher 
demonstrating that the acetylome is probably more fixed than variable 
although this may be cell- and species-dependent (Imhof et al. 2015).  
1.8.1.1 HDACs 
HDACs 1 and 2 are important for the repair and remodelling of the airways.  
During development HDAC1/2 knockout mice affect the expression of the 
lung-specific progenitor Sox2 (Wang Y et al., 2013).  However, HDAC1/2 
ablation post-natally in airway epithelial cells does not affect Sox2 expression 
but increases the expression of the cell cycle regulators Rb1, p21/Cdkn1a and 
p16/Ink4a after injury causing cell cycle stalling and the loss of epithelial 
membrane barrier function (Y Wang et al. 2013).   
 
Acetylation can modulate transcription factor binding to genes and acetylation 
of H3K9 and H3K27 can be read by proteins such as bromodomain containing 
proteins such as bromodomain and extraterminal domain proteins (BET) and 
cAMP response element-binding protein-binding protein (CBP) and Protein 
wise E1A binding protein p300 (EP300/p300)(Zeng & Zhou 2002).  Brd4, a 
BET protein, has two bromodomain regions so can bring together two proteins 
with acetylated lysine such as acetylated histones and acetylated p65, one of 
the two elements of NF-κB complex.  p65 activation is further enhanced by 
acetylation on K310 and Brd4 binding is important for controlling NF-κB 
activity in a cell-dependant manner (Belkina et al. 2013).  Brd proteins can 
increase both proliferation and inflammation (Huang et al. 2009a; S. Y. Wu & 
Chiang 2007).  Inhibition of STAT5-activated genes by targeting Brd function 
limits Th2 type inflammation (Pinz et al. 2015).  
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Trichostatin A (TSA), a non-selective class 1/2 HDAC inhibitor isolated from 
fungi (Yoshidas 1990) has been shown to enhance histone acetylation and 
increase inflammatory responses in vitro (Ito et al., 2002) but to limit IL-17 and 
T-helper cell numbers and increase Treg cell activation in vivo (Hou et al. 
2014).  An explanation of these seemingly divergent effects has been 
proposed whereby heightened genome-wide histone acetylation prevents 
correct sensing of gene-specific enhancement resulting in a global 
suppression rather than activation of gene expression (Bhadury et al. 2014). 
It is also suggested that the Th2/Th1 balance in asthma is shifted towards Th1 
type inflammation by a non-selective histone deacetylase inhibitor (HDACi) in 
mice as it increases acetylation at the TGFβ promoter resulting in elevated 
BAL TGFβ protein levels (Hou et al. 2014; Choi et al. 2014). 
 
In mouse models of allergic rhinitis HDAC1, HDAC3 and TSLP are 
upregulated and H3K9 acetylation is decreased. Treatment with sodium 
butyrate, another HDACi, in an OVA-induced mouse model of asthma, TSLP 
expression and the promoter-associated H3K9 acetylation levels were 
restored to normal (Wang et al. 2016).  In addition, the levels of OVA-specific 
IgE were decreased by sodium butyrate (Wang et al. 2016).  However H3K18, 
acetylation is differentially expressed in asthmatic epithelium at the ΔNp63, 
EGFR and STAT6 promoters and could not be modified with TSA.  This 
suggests that some modifications are more permanent and have other layers 
of control over them (Stefanowicz et al. 2015). 
 
The reliability of the HDAC inhibitor studies in vivo have been called into 
question as many studies have been unable to replicate the anti-inflammatory 
effects of these drugs (Banerjee et al. 2012; Kim et al. 2012; Kienzler et al. 
2013; Shi et al. 2012) and others which have shown them to increase NF-κB 
mediated inflammation (S. Y. Wu & Chiang 2007; Royce 2012; Hou et al. 
2014).  
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HDACs which reverse the acetylation status of histones can also affect other 
non-histone proteins such as the glucocorticoid receptor (GR).  GR is 
acetylated on lysine residues K494 and K495 within the DNA binding domain 
of GR.   Acetylation of these residues does not affect GR nuclear import, 
association with DNA at GREs (Ito et al., JEM 2006).  Selective knockdown of 
HDAC2 resulted in increased GR acetylation and attenuated the ability of GR 
to associate with the p65 subunit of NF-κB and thereby block inflammatory 
gene expression.  In addition, site-directed mutagenesis of K494 and K495 
reduced GR acetylation and GR suppression of NF-κB-driven inflammation is 
no longer affected by histone deacetylase blockade (Ito et al., JEM 2006). 
This is important in severe asthmatics who are CS insensitive where there is 
often defective HDAC2 expression  (Ito et al. 2006; Marwick et al. 2009).  
However, Butler and colleagues were unable to detect reduced HDAC2 in 
severe asthma biopsies and reported that increased epithelial remodelling 
associated with severity correlated with enhanced HDAC1 expression (Butler 
et al. 2012). The mechanisms of glucocorticosteroid anti-inflammatory actions 
are multi-factorial and include effects on both HAT and HDAC expression and 
activity and there is evidence that reduced HDAC2 activity is linked to steroid 
insensitivity (Royce & Karagiannis 2014).  Theophylline, a weak 
bronchodilator drug used clinically, can enhance the activity of HDAC2 and is 
able to improve steroid sensitivity in vitro and in vivo (Barnes 2013). 
1.8.1.2 Bromodomains Proteins 
Brd4 has two bromodomain regions which gives it the opportunity to bind two 
proteins with acetylated lysine and act as a bridge (S. Y. Wu & Chiang 2007). 
Brd4 has been shown to bind to the p65 subunit of NF-κB, acetylated histones 
and p-TEFB which in turn can bind RNA Pol II to promote transcription (Zhang 
et al. 2012).  
 
CXCL8 gene promoter histone acetylation status is abnormal in airway 
smooth muscle cells from asthmatic patients.  This has been associated with 
a specific increase in H3K18 acetylation due to enhanced EP300 promoter 
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binding.  The binding of the acetylated histone reader proteins Brd3 and Brd4 
to the CXCL8 promoter was also seen and accounts for the ability of Brd 
inhibitors to suppress CXCL8 expression and to limit local histone acetylation 
status (Clifford et al. 2015). 
 
The ability of BET inhibitors to limit proliferation has been appealing for those 
looking to create anti-cancer drugs however, many such compounds such as 
JQ1 have relatively broad effects.  The discovery of Brd inhibitors or mimics 
resulted from a research group researching small-molecule modulators of 
epigenetic targets as cancer therapeutics utilising high-throughput screening 
platforms for bromodomain isoforms (Frye 2010; Oprea et al. 2009). The first 
patent was from Mitsubishi Pharmaceuticals who demonstrated that simple 
thienodiazepines possessed binding activity for BRD4 (Miyoshi et al. 2009). 
Studying the structure-activity relationships and the binding pocket of Brd4 
allowed the creating of a prototype ligand racemic molecule, JQ1, which is 
small and highly specific for Brds.  Researchers have subsequently created 
each enantiomer separately providing a positive effective enantiomer and a 
suitable inactive control (Filippakopoulos et al. 2010).  
 
JQ1 inhibits Brd-mediated functions including those involving NF-κB and p-
TEFB by competitively binding the Lysine reader region on Brds 
(Filippakopoulos et al. 2010). An overview of interactions can be seen in 
Figure 1.2. The JQ1 molecule binds competitively to acetyl-lysine recognition 
motifs and may inhibit Brd4 binding to bromodomains leading to reduction in 
asthma relevant processes including IL-1β-induced inflammation 
(Filippakopoulos et al. 2010; Khan et al. 2014). 
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Figure 1.2 Interactions of Brd4 
Brd4 is able to bind using its two bromodomain regions to the p65 subunit of 
NF-κB which and also to pTEFb by acetylated lysine. This is able to mediate 
the pro-transcriptional nature of NF-κB. JQ1 competes to bind Brd4s BET 
acetylated lysine reader region. 
 
 It has also been suggested that most clinical trials using BET inhibitors have 
used them at a far too high a dose to be specific or biologically relevant, as 
JQ1 with a reported Kd of 50nM for Brd4 was used at 2-20mM to treat breast 
cancer cell lines and may risk having off-target and/or toxic effects (Andrieu et 
al. 2016; Shu et al. 2016).   
 
Other off-target effects of BET mimics include reactivating latent HIV virus in 
carriers  of the virus and as such these drugs could be dangerous in clinical 
use in at-risk individuals and more selective drugs should be developed (Z. Li 
et al. 2013).  
1.8.1.3 CBP/p300 
CBP and p300, are two homologous proteins which act as transcriptional co-
activators, histone acetylases and have bromodomains. CBP/p300 has been 
shown to be important in cell growth, tumorigenesis, hematopoiesis and cell 
growth and differentiation (Goodman & Smolik 2000) and modulate gene 
expression in part through the acetylation of H3K18 and H3K27 (Jin et al. 
2011). 
 
JQ1
p65
p50
Brd4
RNA Pol II
pTEFb
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Inhibition of these proteins inhibits the regulatory ability of Treg cells and has 
been suggested as a treatment for cancers which recruit Treg cells to limit 
cytotoxic T-cell killing of cancerous cells (Ghosh et al. 2016).  When p300 is 
inhibited in Foxp3+ Tregs of mice, the cells demonstrate an increased anti-
tumour function (Y. Liu et al. 2013).  
 
CBP30 selectively binds to the Bromodomain of CBP/p300 and inhibits 
CBP/p300 functions (Hay et al. 2014). CBP has been shown to suppress 
Th17 responses including the release of IL-17A.  CBP30 demonstrated a 
more restricted effect than the pan-BET inhibitor JQ1 and may suggest that 
more selective BET mimics may be more suitable for clinical develpment as 
they may result in fewer side effects (Hammitzsch et al. 2015).  This concept 
needs to be tested in mouse models and, most importantly, clinically.  
 
C646 is a highly potent histone acetyl-transferase inhibitor which is selective 
for p300 by targeting its Lys-CoA binding pocket  at low concentrations and 
inhibits pro-inflammatory gene expression in murine macrophage lines by 
inhibiting the effects of acetylation at NF-κB sites in target gene promoters 
(Bowers et al. 2010; Van Den Bosch et al. 2016).  Cbp/p300-interacting 
transactivator 2 coded for by the CITED2 gene is able to limit acetylation by 
removing p300 from activated genes under hypoxic conditions and targeting 
selective histone acetylation events might be a more useful way to treat 
chronic inflammatory diseases in the future despite the current limitations of 
this approach (Yoon et al. 2011).  Targeting of p300 has also been achieved 
using CRISPR-Cas9 but this may not be a feasible approach in man where 
complete ablation is not required (Hilton et al. 2015). 
 
There is evidence for cross-talk between different histone marks.  For 
example, in Th2 cells expressing high levels of IL-13 and possessing high 
levels of H3K27ac at the IL13 locus, knockout of the DNA methyltransferase 
3a resulted in increased IL-13 expression and greater levels of airway 
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inflammation in a mouse allergic airway inflammation model of asthma (Yu et 
al. 2012).   
 
1.8.2 Histone Methylation 
There are multiple residues in the histone tail which can be either mono, di or 
tri-methylated. The functional effect can either be an increase or decrease in 
transcription depending on modified residue, the level of methylation (mono, di 
or tri) and where on the gene or promoter the modification is located (Young 
et al. 2011). 
 
The promoter and enhancer regions of genes regulate the gene’s expression 
and histone methylation in these regions can both increase and decrease 
transcription. When the regulatory regions of a gene contain both pro-
transcriptional and suppressor histone modifications this is known as a 
bivalent gene.  Inhibitory histone modifications take priority until removed and, 
as such, the gene is considered as primed (Simon & Lange 2008). In the 
primed state the transcription complex may be present, but halted and unable 
to produce RNA.  H3K4 di-methylation is often found poised at active 
enhancer regions (Koche et al. 2011). One of the clearest examples of this is 
on a single stretch of chromosome 5 where IL-4, IL-5 and IL-13 are coded 
along with the DNA repair protein RAD50 (Vijayanand et al. 2012).  RAD50 
has H3K4me1 at its four conserved enhancer regions in its introns and the 
levels of this modification is increased in T-cells from asthmatic patients 
suggesting higher basal histone methylation and transcriptional pause occurs 
for this gene (Seumois et al. 2014).  
 
1.8.3 H3K4 
Histone methylation is often associated with T-cell differentiation including 
CD4+ T-cell differentiation (Wei et al. 2009).  The Il4/Il13 locus in mouse Th2 
cells is tri-methylated on H3K4 suggesting that methylation activates the 
transcription of these genes.  However, H3K27 tri-methylation is also found in 
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the same position in Th1 cells where it is associated with transcriptional 
repression (Wei et al. 2009).  The mixed linage leukemia gene (MLL) is an 
H3K4-selective histone methyltransferase which is key for maintaining H3K4 
modification at the Gata3 and Il4/Il13 locus in T memory cells.  However, MLL 
does not seem to be involved in applying H3K4 methylation in differentiating 
Th2 cells demonstrating that multiple methylases are required depending 
upon the precise state of the cell (Yamashita et al. 2006).  
 
Chromatin immunoprecipitation-sequencing (ChIP-Seq), a method to measure 
the location of every histone modification on a cells genome, which when 
combined with GWAS in Th1, Th2 and naïve T-cells shows that there is an 
up-regulation of H3K4me2 at SNPs within the promoters of regulatory regions 
of asthma-linked genes including CCR4 and CCL5 (Seumois et al. 2014).  
CCR4 is linked to Th2 recruitment to the lung and CCL5 is chemotactic for T-
cells (Perros et al. 2009; Chan et al. 2012).  
 
The H3K4me2 mark is localised to enhancers during Th2-cell differentiation 
which enables an asthmatic phenotype to prevail (Seumois et al. 2014).  In 
contrast, increased transcription of both IFNG and IL4 is linked with H3K4me3 
marks across stretches of the gene and in the promoter region (Wei et al. 
2009). 
 
Though there are currently no licensed drugs which target histone methylation 
there are new tool compounds which can be used in disease models.  PFI-2 is 
a compound which targets the histone methyltransferase SET (domain 
containing) (SETD7) which is specific for H3K4.  SETD7 plays a role in 
inflammation as it has been shown to activate inflammatory gene expression 
by inducing H3K4 methylation at NF-κB binding sites in cancer cell lines 
(Barsyte-Lovejoy et al. 2014; Wang et al. 2001). 
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1.8.4 H3K9 
The H3K9me3 mark is associated with gene repression when localised to  
gene promoters by preventing RNA Pol II binding to these sites  (Zhu et al. 
2012).  Vascular endothelial growth factor (VEGF) is a signal protein which is 
hyper-secreted by airway smooth muscle (ASM) cells in asthmatic airways 
and may account for airway remodelling which is a cardinal feature of asthma 
(Yuksel et al. 2013).  In asthmatic ASM the H3K9 repressive complex at the 
promoter of the VEGF gene is decreased allowing for the hypersecretion.  In 
healthy patients the G9a methyltransferase is vital for the repression of VEGF 
release (Clifford et al. 2012).   
 
The H3K9me3 demethylase, JMJD2D, is able to activate transcription of Mdc 
and Il12b in dendritic cells and macrophages by removing the H3K9 
methylation mark after exposure to an external stimulus  (Zhu et al. 2012; 
Whetstine et al. 2006). UNC0642, an inhibitor of G9a histone 3 binding may 
be useful for future studies, however, inhibition of G9a generally could be 
dangerous in vivo as it is vital for embryogenesis (F. Liu et al. 2013; Clifford et 
al. 2012; Tachibana et al. 2002). 
 
1.8.5 H3K27 
The location of H3K27 methylation marks within a gene can vary its functional 
effects.  H3K27me3 marks found in the center of the gene is associated with 
inhibition of gene expression, whilst when found at transcriptional start sites, 
H3K27me3 marks are associated with bivalent genes and transcriptional 
pause (Young et al. 2011).  Finally, when localized to the promoter region of a 
gene it is associated with increased transcription of that gene (Young et al. 
2011). 
 
EZH2 is a histone lysine methyltransferase which specifically catalyses the tri-
methylation of H3K27 and has been associated with gene repression effects 
of H3K27me3 (Simon & Lange 2008).  EZH2 is vital for CD4+ differentiation 
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as it methylates H3K27 to block the production of IL-4 and IL13 in Th1 cells 
and prevent the expression of IFNG in Th2 cells. (Yamashita et al. 2006; 
Tumes et al. 2013). Adoptive transfer of Th2 cells from OVA-sensitised Ezh2 
KO animals to wild type mice who were subsequently given an acute OVA 
challenge resulted in higher levels of eosinophilia, IL-4, IL-5 and IL-13, and 
mucus hypersecretion compared to mice which had been transferred Th2 
cells from wild type mice (Tumes et al. 2013). There was also an 
overproduction of IFN-γ resulting in increased Th1 type inflammation (Tumes 
et al. 2013). 
 
Two H3K27-specific demethylases, JMJD3 and tetratricopeptide, X 
chromosome (UTX), remove these repressive marks and are important for 
pro-inflammatory gene regulation and Th cell development (Miller et al. 2010; 
Xiang et al. 2007; Satoh et al. 2010).  JMJD3 knockdown in the THP-1 
monocyte cell line and in macrophages increased H3K27me3 marks at the 
promoters of NF-κB inducible genes leading to decreases inflammatory gene 
expression (Xiang et al. 2007; Ishii et al. 2009).  Treatment of DCs with the 
JMJD3 inhibitor GSK-J4 (Kruidenier et al. 2012) has been shown to 
specifically attenuate Treg stability and suppressive effects without affecting 
Th1 and Th17 cells via dendritic cell suppression (Doñas et al. 2016). 
 
IL-4 treatment of airway epithelial cells results in demethylation of the 
H3K27me3 mark at the ALOX15 promoter, thus increasing ALOX15 gene 
expression. The demethylation is under the control of UTX and is required for 
this IL-4 induced activation (Han et al. 2014; Kuperman et al. 2005).  ALOX15 
codes for a protein which oxygenates poly-unsaturated fatty acids to 
synthesise inflammatory signaling mediators and its expression is positively 
correlated with asthma severity (Kuperman et al. 2005).  Whether this effect is 
causal or just correlative in asthma may be studied in future using GSK-J4.  
GSK-J1 and J4 have been shown to prevent LPS-induced inflammation in 
macrophages (Kruidenier et al. 2012). 
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Histone demethylation is essential for T-cell differentiation where large 
changes in epigenetic states occur.  However, demethylases that inhibit 
repression such as JMJD3 are expressed in terminally differentiated cells 
suggesting that they have a broader role in mediating cellular responses.  
JMJD3 has additional roles in targeting histone modifications and regulating 
chromatin remodeling such as mediating the interaction T-bet and a Brg1-
containing SWI/SNF DNA remodeling complex and so tool compounds which 
target protein may have off-target effects (Miller et al. 2010). 
  
DNA Methylation 
DNA methylation is associated with gene repression and is found on 
complementary pairs of cysteine residues followed by a guanine (CpG) (Law 
& Jacobsen 2010).  DNA methylation can control cell fate, inactivation of X 
chromosomes and gene specific activation and silencing.  DNA 
methyltransferase (DNMT)1 maintains methylation marks between 
generations of cells as it converts hemi-methylated DNA into fully methylated 
DNA (Hermann et al. 2004).  During the production of germ cells, cell-specific 
methylation is removed and then re-established by DNMT3A and 3B which 
create specific parental gene expression profiles in a process called genetic 
imprinting (Law & Jacobsen 2010).  
 
The IL-4 promoter in naïve CD4+ T-cells is transcriptionally limited by 
methylated CpG regions.  However, dust mite exposure decreases DNA 
methylation at the IL4 locus in cells from asthmatic subjects but not in cells 
from non-asthmatic subjects.  This results in enhanced IL-4 release from 
asthmatic cells which is correlated with the reduction in DNA methylation and 
demonstrates active and specific demethylation (Kwon et al. 2008; 
Santangelo et al. 2009).  To back up the change to Th2 type CD4+, the 
expression of Th1 type genes and proteins such as IFNG was blocked by dust 
mite exposure which was associated with increased IFNG promoter 
methylation (Brand et al. 2012).  IFNG production can be reactivated in Th2 
genes by demethylating the DNA of the IFNG gene, this is mediated by 
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GATA3 and T-Bet, demonstrating the extent to which the epigenome can be 
plastic (Williams et al. 2013).  
 
In mouse OVA-driven mouse asthma models, DNMT1 expression has been 
shown to be self-regulating.  Allergic stimulation decreased DNMT1 
expression in the lung which was linked to DNMT1 promoter DNA methylation 
(Verma et al. 2013). 
 
FOXP3 expression is controlled by DNA methylation and the methylation 
status of the FOXP3 promoter is able to discriminate Tregs from activated T-
cells resulting from altered FOXP3 expression (Floess et al. 2007; Baron et al. 
2007; Polansky et al. 2008).  FOXP3-regulated genes are then themselves 
hypo-methylated in human T-Reg cells.  CD4+ and Tregs had comparative 
methylated DNA sequencing carried out. There were 2315 differentially 
methylated cytosine–guanosine dinucleotides shown between Tregs and 
CD4+ cells in 127 regions of differential methylation (RDM). The RDMs for 
putative FOXP3 binding sites were hypomethylated  in Tregs suggesting a link 
between the methylation and FOXP3 binding (Zhang et al. 2013). 
 
Cross-talk can occur between epigenetic processes such as H3K27 
methylation and DNA methylation.  In zebra fish, the development of the lef1 
gene, a neurogenesis regulator, is controlled by a network that includes 
Dnmt3 and G9a and these work together to silence cell fate regulators (Rai et 
al. 2010).  Cross-talk also occurs between RNA and DNMT1 where a section 
of RNA from the CEBPA locus is able to interact with DNMT1 and prevent 
methylation of its own gene, thus increasing its own transcription (Di Ruscio et 
al. 2013).  
 
The combination of GWAS studies and DNA methylation studies has 
demonstrated that there is an increased risk of asthma at age 18 with high 
DNA methylation at asthma relevant SNPs such as those at the IL-4R gene 
(Zhang et al. 2014).  DNA methylation at 36 loci in peripheral blood 
 59 
eosinophils is also strongly linked to serum IgE levels (Liang et al. 2015).  
These loci encode important eosinophil products and phospholipid 
inflammatory mediators and the unknown genes are potential new targets for 
treatment. 
 
DNA methylation is vital to the activation of asthmatic immune responses and 
modifying the DNA methylome in certain cells may be of therapeutic benefit to 
some patients. Anti-cancer drugs have been developed which target DNMT1-
Stat3 complexes giving a level of specificity to the targeted inhibition of the 
DNA methylase.  In this instance, it was possible to limit the differentiation of 
Th17 cells without causing global hypomethylation which could lead to 
catastrophic effects on the epigenetic control of many cells (Cheray et al. 
2014).  The newly synthesised tool compounds from the Cheray, 2014 paper 
bind to DNMT1 complexed with either HDAC1, STAT3, PCNA, CFP1 or USP7 
give a wide variety of specific agents with which to explore the relationship 
between DNA methylation and T-cell differentiation (Robertson et al. 2000; 
Cheray et al. 2014). 
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1.9 Hypothesis and Aims 
The bronchial airway epithelium is a relatively accessible target for highly 
selective epigenetic modifying drugs.  By studying the mechanism(s) by which 
the epithelial epigenome is primed in asthma and by testing epigenome 
modifying tool compounds on epithelial inflammation it will be possible to 
determine new targets for drug development.  CD8+ T-cells appear to have a 
critical role in the severe-asthma phenotype with highly differentially 
expressed transcriptome. Therefore, I hypothesise histone modifications play 
a key role in regulating epithelial and CD8+ T-cell dysfunction in the severe 
asthma phenotype and by investigating the role of histone modifications other 
mechanisms of disease will become apperent. To investigate this hypothesis, 
I will undertake the following specific aims: 
 
• To examine the transcriptomic and epigenetic status in the asthmatic 
airway epithelium and study their response to epigenome modifying 
compounds 
• To investigate the transcriptomic and epigenetic status of CD8+ T-cells 
in severe and non-severe asthmatics and study the effect of 
epigenome modifying compounds 
• To determine the pathways by which these epigenetic mechanisms 
and cellular functions are controlled using unbiased gene networking 
analysis 
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Chapter 2: Materials & 
Methods 
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2.1 General Methods 
2.1.1 Enzyme Linked Immunosorbent Assays (ELISA) 
CXCL8, IL-6 and MIP1α levels were measured using duo-set ELISA, following 
manufacturer’s instructions (R&D systems, Abingdon, UK). The manufacturer 
states that there is < 0.5% cross reactivity observed with available related 
molecules in all used ELISAs.  In brief, 96-well Nunc Maxisorb Plate 
(eBiosciences, CA, USA.) were coated overnight at room temperature (RT) 
with the relevant capture antibody e.g. anti-CXCL8, then blocked (to prevent 
non-specific binding) with 1% bovine serum albumin (BSA) in PBS for 2 hours. 
Samples were added in duplicate to the wells alongside an eight point 
standard curve. Following 2 hour incubation at RT the plate was washed with 
PBS-Tween from powder (Sigma Aldrich) and detection antibody in PBS was 
added for two hours. The plates were washed again and Streptavidin-HRP 
added and incubated for 20 minutes (mins) at RT. After a final wash the 
Substrate Reagent Pack (TMB, BD Sciences, Erembodegem, Belgium) 
components were mixed 1:1 and added to the plate and the colour reaction 
stopped with 2N H2SO4 after 20 mins. The intensity of the colour change was 
measured by absorbance 450-570 (Bio Tec Instruments Microplate Reader & 
Gen 5 Analysis Software; Winooski, VT, USA). The values of the unknown 
samples were interpolated using the standard curve.  
 
2.1.2 Viability Assay 
Cell viability was approximated by studying mitochondrial activity and was 
measured using (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), which is soluble and able to enter a cell, where it is reduced to 
insoluble formazan. Formazan’s purple colour can be measured and was 
used to determine cell viability. 1mg/ml (final concentration) of MTT solution in 
media was added to the samples and incubated for 30 mins at 37°C after 
which the MTT solution was removed from the plate. The plate was then 
blotted and left to dry. Once dry 50µl of DMSO (Dimethyl Sulfoxide) was 
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added to each well, the plate was manually agitated for 30s and absorbance 
(570nm) was measured on a photo-spectrometer (Bio Tec Instruments 
Microplate Reader & Gen 5 Analysis Software; Winooski, VT, USA). 
Background absorbance was determined by adding MTT solution to wells with 
no cells and the measurements are normalised to untreated cells. 
 
2.2 Cell proliferation Assay 
Cell proliferation was determined using the BrdU assay, which measures the 
amount of bromodeoxiuridine (BrdU) incorporated into the DNA during 
synthesis in proliferating cells. The amount of incorporated BrdU can 
subsequently be measured by colorimetric analysis. The Cell Proliferation 
ELISA BrdU (Colorimetric) kit (Roche, Mannheim, Germany Cat: 11 647 229 
001) was used following the manufactures protocol and is explained here in 
brief.  
Cells were seeded 1x104 cells/well in 96-well plates and incubated for 48 
hours. Subsequently, the BrdU (100µM final concentration) was added to 
each well. After 24 hours, the media was removed, and FixDent solution 
added to each well after 30 mins at room temperature. It was removed and 
the Anti-BrdU-POD antibody is added (90 mins RT).  The plate was washed 
with wash solution and finally 100µl of substrate solution is added. After 
incubating for 3 mins the luminescence was read on a photospectrometer (Bio 
Tec Instruments Microplate Reader & Gen 5 Analysis Software; Winooski, VT, 
USA). Background luminescence was controlled for by removing the value of 
control wells without BrdU from the read value of BrdU wells. 
 
2.3 Human Bronchial Cell Models 
2.3.1 BEAS-2B Culture 
BEAS-2B cells, a human virus transformed bronchial epithelial cell line, 
(ATCC, VA, USA) were grown in Keratinocyte Serum-Free Media (SFM) (Life 
Technologies, Paisley, UK) supplemented with Supplements for Keratinocyte-
SFM (Endothelial Growth Factor (EGF) 2.5µg and Bovine Pituitary Extract 
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(BPE) 25mg) (Life Technologies) and incubated at 37°C with 5% CO2. They 
were passaged by washing with Phosphate Buffered Saline (PBS), detached 
by using trypsin (Sigma-Aldrich, Dorset, UK) and resuspended at 0.25 
x106/ml. BEAS-2B cells were used between passages 10 and 20. 
 
2.3.2 Normal Human Bronchial Epithelial Cell Culture 
Normal human bronchial epithelial (nHBE) cells (Lonza, Cat: CC-2540, Lot: 
0000259108) were grown in Bronchial Epithelial Cell Basal Media (BEBM) 
with Bronchial Epithelial Cell Growth Media (BEGM) SingleQuots supplements 
(BPE, Insulin, Hydrocortisone, GA-1000 (Gentamicin and Amphotericin), 
Retinoic Acid, Transferrin, Triiodothyronine, Epinephrine, human EGF) 
(Lonza) and incubated at 37°C with 5% CO2. Cells were grown to 70-80% 
confluence before passaging by washing with 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES)-buffered saline, detaching from the 
flask using trypsin/ Ethylenediaminetetraacetic acid (EDTA) for 5 mins and 
neutralising with Trypsin Neutralising Solution (All Lonza). Cells were 
resuspended at 0.25x106/ml in 25ml of BEBM and used at passages 3-7.  
 
2.3.3 BEAS-2B Epigenetic Probe/Mimic Treatments  
The effects of a variety of epigenetic probes or mimics obtained from the 
Structural Genomics Consortium (SGC) (Oxford, UK) (Table 2.1) on BEAS-2B 
cell proliferation and the release of CXCL8 in response to IL-1β stimulation 
was studied.  
BEAS-2B cells were grown until 70% confluent in a 96-well plate. Probes or 
mimics were diluted 1 in 2. The concentrations were selected based on those 
suggested by the SGC.  Cells were pre-treated with the probe/mimic for two 
hours before being stimulated with 1ng/ml IL-1β for 24 hours.  CXCL8 and IL-
6 release were measured by ELISA (see Enzyme Linked Immunosorbent 
Assays (ELISA) section), viability was measured by MTT assay (Viability 
Assay) and proliferation was measured using a BrdU assay (Cell proliferation 
Assay). 
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Table 2.1. List of Epigenetic Probes/mimics used 
Probe compound, reported target and top concentration used in BEAS-2B cell 
response studies and cross reactivity notes from Structural Genome 
Consortium.  
Probe/mi
mic Target 
Top Concentration 
(nM) 
Cross reactivity Notes 
UNC0638 G9a (EHMT2)/ 
probe 2048 
G9a IC50 = <15nM 
GLP  IC50 = 19nM 
UNC0642 G9a 
(EHMT2)/GLP 
(EHMT1) Probe 
512 
N/A 
UNC1999 EZH2/1 Probe 2048 Greater than 50% inhibition of 4 7TM targets @ 10 µM. 
SGC-
CBP30 CBP/p300 Probe 1136 
40 fold selective for CBP 
over Brd4, next most 
efficacious target. 
Bromospo
rine BRD4 + CBP 4096 
Has similar thermal melt 
temperatures for BRD2, 
BRD3, BRD4, BRDT, 
CECR2, PB1, CBP 
GSK343 
EZH2 Probe 1136 
Minimum selectivity over 
EZH1 is 100 times more 
selective. 
GSK2801 BAZ2B/A 16384 Melatonin (MT-1) receptor 4% inhibition. 
GSK-J1 
JMJD3 Probe 256 
JMJD3 IC50 = 0.06µM 
Jarid1b IC50 = 0.95µM 
Jarid1c IC50 = 1.76µM 
JMJD2e IC50 = 19.6µM 
GSK-J4 J1 Pro-drug 256 As above  
JSK-J5 GSK-4 Negative 
Control 256 
NA 
JQ1(+) 
BrdT + Brd4 1024 
BRD4 Kd = 49.0nM 
BRD3 Kd = 82.0nM 
BRD2 Kd = 128.4nM 
 
JQ1(-) JQ1(+) Negative 
Control 1024 
NA 
PFI-2 
SETD7 512 
SETD7 IC50 = 2nM  
PFI-2 is highly selective 
(>1,000-fold) for SETD7, 
over a panel of 18 other 
human protein methyl- 
transferases and DNMT1. 
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2.3.4 Treatment of nHBE Cells with Epigenetic Probes/mimics 
The effects of JQ1(+), JQ1(-), GSK-J4, GSK-J5 and Bromosporine on normal 
human bronchial epithelial release of CXCL8 in response to IL-1β was 
measured by ELISA. nHBEs were grown until 70% confluent in a 96-well 
plate. Probes were diluted 1:1.  Cells were pre-treated with the probe/mimics 
for two hours before being stimulated with 1ng/ml IL-1β for 24 hours.  CXCL8 
release was measured by ELISA and viability was measured by MTT assay.  
 
2.3.5 Effect of Probes/mimics in combination with a 
corticosteroid in BEAS-2B Cells 
The effect of epigenetic probes/mimics in combination with CS on the release 
of CXCL8 and viability in response to IL-1β in BEAS-2B cells was studied.  
Probes were diluted 1:1. Cells were pre-treated with the probe and fluticasone 
propionate (FP) (10-8M) a common inhaled corticosteroid for two hours before 
being stimulated with 1ng/ml IL-1β. CXCL8 release was measured by ELISA 
and viability was measured by MTT. 
 
2.3.6 SILAC Proteomics Methods 
Stable isotope labelling by amino acids in cell culture (SILAC) is a proteomics 
method which integrates atomic isotope labelled amino acids into the proteins 
of cultured cells and uses mass spectrometry to measure the difference in 
ratios of proteins between treatment groups by comparing adjacent peaks in 
the spectrograph. In this case between unstimulated cells, IL-1β stimulated 
cells and IL-1β and FP-treated cells.   
 
2.3.7 SILAC labelling and Cell culture 
3 sets of normal human epithelial cells from different patients were obtained 
commercially (Lonza) from non-asthmatic patients (nHBE) and cultured in 
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bronchial epithelial growth media. Cells were grown to 80% confluence in a 
six well plate, and before stimulation were transferred to SILAC media for 5 
days with media changed daily.  The SILAC media was modified RPMI-1640 
media including L-Glutamine and sodium bicarbonate but without L-Arginine 
(R), L-Leucine (L), L-lysine (K) or phenol red (Sigma-Aldrich) and 
supplemented with 10% dialysed (to remove unlabelled amino acids) foetal 
calf serum (FSC) (Sigma-Aldrich). Specifically labelled amino acids 
(Cambridge Isotope Laboratories Ltd, Andover, MA, USA) were added as 
described in Table 2.2. The cells were then treated with FP (10-8M) and IL-1β 
(1ng/ml) (both Sigma-Aldrich) for 24 hours. The cell work was carried out by 
Dr. Andrew Durham.  
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Group Leucine Lysine Arginine 
Control Unlabelled Unlabelled Unlabelled 
IL-1β Unlabelled 2H4-Lys 
(DLM-2640-PK) 
13C6-Arg 
(CLM-2265-H-PK) 
IL-1β & 
FP 
Unlabelled 13C615N2-Lys 
NLM-291-H-PK) 
13C615N4-Arg 
(CNLM-539-H-PK) 
Table 2.2. SILAC Treatment and Label for nHBECs 
Modified isotope amino acid SILAC labelling with each treatment. Labelled 
amino acids used for each group and their catalogue numbers (Cambridge 
Isotope Laboratories) are listed. 
 
2.4 SILAC Methods 
2.4.1 SILAC Protein Extraction  
After stimulation, media was removed and the cells were washed with PBS 
and lysed with Radioimmunoprecipitation (RIPA) buffer (Sigma-Aldrich) 
supplemented with protease and phosphatase inhibitors (Halt Protease 
Inhibitor Cocktail and Halt Phosphatase Inhibitor Cocktail; Thermo Scientific, 
Warrington, UK). Protein content of the whole cell extracts were quantified 
using the bininchoninic acid (BCA) assay to measure protein mass as 
following manufacturers methods. (Sigma Aldrich). Cells were normalised to 
the same concentration of protein and SILAC proteomic analysis was carried 
out. 
 
2.4.2 Proteomics using mass spectroscopy 
Proteomics was carried out by Dr. Kate Heesom at Bristol University. Pooled 
Protein samples were fractionated on 10% SDS-PAGE gels. Using a ProGest 
automated digestion unit (Digilab, Marlborough, MA, USA) the gel lanes were 
given an in-gel tryptic digestion. The peptides were fractionated using a 
Dionex Ultimate 3000 nanoHPLC system in line with an LTQ-Orbitrap Velos 
mass spectrometer (Thermo Scientific).  The Acclaim PepMap C18 nano-trap 
column (Dionex) had the resulting peptides in 1% (vol/vol) formic acid injected 
into it. The formic acid peptides were washed with 0.5% (vol/vol) acetonitrile 
0.1% (vol/vol) and resolved on a 250mm × 75μm Acclaim PepMap C18 
reverse phase analytical column (Dionex) over a 150min organic gradient, 
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using 7 gradient segments (1-6% solvent B over 1min., 6-15% B over 58 min., 
15-32%B over 58min., 32-40%B over 3min., 40-90%B over 1min., held at 
90%B for 6min and then reduced to 1%B over 1min) with a flow rate of 300nl 
min−1.  Where Solvent A was 0.1% formic acid and Solvent B was aqueous 
80% acetonitrile in 0.1% formic acid. Using a nano-electrospray ionization at 
2.1 kV using a stainless-steel emitter with an internal diameter of 30 μm 
(Thermo Scientific) and a capillary temperature of 250°C peptides were 
ionised.  Tandem mass spectra were captured using an LTQ-Orbitrap Velos 
mass spectrometer controlled by Xcalibur 2.1 software (Thermo Scientific) 
operated in data-dependent acquisition mode.  The LTQ-Orbitrap was set to 
analyse the survey scans at 60,000 resolution (at m/z 400) in the mass range 
m/z 300 to 2000 and the top six multiply charged ions in each duty cycle 
selected for MS/MS in the LTQ linear ion trap.  Charge state filtering, where 
unassigned precursor ions were not selected for fragmentation, and dynamic 
exclusion (repeat count, 1; repeat duration, 30s; exclusion list size, 500) were 
used.  The conditions for fragmentation in the LTQ were as follows: 
normalized collision energy, 40%; activation q, 0.25; activation time 10ms; 
and minimum ion selection intensity, 500 counts. 
 
Using Proteome Discoverer software v1.2 (Thermo Scientific) the raw data 
files were processed, quantified and searched against the UniProt/SwissProt 
Human database using the SEQUEST (Version 28 Revision 13) algorithm.   
 
Peptide precursor mass tolerance was set at 10ppm, and MS/MS tolerance 
was set at 0.8Da.  Search criteria included carbamidomethylation of cysteine 
(+57.0214) as a fixed modification and oxidation of methionine (+15.9949) 
and appropriate SILAC labels (2H4-Lys, 13C6-Arg for duplex and 13C615N2-Lys 
and 13C615N4-Arg for triplex) as variable modifications.  The reverse database 
search option was enabled and all peptide data was filtered to satisfy false 
discovery rate (FDR) of 5%.  The minimum cross-correlation factor (Xcorr) 
filter was readjusted for each individual charge state separately to optimally 
meet the predetermined target FDR of 5% based on the number of random 
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false positive matches from the reverse decoy database.  Thus, each data set 
has its own parsing parameters.  Quantitation was performed using a mass 
precision of 2ppm.  After extracting each ion chromatogram several filters 
were used to check for interfering peaks and the presence of the expected 
isotope pattern using the Proteome Discoverer software.  Peptides which did 
not pass these filters were not used in calculating the final ratio for each 
protein. Results are presented as protein ratios and represent the median of 
the raw measured peptide ratios for each protein.  
 
2.5 Histone Purification and Analysis 
2.5.1 Global Histone Modification analysis 
nHBE cells were grown to confluence in 6-well plates.  The nHBE cells were 
then treated with FP (10-8M) and stimulated after 2 hours with IL-1β (1ng/ml). 
The concentrations were governed by concentration response curves carried 
out in BEAS-2B cells. Global histone modifications are investigated by 
isolating the histones and then running purified histones on a multiplex ELISA 
to give relative concentrations and changes after treatment with a CS to 
represent the standard anti-inflammatory asthma treatment. 
 
2.5.2 Histone Purification  
Histone purification was carried out using the Active Motif Histone Purification 
Kit (Active Motif, Brussels, Belgium. Cat: 102385) according to the 
manufacturer’s instructions, which will be briefly described here. The samples 
were extracted by washing the adhered cells with serum free media and 
scraped in the presence of 0.3ml of extraction buffer. The cells were pipetted 
to homogenise and incubated for 2 hours at 4°C. Following this the 
homogenate was spun at 12,000 xg for 5 mins and then the supernatant 
transferred to a new tube where it had a quarter of the original volume of 
extraction buffer added. To purify the histones the crude histones were 
incubated with 0.5ml of Equilibration buffer before being added to the spin 
columns and centrifuged at 500 g for 3 mins at 4°C. The run through was 
 71 
removed and 0.5ml histone wash buffer was added to the column before 
centrifugation.  The washing step was repeated 3 times.  Finally, the columns 
were added to new tubes and 100µL of histone elution buffer was added to 
the columns before being spun.  
The final stage was to precipitate out the histones using 4% perchloic acid 
overnight at 4°C. The samples were subsequently spun at 12,000 g for 1 hour 
at 4°C. The pellet was washed with 1ml of cold 4% perchloric acid for 5 mins 
at full speed and the process repeated 3 times. Finally, the pellet was washed 
with acetone before being repelleted. The supernatant was then removed and 
the pellet allowed to air dry.  Finally, the pellet was resuspended in 35µL of 
sterile water. The concentration of the histones was quantified using a photo-
spectrometer measuring absorbance at 230nm when diluted 1:10 in water in a 
Corning Costar UV-Transparent Microplates plate. An OD of 0.42 indicated a 
protein concentration of 1mg/ml. 
 
2.5.3 Histone H3 Post Transcriptional Modification Multiplex 
ELISA 
Changes in histone modification was measured using the Histone H3 PTM 
Multiplex Kit, following the manufacturer’s instructions (Active Motif, Brussels, 
Belgium Cat: 103952) and the Luminex Magipix Plate Reader using 
xPONENT for Magipix 4.2 software. The assay works by staining the specific 
modifications with different colour antibodies and measuring the fluorescent 
intensity of each wavelength. 
Buffer solution containing deacetylase inhibitor, protease inhibitor and 
phosphatase inhibitor was used to dilute the histones to 150ng/25ul. The 
multiplex bead master mix was made up with 1µL of each Ab-Conjugated 
Beads from Table 2.3 made up to 25µL with buffer for each well.  
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Antibody Conjugated Beads Catalogue Number Lot Number 
H3 total 33116 29113002 
H3K4me3  33121 11213001 
H3K9me1  33118 11213001 
H3K9me2  33119 11213001 
H3K9me3  33120 11213001 
H3K9ac  33117 29312001 
H3T11ph 33128 01001001 
H3K27ac 33127 01001001 
H3K27me2  33124 11213001 
H3K27me3  33125 11213001 
H3K56ac  33126 01001001 
H3 pan-acetyl 33123 11213001 
Table 2.3. Histone Modification Binding Conjugated Antibodies 
Conjugated Antibody beads for Histone Multiplex ELISA (All Active Motif). 
 
1:1 of master mix and diluted histone sample or positive control were added to 
the wells to a total of 50µl. The wells were then covered with adhesive sealant 
and tin foil and incubated for 1 hour on an orbital shaker.  Following this the 
plate was washed by setting the plate on a 96-well magnet for 60 seconds 
and washing with wash buffer and then removing the buffer by flicking whilst 
the plate was still attached to the magnet. This was repeated 3 times. Next 
50µL diluted biotinylated antibody was added to each well, the plate covered 
and incubated for one hour on an orbital shaker. The wash steps were 
repeated and followed by adding 50µL diluted Streptavidin-PE to each well. 
The plate was covered and incubated again on an orbital shaker for 30 mins. 
The supernatant was removed using a 96-well magnet and the beads 
resuspended in 100µL of wash buffer. The plate was then read on a Magpix 
Luminex Plate Reader (Luminex Corp. Austin, Texas, USA) following the 
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instructions on the xPONENT software and normalised against total H3 
histones.  
 
2.6 Isolation of CD8+ T-Cells from Asthmatics  
2.6.1 Patient Selection Criteria for CD8+ T-cells Collection 
Severe and non-severe asthmatics were selected following these inclusion:  
• All patients had a physician diagnosis of asthma, were aged 18-60, be a 
non-smoker or ex-smoker with a less than 5 pack year history. 
• Non-severe asthmatics were well controlled with minimal symptoms while 
on an ICS therapy not exceeding 2000µg beclomethasone equivalent. 
• Severe asthmatics had to either have had treatment with continuous or 
near continuous (>50% of the year) oral CS or a requirement for treatment 
with high dose inhaled steroids. As well as this they must have at least two 
of the following: 
• Requirement for daily treatment with controller medication in addition 
to ICS e.g. Long acting beta-adrenoreceptor agonists, theophylline or 
leukotriene antagonists 
• Asthma symptoms requiring short acting beta-adrenoreceptor agonists 
on a daily or near daily basis 
• Persistent airways obstructions (FEV1 <80% predicted, diurnal PEF 
variation >20%) 
• One or more emergency care visits a year 
• 3 or more steroid “bursts” a year 
• Prompt deterioration in symptoms with < 25% reduction in oral or ICS 
• Near fatal asthma event in the past 
 
The exclusion criteria for all patient types were: 
• Current smoker or less than 3 years since smoking cessation 
• Less than 4 weeks since the last exacerbation 
• On platelet or anti-coagulant drugs 
• Low platelet count 
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• On steroid sparing agent or immunosuppressant drugs such as 
azathioprine, methotrexate and cyclosporine.  
• Concomitant anti-IgE therapy  
• Pregnant or breastfeeding 
• Intubation for asthma within 6 months of entry into this study. 
 
2.6.2 CD8+ Isolation 
Cells were extracted using Ficoll-Paque and negative selection using 
magnetic beads. The protocol is below described in brief.  
2.6.3 Ficoll-Paque Isolation 
Blood was collected from patients and mixed with 1ml ACD (Acid Citrate 
Dextrose Solution)/10ml blood. ACD containing blood samples were mixed 
with PBS (1:1) and carefully layered onto Ficoll-Paque (GE Healthcare, 
Buckinghamshire, UK) and spun at 400g for 30 mins at RT with acceleration 
set to 5 and brake rate at 2. The layer containing the mononuclear cells was 
removed using Pasteur pipettes. The mononuclear cell layer was spun at 
200g for 10 mins and the pellet resuspended in 5ml of ice cold water to lyse 
red blood cells before being centrifuged, resuspended in PBS and repelleted 
as before. Cells were counted and 250,000 cells were put in FACS fix (2% 
Formaldehyde in PBS). 
 
2.6.4 CD8+ T-Cell Isolation 
CD8+ T-cells were enriched by removing non-CD8+-T-cells using the CD8+ T-
cell Isolation Kit (Miltenyi Biotec, Surrey, UK). The T-cell isolation kit uses 
negative selection by using magnetic CD4, CD15, CD16, CD19, CD34, CD36, 
CD56, CD123, TCRγ/δ, and CD235a (Glycophorin A) binding antibodies to 
pull out all non-CD8+-T-cells. 
 
The pellet was resuspended in Isolation Buffer (PBS, 0.5% BSA, 1:10 ACD) 
and 10µl of CD8+ T-cell Biotin-Antibody Cocktail per 107 cells was added and 
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incubated for 10 mins between 2-8°C. Then 20µl of CD8 T-cell MicroBead 
Cocktail was added per 107 cells added and incubated for 15 mins at 2-8°C. 
Then the solution was spun at 300g for 10 mins at 4°C and resuspended in 
500µl of isolation buffer. The LS MACS Columns (Miltenyi Biotec) was put into 
the QuadroMACS Separator (Miltenyi Biotec) a magnetic stand and the cells 
were washed through with buffer. Cells were counted and 250,000 cells were 
put in FACS fix. When the cell count was lower than 2 million, half the cells 
were suspended in either 20% formaldehyde to crosslink DNA to histones and 
then quenched with glycine for ChIP-seq analysis and the other half were 
suspended in RTL lysis buffer (Qiagen, West Sussex, UK) and β-
mercaptoethanol (Sigma-Aldrich) for RNA extraction for transcriptomic 
analysis by gene arrays. When >2 million cells were obtained, 1 million cells 
were set aside for gene array and the remainder was used for ChIP-Seq. 
 
2.7 CD8+ T-cells Extraction and analysis 
2.7.1.1 RNA Extraction 
RNA was extracted from the CD8+ T-cells with the RNeasy Mini Kit (Qiagen) 
following manufacturer’s instructions by using a silica-membrane which binds 
RNA when primed with ethanol and releases it in aqueous solutions. In brief 
cells were lysed by spinning for 3 mins in a QIAshredder lysis columns. The 
supernatant from this tube was added to the top of the extraction column after 
being mixed with 350ul of ethanol (70%) and spun, then with RW1 buffer and 
then with RPE buffer. The RNA is then eluted with RNase free water. RNA 
quality was run on a Pico RNA Bioanalyser when being used for gene array 
(Agilent Technologies, Kidlington, UK as described in 2.7.1.6).  
 
2.7.1.2 Reverse Transcription and Amplification for Gene Array 
For gene arrays cDNA was created from mRNA using the cDNA Ovation Pico 
WTA System (NuGen, CA, USA). This was carried out as per manufacturer’s 
instructions and is described in brief here. The generation of the first strand of 
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cDNA was by using a proprietary mix of random and oligo dT primers so that 
priming occurs across the whole transcript and reverse transcriptase. The first 
cDNA/mRNA hybrid also contains a unique SPIA-RNA tag as a priming site 
for the SPIA process. The DNA was purified at this stage. The generation of a 
DNA/RNA Hetreoduplex Double Strand cDNA was carried out by 
fragmentation of the mRNA in the heteroduplex to allow DNA polymerase to 
synthesise a second cDNA strand with a complimentary SPIA-Tag. The final 
SPIA amplification step used the DNA/RNA chimeric primer, DNA polymerase 
and RNase H. RNase H removes the RNA portion of the heteroduplex SPIA 
tag revealing a binding site for the SPIA primer. DNA polymerase starts at the 
3’ end of the primer and displaces the existing forward strand when 
synthesising cDNA. The chimeric SPIA primer reproduces the SPIA tag and 
creates a new substrate for RNase H and starts the next round of cDNA 
synthesis. This was repeated for a fast and high yield amplification. The SPIA 
cDNA was then purified with MinElute Reaction Cleanup Kit (Qiagen) and 
analysed using a Nano DNA Bioanalyser in order to assess quality and 
quantity of RNA. 
 
2.7.1.3 Biotinylation 
The process of biotinylating amplified cDNA is to create labelled binding 
targets for the Genome Expression BeadChips using the Encore Biotin 
Module (Nugen, CA, USA). The manufacture’s instructions were followed but 
are explained in brief here. The uracil-DNA glycosylase is used to remove 
uracil bases which were incorporated in the amplification step creating an 
abasic site on the cDNA strand. This is where the biotin moiety will bind to the 
strand. The sample was then purified with MinElute Spin Column (Qiagen).  
 
2.7.1.4 Gene Array 
The hybridization cocktail was prepared from the fragmented biotin-labelled 
cDNA by using the Affymetrix Hybridization, Wash and Stain kit 
(ThermoFisher, Scientific, MA, USA) and hybridised to the Affymetrix 
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GeneChip Human Gene 1.0 ST Array (ThermoFisher Scientific) for 18 hours. 
Once hybridisation was completed washing and staining steps were 
performed on an Affymetrix GeneChip Fluidics Station 450 Affymetrix 
GeneChip Fluidics Station 450, and arrays were scanned with an Affymetrix 
GeneChip 3000 7G scanner (ThermoFisher Scientific). Microarray data 
normalization was carried out using a robust multichip average method and 
quality checks using Partek Genomics Suite 6.6 (Partek GS).  
 
Partek software was also used to carry out a principal component analysis 
(PCA). This process find the sources of variability in a data set then is able to 
present it as values that represents groups of highly variable genes. The 
software takes all the variables, in this case genes, and plots them against 
each other, ranks them into orders of variability and then assembles groups of 
genes with similar variability as PC1, PC2 then PC3.  The PCA is then plotted 
on a 3 axis graph allowing to see groupings of the patients. 
 
2.7.1.5 WGCNA Analysis of CD8+ Data 
The WGCNA method (Zhang et al. 2005) within the WGCNA-Package in 
Bioconductor R (Langfelder & Horvath 2008) was used to find groups of 
significant genes that move together and were correlated to clinical outcomes.  
In short, a network is constructed using Pearson correlations which gives 
weighted values for each gene, then using a Topological Overlap Matrix 
(TOM) a module is identified.  The eigengene (1st Principal Component) of 
each module is used to find a single representative of each module and this 
can then be taken on into further analysis of module significance with patient 
traits which here was clinical outcomes. As using all the data from the gene 
arrays would be too computationally intensive only the genes with p<0.05 by 
ANOVA in Partek (2042 genes) from gene arrays were used although this 
reduced the unbiased nature of the analysis. The reason genes were chosen 
like this (as opposed to by fold change) is because WGCNA will be able to 
group by small movements in expression, whereas if the genes were selected 
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by fold change then there would only be one large network created which 
would not show anything other than the genes put into the analysis. 
 
2.7.1.6 RNA/DNA Method Bioanalyser Protocol 
DNA and RNA quality and quantity was measured with a High Sensitivity DNA 
Kit or a Nano (25-500ng/µl) or Pico (50–5000pg/μL) RNA Kit (Aligent 
Technologies CA, USA) depending on quantity of RNA. Manufacturer’s 
instructions were followed, but in brief are described below.  
Dye and gel reagents were mixed and used to prime the Assay chip by adding 
to the “Gel” well, and using the chip priming station to use air pressure to force 
the gel into the chip. Next the marker was added to all wells including the 
ladder well. Then 1µl of ladder or sample was added to each well, 12 samples 
were run per chip. After being vortexed the chip was placed in an Aligent 2100 
Bioanalyser and run on the suitable setting to produce a RNA Integrity 
Number (RIN) number (Schroeder et al. 2006) and RNA quantity by using 
electrophoresis.  
 
2.7.1.7 CD8+ Flow Cytometry Staining 
For confirmation of cell isolation and purity, flow cytometry was used. Cells 
were stored at 500,000 cells/ml in 0.5ml of FacsFix (4% Formaldehyde in 
PBS) from before and after the isolation step at 4°C and kept from light.  
Before running the cells through FACS the cells were centrifuged at 300 xg for 
10 mins, resuspended in 100µL buffer and mixed with 10 µL of both CD8-PE 
(Milteny Biotec, Cat: 130-098-075) and CD3-FITC (Milteny Biotec, Cat:130-
098-162) for 10 mins in a refrigerator in the dark. This allowed the FACS 
machine to discriminate the CD8+ CD3+ cells. The cells were washed with 
1ml of buffer, spun for 10 mins at 300 xg, the supernatant was removed and 
cells resuspended in 200µL of buffer in a FACS tube. The cells were finally 
run through a FACS Canto 3 (BD Bioscience) and the data was analysed 
using FlowJo (Treestar, USA).  
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2.7.1.8 PCR Confirmation of differentially expressed genes 
Real Time quantitative Polymerase Chain Reaction (RT-qPCR) was used to 
confirm fold change (FC) results from the gene arrays using a QuantitTect 
SYBRGreen (Qiagen) and Rotor-Gene 3000 Machine (Corbett Research, 
Crawley, UK) and analysed using Rotor-Gene 6 Software (Corbett Research).   
 
Component Volume 
2X QuantiTect SYBR Green PCR Master Mix 10µl 
Forward Primer (10µM) 1µl 
Backward Primer (10µM) 1µl 
RNase-Free Water 3µl 
Total Master Mix reaction volume 15µl 
cDNA Product  5µl 
Table 2.4. Components for Sybr Green RT-qPCR master mix 
 
 
Gene Product 
18s 
Forward 5’-CTTAGAGGGACAAGTGGCG-3’  
Backward: 5’-ACGCTGAGCCAGTCAGTGTA-3’  
DUSP1 
Forward: 5’-ACCACCACCGTGTTCAACTT-3’ 
Backward: 5’-GAGGTCGTAATGGGGCTCTG-3’  
GAPDH 
Forward: 5’-TTCCAGGAGCGAGATCCCT-3’ 
Backward: 5’-CACCCATGACGAACATGGG-3’ 
MPO Qiagen, QuantiTect Primer Assay – Cat No: QT00067613 
DEF1B Qiagen, QuantiTect Primer Assay – Cat No: QT01529234 
ZFP36 Qiagen, QuantiTect Primer Assay – Cat No: QT00091357 
CD81 Qiagen, QuantiTect Primer Assay – Cat No: QT00010591 
GGA1 Qiagen, QuantiTect Primer Assay – Cat No: QT01018213 
NDUFB8 Qiagen, QuantiTect Primer Assay – Cat No: QT00088704 
TAGAP Qiagen, QuantiTect Primer Assay – Cat No: QT01029770 
HIST1H1C Qiagen, QuantiTect Primer Assay – Cat No: QT00200410 
Table 2.5. PCR Primers for Sybr Green 
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The total reaction volume for each PCR was 20μl. See Table 2.4 for 
components used for Sybr Green Master Mix and Table 2.5 for primers used. 
To account for variations within the protocol, gene transcript levels of 18S or 
GAPDH rRNA, housekeeping genes, were also quantified and used for 
normalisation. The reaction involved an initial heat step of 95°C for 15 mins to 
activate the DNA polymerase followed by 30-40 cycles of denaturation (94°C 
for 15 seconds), annealing (55-60°C for 30 seconds) and extension (72°C for 
30 seconds) using a Rotor-Gene 3000 Machine (Corbett Research, Crawley, 
UK) and analysed using Rotor-Gene 6 Software (Corbett Research; 
Australia).   
 
2.8 Chromatin Immunoprecipitation-Sequencing 
(ChIP-seq) 
2.8.1 Chromatin Preparation 
The chromatin was cross-linked with 37% formaldehyde prior to being flash 
frozen in liquid nitrogen. A ChIP protocol was used for immunoprecipitating 
Histone 3 Lysine 27 trimethylation-associated DNA. The cells were lysed by 
freeze/thawing and micrococcal nuclease (MNase, 10U/µl) (New England 
Biolabs Inc., MA, USA) was added to cell fragments in MNase Digest Buffer 
(Table 2.6) to break the DNA into mono-nucleosomes. This was carried out 
for 5 mins at 37°C and stopped with 20mM EDTA (pH 8.0). After spinning, the 
supernatant was stored and the pellet was resuspended for sonication in 
sonication buffer (Table 2.7). Sonication took place at 80% power on a 
Vibracell (ProScientific; NT, USA) with a 3mm probe for 5 bursts of 20 
seconds whilst on ice and with at least 60 second cooling time between each 
burst. The sample was spun and resuspended in Dialysis buffer (Table 2.8). 
 
An aliquot of a sample was taken, reverse cross-linked and DNA extracted as 
described below before being run on a DNA Bioanalyser chip to measure 
yield. 
 
 81 
2.8.1.1 ChIP-Seq ChIP Protocol 
10% of each sample was set aside to be used as an input. The sonicated 
DNA was mixed with 500µl RIPA buffer (Table 2.9) with 4µl anti-trimethyl-
Histone H3 (Lys27) antibody (Merck Millipore, Darmstadt, Germany; Cat: 07-
449) and 25µl Novex Dynabeads Protein G Magnetic Beads (ThermoFisher 
Scientific) and incubated overnight at 4°C. The samples were put on a 
magnetic stand to pellet beads which were washed with wash buffer 1 (Table 
2.10), wash buffer 2 (Table 2.11) and Tris-EDTA (TE) buffer. The beads were 
then resuspended in Elution Buffer (Table 2.12) and returned to the magnetic 
stand where the supernatant contained the eluted DNA. The DNA prepared by 
reverse crosslinking and DNA extraction as detailed below was amplified 
using the NEBNext ChIP-Seq Library Prep Master mix set. 
 
 
Compound Concentration 
Sucrose 0.32M 
Tris-Cl (pH 7.5) 50mM 
MgCl2  4mM 
CaCl2 1mM 
Protease and Phosphatase Inhibitors (Table 2.13 
and Table 2.14) 
 
Table 2.6. ChIP MNase Digest Buffer Components 
 
 
Compound Concentration 
Hepes (pH 7.5) 50mM 
NaCl 140mM 
EDTA 1mM 
Triton 1% 
SDS 0.1% 
Sodium deoxycholate 0.1% 
Table 2.7. ChIP Sonication buffer 
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Compound Concentration 
Tris-Cl (pH 7.5) 1mM 
EDTA 0.2mM 
Protease and Phosphatase Inhibitors (Table 2.13 
and Table 2.14) 
 
Table 2.8. ChIP Dialysis Buffer 
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Compound Concentration 
NaCl 140mM 
Tris (pH7.5) 10mM 
EDTA 1mM 
EGTA 0.5mM 
TX-100 1% 
SDS 0.01% 
Sodium Deoxycholate 0.1% 
Protease and Phosphatase Inhibitors (Table 2.13 
and Table 2.14) 
 
Table 2.9. Modified RIPA Buffer 
 
 
Compound Concentration 
Tris.Cl (pH 8.1) 20mM 
NaCl 50mM 
EDTA 2mM 
TX-100 1% 
SDS 0.1% 
Table 2.10. ChIP Wash Buffer 1 
 
 
Compound Concentration 
Tris.Cl (pH 8.1) 10mM 
NaCl 150mM 
EDTA 1mM 
NP40 1% 
Na deoxycholate 1% 
LiCl 250 mM 
Table 2.11. ChIP Wash Buffer 2 
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Compound Concentration 
NaHCO3 0.1M 
SDS 1% 
Table 2.12. ChIP Elution Buffer 
Compound Concentration 
AEBSF (4-(2-Aminoethyl) benzenesulfonyl fluoride 
hydrochloride) 
104mM 
Aprotinin 80μM 
Leupeptin 2mM 
Bestatin 4mM 
Pepstatin 1.5mM 
E-64 1.4mM 
Table 2.13. Protease Inhibitors Cocktail 100 x stock 
(Sigma Aldrich, Dorset, UK)  
 
 
Compound Concentration 
Imidazole 200mM 
Sodium Fluoride 100mM 
Sodium Moybdate 115mM 
Sodium Orthovanadate 100mM 
Sodium Tartrate Dihydrate 400mM 
Table 2.14. Calbiochem Phosphatase Inhibitors Cocktail Set II 
(Merck Millipore) 100x stock components. 
2.8.1.2 Reverse Crosslinking 
The samples were reverse cross-linked by incubating for four hours with 
RNase A (10 μg/μl) and NaCl at a final concentration of 250mM at 65°C. Then 
incubated in the presence of proteinase K (0.5 μg/μl) at 37°C for 1hr.  
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2.8.1.3 DNA Extraction 
DNA was extracted using phenol:chloroform:isoamyl-alcohol (25:24:1) 
extraction. Equal volumes of the phenol-chloroform was added to each 
sample and mixed by vortexing. After settling the upper aqueous layer was 
removed and NaCl (250mM final concentration) was added along with 40µg of 
glycogen and an equal volume of iso-propanol. This was mixed and DNA 
precipitated at -80°C for 2 hours. After thawing, the sample was centrifuged at 
18,000g for 15 mins at 4°C and the supernatant was discarded. The pellet 
was washed with 70% ethanol, microcentrifuged as above, the supernatant 
removed and the pellet allowed to air dry. 
2.8.1.4 DNA Clean-up and Tagging for ChIP-Seq 
DNA cleanup was carried out using the NEBNext DNA Library Prep 
MasterMix Set for Illumina (New England BioLabs Inc.) following 
manufacturer’s instructions. The process of the kit is to “end-repair” or blunt-
end the DNA fragments by chewing back 3’ and 5’ overhangs to allow for 
adenylation of the 3’ tail. The adenylated or dA-tailed DNA allows adaptor 
ligation. Adapters were attached as barcodes to the DNA so that multiple 
libraries can be run at once. The adaptors are loops and following the cutting 
of these loops using the USER enzyme, PCR can take place.  
 
Between each step AMPure beads are used to wash the previous reagents 
away. These are polystyrene beads surrounded by a layer of paramagnetic 
(magnetic only in a magnetic field) magnetite. The paramagnetic quality stops 
the beads clumping and falling out of solution. The final layer of the bead is 
made of carboxyl molecules which allows the DNA to reversibly bind to the 
beads in the presence of polyethylene glycol (PEG) and NaCl (~20% PEG, 
2.5M NaCl). The immobilisation is dependant on the concentration of PEG 
and NaCl.  
 
The step following adapter ligation was used to size select only mono-
nucleosomes with adapter so the protocol was followed for 200bp samples.  
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PCR Enrichment of Adaptor Ligated DNA used 15µl sample, 10µl 
Index/Universal Primer Mix and 25µl NEBNext Q5 Hot Start HiFi PCR Master 
mix for a total volume of 50µl. The cycling conditions are described in Table 
2.15. Following this, a further AMPure cleanup step was performed and the 
amplified DNA was run on an Aligent Bioanlyser. The libraries with adequate 
DNA were sequenced on an Illumina HiSeq using single-end 50bp reads. Dr. 
Audrey Kelly helped greatly with these steps and the King’s Genomic Centre 
carried out the sequencing. 
 
Cycle Step Temp Time Cycles 
Initial Denaturation 98°C 30 Seconds 1 
Denaturation 
Annelaing/Extention   
98°C 
65°C 
10 Seconds 
75 Seconds 
4 
Final Extension 65°C 5 Seconds 1 
Hold 4°C ∞ - 
Table 2.15. PCR Cycling Conditions 
PCR Cycling Conditions for NEBNexDNA Library Prep Amplification 
2.8.1.5 ChIP-Seq Analysis 
To analyse the sequence data, Galaxy (https://usegalaxy.org, Version 2.3.5.0) 
(Blankenberg, Kuster, et al. 2010), an open source web based platform for 
data intensive biomedical research, was used. The workflow had six steps.  
1. The FASTQ data from the Illumina HiSeq was converted to Sanger format 
using the FastQ Groomer (v.1.0.4) (Blankenberg, Gordon, et al. 2010).  
2. The first 5 base pairs from sequences which often contain erroneous 
information was removed using the Trim Sequence (Galaxy 1.0.0) tool. 
3. Over represented sequences were removed using Clip (Version 1.0.1)’ 
4. Alignment of sequences to the hg19 version of the reference human 
genome was performed using Bowtie2 (Langmead & Salzberg 2012; 
Langmead et al. 2009).  
5. FastQC (version 0.63) was used to provide quality control outputs for the 
runs.  
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6. Files were converted from the Galaxy Bam files to bigWig files using 
deepTools2 (Ramirez et al. 2016). The fragments were normalised to 
fragments per kilo base per million Reads Per Kilobase of transcript per 
Million mapped reads (RPKM).  The bigwig files were displayed on the 
UCSC Genome Browser v338 and shown alongside H3K27ac peaks from 
7 other studies (Table 2.16). 
 
Colour Cell Type GEO Accession 
Number 
Red GM12878 - B-Lymphocyte  GSM733771 
Orange Human Embryonic Stem Cells GSM733718 
Green Human Skeletal Muscle Myoblasts GSM733755 
Blue HUVEC (Human Umbilical Vein Endothelial Cells) GSM733691 
Indigo K562- Leukaemia GSM733656 
Purple Human Epidermal Keratinocytes GSM733674 
Pink Human Lung Fibroblasts GSM733646 
Table 2.16. ChIP-Seq Traces for H3K27ac 
H3K27ac ChIP-seq traces shown alongside ChIP-seq data collected. 
 
2.9 CD8+ T-Cell Activation Model 
2.9.1 Cell Culture Methods for CD8+ T-Cells 
CD8+ T-cells were grown in Iscove’s Modified Dulbecco’s Medium (IMDM) 
(ATCC) supplemented with Human Albumin 2.5μg/ml (Sigma-Aldrich), D-
Mannitol 0. 5μg/ml (Sigma-Aldrich) and 20% Foetal bovine serum. The media 
was regularly replenished with Human IL-2 (100units/ml diluted in 100mM 
Acetic Acid and 5% trehalose carrier protein). Cells were maintained at 
between 4x105 and 1x106 cells/ml at 37°C. 
2.9.2 Stimulation CD8+ T-cells 
Suitable stimulation protocols to induce Macrophage Inflammatory Protein 1α 
(MIP1α) release in TALL-104 cells were studied in 96-well plate at 8x104 
cells/well. Dynabeads® CD3/CD28 Human T-Activators (Thermofisher 
Scientific) were used at their recommended concentration of 4x107 Beads/ml. 
MIP1α was measured by ELISA as described in the Enzyme Linked 
Immunosorbent Assays (ELISA) section. 
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2.9.3 Dynabead Concentration response 
A submaximal concentration of Dynabeads was used to stimulate CD8+ T-
cells in 96-well plates at 8x105 cells/ml. 7 1:2 steps from 1,600,000 
dynabeads/ml were used. MIP1α was measured by ELISA as in section 2.1.1. 
 
2.10 Epigenetic Probe/mimic concentration responses 
in CD8+ T-cells  
CD8+ T-cells cells (8x105 cells/ml) were treated with a range of probe/mimic 
concentrations for one hour (Table 2.1) in a 96-well plate before being 
stimulated with Dynabeads (2x105 Beads/ml) for 24 hours. The supernatants 
were analysed for MIP1α release and cell viability was measured with MTT. 
 
2.11 PCR and single gene CBP ChIP for CD8+ T-Cells 
Cells were plated at 8x105 cells/ml in 6 well plates and treated with SGC-
CBP30 (400nM) for one hour and stimulated with Dynabeads (2x105 
Beads/ml) for 2 hours for PCR and ChIP analysis or for 24 hours for ChIP 
analysis.  
For PCR, RNA was extracted as in Section 2.7.1.1. RNA concentration was 
determined using a NanoDrop 2000c spectrophotometer and standardised to 
500ng/µL.  Reverse transcription to create single stranded cDNA was 
performed using a high-capacity cDNA kit (Applied Biosystems, Foster City, 
CA, USA), following the manufacturer's instructions. qPCR was performed in a 
Rotor-Gene 3000 PCR machine (Corbett Research, Cambridge, UK) using a 
QuantiTect SYBR Green PCR kit and normalised to 18S as described in 
Section 2.7.1.8. The genes expression of FOXP3, TUBA1A, JUND, DEFA1A, 
CD81, IFNG and CCL3 (MIP1α gene) (All QuantiTect from Qiagen) were 
measured. Data are presented as delta FC using the delta-delta CT (2-ΔΔCT) 
method. 
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To perform single gene ChIP, the MIlipore EZ-ChIP kit (Cat: 17-371, Merk 
Millipore, Watford, UK) was used exactly as described by the manufacturer. 
Protein-DNA was cross-linked using 1% formaldehyde before cells were lysed 
and the sample sonicated using eight 15 second bursts of 40% amplitude in a 
Vibracell Sonicator (ProScientific) to fragment the DNA. Sonication was 
performed on ice with at least a 30 second break between each burst to avoid 
heat damage. Aliquots of sonicated material were immunoprecipitated with 
5ug of CBP antibody (Thermofisher Scientific; Cat No. PA1-847). The DNA 
input and output was run on q-PCR using the protocol above using selected 
primers for the CREB region of the FOXP3 DNA sequence (5’ Primer: 
GGGGTATCTGCCCTCTTCTC, 3’ Primer: TCCCTTTCTGACTGGGTTTC), 
the CREB region of CCL3 MIP1α gene (5’ Primer: 
CAATTCCATCCACATGACCA, 3’ Primer: TATCAATCCCCAAACCAGGA) 
and a region of the IFNG (5’ Primer: TCCCATGGGTTGTGTGTTTA, 3’ Primer: 
AAGCACCAGGCATGAAATCT). The data is shown as input-output ratio, 
where the input is DNA from the samples prior to immunoprecipitation. Data is 
displayed as individual patients at the 2 hours and 24 hours. 
 
2.12 Statistical analysis 
Results are expressed as mean ± standard error of mean (SEM) unless 
otherwise stated. EC50 values were calculated from concentration response 
curves, and considered to be the concentration of compound that inhibits or 
induces the effect by 50% of the maximal response. GraphPad Prism was 
used for statistical analysis, analysis of variance (ANOVA) was performed by 
Kruskal-Wallis analysis (non-parametric) and for significant results; Dunn’s 
post-test was used. For matched paired non-parametric multiple comparisons 
Freidman’s test was used with Dunn’s multiple comparison.  p-values less 
than 0.05 were considered statistically significant. U-BIOPRED data was 
analysed on Array studio (Omicssoft Corporation, Cary, NC, USA) based on 
general linear model and with False discovery rate (FDR) adjusted p-value. 
WGCNA and gene array analysis is described under the corresponding 
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methodology heading. Pathway analysis was carried out using gProfiler 
(Reimand et al. 2016).  
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Chapter 3: Epigenetic 
Mechanisms in 
Asthmatic Bronchial 
Epithelium 
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3.1 Chapter Introduction 
Histone modifications, and their readers, have the potential to effect 
differential changes in gene expression that occurs between severe and non-
severe asthmatics.  Histone acetyl-transferase (HAT) activity is increased in 
children with increasing severity of asthma (Su et al. 2008) and enhanced 
histone acetylation allows for the binding of transcription factors and histone 
code readers such as Brd4, which is implicated in NF-κB p65-induced 
stimulation of inflammation (Belkina et al. 2013; Huang et al. 2009b; S.-Y. Wu 
& Chiang 2007). Tool compounds such as JQ1(+) and bromosporine inhibit 
the function of Bromodomain readers such as Brd4 and the more selective 
SGC-CBP30 is able to inhibit both CBP and EP300 bromodomain readers.  
Epithelial cells can respond to IL-4 by demethylating the H3K27me3 tagged 
ALOX15 gene thus increasing IL4 transcription (Han et al. 2014). ALOX15 
codes for a protein which oxygenates polyunsaturated fatty acids to 
synthesise potent signalling mediators and it’s expression correlates with 
increasing severity of asthma (Kuperman et al. 2005). ALOX15 promoter 
demethylation is controlled by JMJD3/UTX which allows for inhibition with 
GSK-J1 and GSK-J4 (Kruidenier et al. 2012). 
 
The bronchial epithelium acts as frontline between environment and the body. 
Not only is it a physical barrier, but it also possesses immunological functions. 
Immunological functions relevant to asthma include the induction of 
proliferation of CD4+ T-cells by release of TSLP (Soumelis et al. 2002) and IL-
6 (Poynter 2012). The airway is also able to respond to and release IL-13; a 
mediator of lung repair and central cytokine in Th2-driven allergic asthma 
(Woodruff et al. 2009). The  bronchial epithelium is also able to mount innate 
responses against pathogens in releasing defensins, prostaglandins and 
interferons (Bals & Hiemstra 2004). 
 
Oral and inhaled CS are gold standard treatments for severe asthma, 
however in severe asthma there can be a relative steroid insensitivity.  In 
steroid-sensitive asthmatics CS are able to inhibit release of inflammatory 
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mediators via mechanisms including inhibition of histone acetyl transferase 
expression and activity and by recruiting and/or activating histone deacetylase 
(HDAC), these events are less evident in severe asthmatics in response to 
GSC (Barnes et al. 2005). 
 
Leverage of pre-existing ‘-omics’ data sets is a useful way to identify the most 
relevant histone modifications in asthma before moving to more targeted 
studies designed for studying histone modifications. The data sets that will be 
explored in this chapter are from Unbiased BIOmarkers in PREDiction of 
respiratory disease outcomes (U-BIOPRED) a large clinical asthma study 
where samples including blood, airway brushings, nasal brushings, induced 
sputum and lung biopsies were taken from a large cohort of severe 
asthmatics, non-severe asthmatics and healthy subjects.  Gene array analysis 
of bronchial biopsies and brushings was carried out in initial studies.  I also 
used a proteomics dataset obtained from normal human bronchial cells 
(HBECs) that were stimulated with IL-1β in the presence and absence of 
fluticasone propionate and analysed using SILAC (Stable Isotope labelling 
with amino acids in culture).  These approaches may provide evidence for the 
role of some epigenetic mechanisms in asthma and in response to GCS.  
 
3.2 Chapter Hypothesis and Aims 
Epigenetic mechanisms, including histone acetylation and methylation in 
bronchial epithelial cells will be associated with asthmatic cell traits and 
responses to anti-inflammatory GCS (and proxies for it).  As a result, epithelial 
cells from severe asthmatics will be defined by a specific pattern of histone 3 
lysine 27 acetylation and tri-methylation. These epigenetic mechanisms can 
be altered by GCs and inhibitors of epigenetic mechanisms. 
This hypothesis will be tested by examining whether:  
• The expression of epigenetic tags or enzymes are linked to severe 
asthma by analysing gene arrays from asthmatics, and non-asthmatic 
patients bronchial brushings and biopsies to measure their expression,  
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• Glucocorticosteroids affect the expression of epigenetic tags/enzymes 
in proteomic examinations of bronchial epithelium and 
• Exposure to epigenetic probes affects inflammatory gene expression 
and release of inflammatory proteins in bronchial epithelial cell lines. 
 
3.3 Results 
3.3.1 Gene Expression of Histones and Histone Modifying 
Enzymes in Asthma 
3.3.1.1 Bronchial Brushings and Biopsy Gene Arrays from U-BIOPRED 
Data 
The Unbiased BIOmarkers in PREDiction of respiratory disease outcomes (U-
BIOPRED) Consortium is an international study from which large quantities of 
patient samples have been collected and analysed in an attempt to improve 
diagnosis and treatment for individual asthma patients (Kuo et al. 2016). The 
consortium collected and analysed bronchial biopsies from 40 non-smoking 
severe asthmatics (SAn), 28 non-severe, non-smoking asthmatics (NSA) and 
26 normal healthy volunteers (NHV). Gene arrays were also run on bronchial 
brushings from 49 SAn, 36 NSA and 44 NHV. This data has been tabulated 
here (Table 3.2) to show genes relating to histones and the epigenetics 
modifying enzymes for histones that are differentially expressed ( p-value < 
0.05). The genes of interest are shown in Table 3.1. Expression data of 
bronchial biopsies and epithelial brushing from Unbiased BIOmarkers in 
Prediction of REspiratory Disease outcomes (U-BIOPRED) Project is 
available within Gene Expression Omnibus at GSE76227.  
 
The aim of this exploration of expression data is to search for genes which 
code for histones and histone modifying enzymes in asthma. If specific 
enzymes are shown to be differentially expressed in asthmatic patients they 
could be targeted in further experiments to study the role of the expressed 
proteins on the asthmatic phenotypes.   
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Table 3.1 Table of Genes of interest for Bronchial Biopsies and Brushing
bromodomain	adjacent	to	zinc	finger	domain,	1A	 histone	cluster	1,	H1d	 histone	deacetylase	7	
Bromodomain	adjacent	to	zinc	finger	domain,	1B	 histone	cluster	1,	H1e	 histone	deacetylase	9	
bromodomain	adjacent	to	zinc	finger	domain,	2A	 histone	cluster	1,	H2ac	 histone	H4	transcription	factor	
bromodomain	containing	4	 histone	cluster	1,	H2ag	 jumonji	C	domain	containing	histone	demethylase	1	homolog	D	
bromodomain,	testis-specific	 histone	cluster	1,	H2ak	 Jumonji	domain	containing	1C	
E1A	binding	protein	p300	 histone	cluster	1,	H2ak	 jumonji	domain	containing	8	
enhancer	of	zeste	homolog	1	 histone	cluster	1,	H2bb	 lysine	(K)-specific	demethylase	1B	
euchromatic	histone-lysine	N-methyltransferase	1	 histone	cluster	1,	H2bj	 lysine	(K)-specific	demethylase	2A	
Euchromatic	histone-lysine	N-methyltransferase	2	 histone	cluster	1,	H2bk	 lysine	(K)-specific	demethylase	3B	
H1	histone	family,	member	N,	testis-specific	 histone	cluster	1,	H3	 Lysine	(K)-specific	demethylase	4B	
H1	histone	family,	member	X	 Histone	cluster	1,	H3e	 lysine	(K)-specific	demethylase	4C	
H1	histone	family,	member	X	 histone	cluster	1,	H3h	 lysine	(K)-specific	demethylase	4D	
H2A	histone	family,	member	B	 histone	cluster	1,	H4a	 lysine	(K)-specific	demethylase	5A	
H2A	histone	family,	member	V	 histone	cluster	2,	H2aa3	 lysine	(K)-specific	demethylase	5B	
H2A	histone	family,	member	X	 histone	cluster	2,	H2aa4	 lysine	(K)-specific	demethylase	5C	
H2A	histone	family,	member	Y	 Histone	cluster	3,	H2a	 lysine	(K)-specific	demethylase	6A	
H2B	histone	family,	member	M	 histone	cluster	3,	H3	 lysine	(K)-specific	demethylase	6B	
H2B	histone	family,	member	X,	pseudogene	 histone	deacetylase	10	 Lysine	(K)-specific	demethylase	8	
H3	histone,	family	3A	///	H3	histone,	family	3B	
(H3.3B)	 histone	deacetylase	11	 SET	domain	containing	(lysine	methyltransferase)	7	
HIR	histone	cell	cycle	regulation	defective	homolog	A	 histone	deacetylase	2	 SNF2	histone	linker	PHD	RING	helicase,	E3	ubiquitin	protein	ligase	
histone	cluster	1,	H1c	 histone	deacetylase	4	
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3.3.1.2 Investigation of gene expression in Bronchial Brushings U-
BIOPRED data 
The data shows more significant differences between SAn and NHV subjects 
(Table 3.2) than between NHV and NSA subjects (Table 3.4) and between 
San and NSA volunteers (Table 3.3). When comparing NHV to SAn, the 
histone cluster H1e is significantly decreased with a log2 FC of 1.39 and an 
FDR corrected p-value of 0.022 (Table 3.2). In contrast, two other histone 
clusters are significantly increased, H2bk and H2bj, with a log2 FC of 1.38 and 
1.25 respectively (Table 3.2). H2bk is marginally increased with a log2 FC of 
1.22 between NSA and SAn along with a small but significant decrease in the 
E1A binding protein p300 (Table 3.3). H2bj also shows a small but significant 
increase between NHV and NSA subjects (Table 3.4). 
3.3.1.3 Investigation of gene expression in the Bronchial Biopsies U-
BIOPRED data 
Comparing NHV and NSA subjects showed no differentially expressed histone 
or histone modifying genes.  When comparing NHV and SAn subjects we see 
an increase in Histone Cluster 1, H1a (log2 FC=1.27 P-Value = 0.0264) and 
Histone Cluster 1, H2bk (log2 FC=1.23 P-Value = 0.0479) (Table 3.5). We 
also see a decrease in expression of Cbp/p300 interacting transactivator (log2 
FC= -1.24 P-Value = 0.0705, Table 3.5) which conversely is significantly 
decreased from moderate to severe asthmatics (log2 FC= -1.23, P-Value = 
0.038, Table 3.6). 
We also see an increase in expression of large selection of histone related 
genes between NSA and SAn including; Histone Cluster1, H1a, H2bk and 3A 
(Table 3.6). 
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Healthy vs Severe 
asthma 
Log2 FC 
Healthy vs Severe 
asthma 
Raw p-value 
Healthy vs Severe 
asthma 
FDR 
Gene Symbol Gene Title 
-1.3849 0.0006 0.022 HIST1H1E Histone cluster 1, H1e 
1.3761 0.0012 0.0316 HIST1H2BK Histone cluster 1, H2bk 
1.2483 0.0024 0.0462 HIST1H2BJ Histone cluster 1, H2bj 
1.1153 0.0054 0.0688 BRDT Bromodomain, testis-specific 
-1.1117 0.0114 0.0988 EP300 E1A binding protein p300 
-1.17365 0.011925 0.094875 BAZ1B Bromodomain adjacent to zinc finger domain, 1B 
-1.1951 0.0141 0.1104 SHPRH SNF2 histone linker PHD RING helicase 
1.0882 0.0225 0.1412 HIST3H3 Histone cluster 3, H3 
-1.12695 0.0234 0.1426 KDM3B Lysine (K)-specific demethylase 3B 
-1.18554 0.0317 0.15394 KDM5A Lysine (K)-specific demethylase 5A 
-1.15355 0.0403 0.155325 H3F3A H3 histone, family 3A  
1.1477 0.0415 0.195 HIST1H2AK Histone cluster 1, H2ak 
1.1022 0.0495 0.20935 HDAC10 Histone deacetylase 10 
Table 3.2. DEGs from Bronchial Brushings Healthy vs. Severe Asthmatics 
Differential expressed genes encoding histones and histone modifying enzymes in bronchial brushings of Healthy vs. Severe non-
smoking Asthmatics.  Highlighting histone and histone modifying genes which show a raw p<0.05. Red values indicate adjusted 
p<0.05. Log2 FC – fold-change, FDR –false discovery rate corrected p-value. n=49 non-smoking severe asthmatics (SAn), n=36 
non-severe, non-smoking asthmatics (NSA) and 44 normal healthy volunteers (NHV). 
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Moderate	vs	Severe	asthma	
Log2 FC	
Moderate	vs	Severe	asthma	
Raw	p-value	
Moderate	vs	Severe	asthma	
FDR	
Gene	Symbol	 Gene	Title	
-1.1449	 0.0018	 0.7383	 EP300	 E1A	binding	protein	p300	
1.0815	 0.0392	 0.8178	 HIST3H3	 Histone	cluster	3,	H3	
1.2261	 0.0421	 0.8189	 HIST1H2BK	 Histone	cluster	1,	H2bk	
Table 3.3. DEGs from Bronchial Brushings Moderate vs. Severe Asthmatics 
Moderate vs Severe Asthmatics Gene Array on Bronchial Brushings from the U-BIOPRED consortium. Highlighting histone and 
histone modifying genes which show raw p<0.05. Log2 FC – fold-change, FDR – false discovery rate corrected p-value. 
 
 
Table 3.4 DEGs from Bronchial Brushings Healthy vs. Moderate Asthmatics 
Healthy vs. Moderate Asthmatic Gene Array on Bronchial Brushings from the U-BIOPRED consortium. Highlighting histone and 
histone modifying genes which show raw p<0.05. Log2 FC – fold-change, FDR – false discovery rate corrected p-value. 
 
 
  
Healthy	vs.	Moderate	asthma	
Log2	FC	
Healthy	vs.	Moderate	asthma	
Raw	p-value	
Healthy	vs.	Moderate	asthma	
FDR	
Gene	Symbol	 Gene	Title	
1.2039	 0.0132	 0.3858	 HIST1H2BJ	 Histone	cluster	1,	H2bj	
1.1687	 0.0406	 0.4917	 HIST1H1D	 Histone	cluster	1,	H1d	
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Healthy	vs	Severe	asthma	
Log2 FC	
Healthy	vs	Severe	asthma	
Raw	p-value	
Healthy	vs	Severe	asthma	
FDR	
Gene	Symbol	 Gene	Title	
1.1399	 0.0264	 0.2211	 H3F3A	 H3	histone,	family	3A	
-1.1604	 0.035	 0.2561	 BAZ2B	 bromodomain	adjacent	to	zinc	finger	domain,	2B	
1.2649	 0.0396	 0.2734	 HIST1H1A	 histone	cluster	1,	H1a	
-1.1818	 0.04476	 0.26684	 EZH1	 enhancer	of	zeste	homolog	1	(Drosophila)	
-1.1584	 0.046	 0.2932	 SETD7	 SET	domain	containing	(lysine	methyltransferase)	7	
1.2278	 0.0479	 0.3003	 HIST1H2BK	 histone	cluster	1,	H2bk	
Table 3.5. DEGs from Bronchial Biopsies Healthy vs. Severe Asthmatics 
Healthy vs Severe Gene Array on Bronchial Biopsies from the U-BIOPRED consortium. Highlighting histone and histone modifying 
genes. Log2 FC – fold-change, FDR – false discovery rate corrected p-value. n=40 non-smoking severe asthmatics (SAn), n=28 
non-severe, non-smoking asthmatics (NSA) and n=26 normal healthy volunteers (NHV) 
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Moderate	vs	severe	asthma	
Log2 FC	
Moderate	vs	Severe	asthma	
Raw	p-value	
Moderate	vs	Severe	asthma	
FDR	
Gene	Symbol	 Gene	Title	
1.34	 0.008	 0.34	 HIST1H1A	 histone	cluster	1,	H1a	
1.29	 0.011	 0.37	 HIST1H2BK	 histone	cluster	1,	H2bk	
1.15	 0.013	 0.38	 H3F3A	 H3	histone,	family	3A	
1.28	 0.018	 0.4	 HIST1H2BH	 histone	cluster	1,	H2bh	
1.18	 0.036	 0.41	 H2AFY	 H2A	histone	family,	member	Y	
-1.23	 0.038	 0.46	 CITED2	 Cbp/p300-interacting	transactivator,	with	Glu/Asp-rich	carboxy-terminal	domain,	2	
1.19	 0.042	 0.48	 HIST1H2BC	 histone	cluster	1,	H2bc	
1.2	 0.049	 0.51	 HIST1H2BD	 histone	cluster	1,	H2bd	
Table 3.6. DEGs from Bronchial Biopsies Moderate vs. Severe Asthmatics 
Moderate vs Severe Gene Array on Bronchial Biopsies from the U-BIOPRED consortium. Highlighting histone and histone 
modifying genes which show p<0.05. Log2 FC – fold-change, FDR – false discovery rate corrected p-value. n=40 non-smoking 
severe asthmatics (SAn), n=28 non-severe, non-smoking asthmatics (NSA) and n=26 normal healthy volunteers (NHV) 
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3.3.2 Stable Isotope Labelling with amino acids in culture 
(SILAC) Data 
3.3.2.1 Protein Quantification of Histones and histone modifying 
Normal Human Bronchial Epithelial Cells (HBECs) were grown under SILAC 
conditions as described in 2.4.  Cells were pre-treated with fluticasone 
propionate (FP, 10-8M) for 2hrs before being stimulated with IL-1β (1ng/ml) for 
24hrs.  Intracellular proteins were extracted and the effect of treatments 
compared by FC and p-value. The experimental work was carried out by Dr. 
Andrew Durham (Imperial College London) and proteomics by Dr. Heesom 
(Bristol University), I performed the data analysis. 
 
IL-1β stimulation increased the isotope ratio of many proteins which reflects a 
change in expression levels, though SILAC is unable to measure post-
transcriptional modifications such as acetylation and methylations.   The top 
differentially expressed proteins ranked according to p-value included 3 
Histone proteins; H4 (log2 FC = 92.70 p=1.41E-04), H1.5 (log2 FC = 96.40 
p=4.06E-04) and H2 type 1-H (log2 FC = 81.80 p=2.20E-03) (Table 3.7).   
When histone and histone-related proteins were examined specifically, two 
additional proteins were found to be significantly increased by IL-1β: Core 
Histone Macro-H2A.1 (log2 FC = 81.80 p=8.40E-03) and Histone 1.2 (log2 FC 
= 63.93 p=0.0108) (Table 3.8).  
 
Pre-treatment of IL-1β-stimulated cells with FP (IL-1β+FP- versus IL-1β-
treated cells) down-regulated the expression of 13 proteins (raw p-value 
<0.05)(Table 3.9).  FP did not significantly affect the expression of any histone 
or epigenome modifying proteins (Table 3.10).  
Though there were limited changes in histone methylase or acetylase protein 
expression this will not necessarily reflect the activity of these enzymes which 
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were subsequently analysed by determining the total cell levels of the 
associated histone modifications. 
 
 103 
 
Accession 
Number 
Log2 FC p-value Protein 
Q96GX5 98.13 7.80E-05 Serine/threonine-protein kinase greatwall  
P62805 92.70 1.41E-04 Histone H4 
B4DYB4 94.00 2.58E-04 Nucleoporin NUP53 (Nucleoporin Nup35) 
P16401 96.40 4.06E-04 Histone H1.5 (Histone H1a) (Histone H1b) (Histone H1s-3) 
P29034 64.23 1.16E-03 Protein S100-A2 (CAN19) (Protein S-100L) 
E9PF10 78.03 1.49E-03 Nuclear pore complex protein Nup155 
K7ES02 80.93 1.69E-03 Bleomycin hydrolase (Fragment) 
Q96KK5 81.80 2.20E-03 Histone H2A type 1-H (Histone H2A/s) 
B4DIT7 44.63 2.56E-03 Protein-glutamine gamma-glutamyltransferase 2  
P62314 73.30 3.24E-03 Small nuclear ribonucleoprotein Sm D1  
Q01469 74.37 4.20E-03 Fatty acid-binding protein, epidermal 
Q70UQ0 75.77 4.44E-03 Inhibitor of nuclear factor kappa-B kinase-interacting protein 
P37198 62.80 4.68E-03 Nuclear pore glycoprotein p62 
P09382 66.57 5.14E-03 Galectin-1 
P10253 60.87 5.18E-03 Lysosomal alpha-glucosidase 
P11586 69.10 5.18E-03 C-1-tetrahydrofolate synthase, cytoplasmic 
P30049 59.87 5.69E-03 ATP synthase subunit delta, mitochondrial 
Table 3.7. Protein change after IL-1β stimulation in nHBECs 
Top IL-1β (1ng/ml) induced proteins ranked according to raw p-value. Log2 FC compared to unstimulated.  Specific histone proteins 
are shown in bold. 
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Accession 
Number 
Log2 FC P-Value Protein 
P62805 92.70 1.41E-04 Histone H4 
P16401 96.40 4.06E-04 Histone H1.5  
Q96KK5 81.80 2.20E-03 Histone H2A type 1-H 
O75367 51.07 8.40E-03 Core histone macro-H2A.1 
P16403 63.93 0.0108 Histone H1.2 
K7EMV3 62.00 0.184 Histone H3 
P57053 51.73 0.184 Histone H2B type F-S 
P0C0S5 -237.50 0.413 Histone H2A.Z 
C9JBC2 11.20 0.423 Histone deacetylase 7 
K7EQB9 -4.43 0.423 Histone-arginine methyltransferase CARM1 
P06899 28.67 0.423 Histone H2B type 1-J 
Q7KZ85 -24.97 0.423 Transcription elongation factor SPT6  
Q86TU7 -12.27 0.423 Histone-lysine N-methyltransferase setd3 
Q9H7B4 -3300.00 0.423 Histone-lysine N-methyltransferase SMYD3 
Q09028 22.73 0.457 Histone-binding protein RBBP4  
P07305 10.33 0.485 Histone H1.0 
B3KRS5 25.43 0.606 Histone deacetylase 
Q92522 5.57 0.778 Histone H1x 
Q8WTS6 3.43 0.835 Histone-lysine N-methyltransferase SETD7 
Q13547 -9.57 0.890 Histone deacetylase 1 (HD1) 
 
Table 3.8. Histone related protein change after IL-1β stimulation in nHBECs 
Effect of IL-1β (1ng/ml) on the expression of histone and histone-related proteins. Log2 FC compared to IL-1β stimulation alone. 
Proteins are ranked according to significance (raw p-value).     
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Accession 
Number 
Log2 FC p-value Protein 
P05161 -41.40 0.0042 Ubiquitin-like protein ISG15 
B4DXZ1 -49.47 0.0088 Asparagine synthetase 
B4DLR8 -81.70 0.0118 NAD(P)H dehydrogenase 
Q9Y617 -20.77 0.0176 Phosphoserine aminotransferas 
Q9ULC3 -28.40 0.0206 Ras-related protein Rab-23 
O00116 -48.10 0.0216 Alkyldihydroxyacetonephosphate synthase 
Q03169 -39.50 0.0220 Tumor necrosis factor alpha-induced protein 2 
P47989 -56.70 0.0279 Xanthine dehydrogenase/oxidase 
A8KA84 -32.53 0.0350 NA 
Q53GA4 -37.43 0.0382 Pleckstrin homology-like domain family A member 2 
Q96AZ6 -36.93 0.0390 Interferon-stimulated gene 20 kDa protein 
P29373 -40.70 0.0436 Cellular retinoic acid-binding protein 2 
O14879 -46.30 0.0442 Interferon-induced protein with tetratricopeptide repeats 3 
Table 3.9. Protein change after FP treatment and IL-1β stimulation in nHBECs 
Effect of fluticasone propionate (10-8M) pre-treatment for 2hrs on IL-1β stimulated protein expression. Log2 FC compared to IL-1β 
stimulation alone. Proteins are ranked according to significance (raw p-value).   
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Accession 
Number Log2 FC P-Value Protein 
C9JBC2 -33.00 0.423 Histone deacetylase 7 (Fragment) 
Q9H7B4 -33.00 0.423 Histone-lysine N-methyltransferase SMYD3 
Q8WTS6 -20.27 0.248 Histone-lysine N-methyltransferase SETD7 
Q09028 -14.77 0.203 Histone-binding protein RBBP4 
Q7KZ85 -14.50 0.423 Transcription elongation factor SPT6 
P0C0S5 -14.43 0.595 Histone H2A.Z (H2A/z) 
Q86TU7 -11.77 0.423 Histone-lysine N-methyltransferase setd3 
K7EQB9 -11.20 0.423 Histone-arginine methyltransferase CARM1 (Fragment) 
P07305 -9.43 0.534 Histone H1.0 
B3KRS5 -5.33 0.727 Histone deacetylase (EC 3.5.1.98) 
Q92522 -3.60 0.802 Histone H1x 
P62805 -2.17 0.639 Histone H4 
P06899 -0.20 0.423 Histone H2B type 1-J (Histone H2B.1) (Histone H2B.r) (H2B/r) 
K7EMV3 -0.17 0.943 Histone H3 
Table 3.10. Histone related protein change after FP treatment and IL-1β stimulation in nHBECs 
Effect of fluticasone propionate (10-8M) pre-treatment for 2hrs on IL-1β stimulated histone and histone-related protein expression. 
Log2 FC compared to IL-1β stimulation alone. Proteins are ranked according to decrease in Log FC. 
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3.3.3 Histone modifications in normal human bronchial 
epithelial cells (nHBECs) 
To investigate the effects of stimulation and CS on global histone 
modifications in nHBECs, cells were stimulated with IL-1β (1ng/ml) in the 
presence or absence of 10-8M FP and all results were normalised to total cell 
histone 3 content to minimise any variability between histone quantities in 
each sample on a multiplex ELISA (Figure 3.1A). The effect of IL-1β and FP 
on cell function was demonstrated by measuring the ability of FP to supress 
IL-1β-induced CXCL8 expression (Figure 3.1B). There were no significant 
changes in total cellular histone 3 pan-acetylation (Figure 3.1C, ANOVA 
p=0.80), H3K9ac (Figure 3.1D, ANOVA p=0.53), H3K27ac (Figure 3.1E, 
ANOVA p=0.82), H3K56ac (Figure 3.1F, ANOVA p=0.57), H3K4me3 (Figure 
3.1G, ANOVA p=0.73), H3K9me2 (Figure 3.1H, ANOVA p=0.50), H3K9me3 
(Figure 3.1I, ANOVA p=0.76), H3K27me2 (Figure 3.1J, ANOVA p=0.59), 
H3K27me3 (Figure 3.1K, ANOVA p=0.87), H3T11ph (Figure 3.1H, ANOVA 
p=0.86) at 24hrs.  The limit of quantitation for this assay is ~25 Relative Units 
(RU of luminance) and so only the trend for IL-1β to enhance pan-acetylation, 
H3K4me3, H3K9me3 and H3K27me2 have any validity. 
Though the investigation into global histone modifications has shown no gross 
changes it is possible that there will be modifications which both increase and 
decrease across the genome, causing a zero net sum. When studying global 
changes this would not show, but could account for changes in gene 
expression.  
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Figure 3.1. Histone Modifications after FP treatment and IL-1β 
stimulation in nHBECs  
Measure of global histone modifications in normal human bronchial epithelial 
cells (nHBECs). RU – Relative Units. nHBECs were treated with 10-8M 
fluticasone propionate (FP) for two hours and then stimulated with IL-1β 
(1ng/ml) for 24 hours. Histones were purified, measured on a histone 
multiplex ELISA, and the values were normalised to total H3 and had 
background readings removed. The supernatant was assayed for levels of 
CXCL8 by ELISA.  Results are expressed as mean±SEM of n=4 independent 
experiments, *p<0.05 compared with unstimulated cells with one way ANOVA 
and Dunn’s multiple comparison. 
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3.3.4 Effects of epigenetic probes on normal Human 
Bronchial Epithelial Cell responses 
To investigate the functional role of histone modifying enzymes a variety of 
compounds which specifically limit the ability of histone modifying enzymes to 
elicit downstream functional responses were used.  The model was an IL-1β-
stimulated model of airway inflammation using Beas2B cells. This will show 
the targets importance in inflammation and proliferation, key aspects of the 
asthmatic phenotype.  
3.3.4.1 Bromodomain Targeting Probes 
As detailed in the Introduction (Section 1.8.1.1), bromodomain-containing 
proteins are able to bind to and read specific acetylated lysines resulting in 
activation of cellular function.  These effects of histone acetylation can be 
attenuated by bromodomain mimics such as bromosporine, JQ1, GSK2801 & 
SGC-CBP30 and may demonstrate anti-inflammatory effects.   
3.3.4.1.1 Bromosporine 
Bromosporine shows a concentration-dependant inhibition of IL-1β-induced 
IL-6 release which reaches significance at 568nM (20.7±4.6% stimulated 
release, P<0.05) with an IC50 = 61.2±1.2nM and a maximal suppression 
(Imax) = 93.4±2.1% (Figure 3.2A). There is also a large significant reduction 
in IL-1β-induced CXCL8 release at concentrations >142nM (43.6±13.1% 
stimulated release, P<0.05)(Figure 3.2B) with an IC50 = 74.9±1.3nm and an 
Imax = 98.7±0.5%. There was no significant effect on Mitochondrial activity as 
a proxy for viability (Figure 3.2C), however, there was a concentration-
dependent decrease in cell proliferation as measured by the BrdU assay 
(Figure 3.2D).  This reached significance at 4096nM with an IC50 of 
335±1.7nM and an Imax = 89.1±9.6% (Table 3.11). 
3.3.4.1.2 JQ1 
JQ1(+) significantly decreased IL-1β-induced IL-6 release with an IC50 of 
152.9±1.4nM and Imax =86.9±8.1% (Figure 3.3A).  There was a strong 
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negative trend towards suppression of IL-1β-induced CXCL8 release although 
this did not reach significance despite almost complete inhibition of CXCL8 
release (Figure 3.3B).  JQ1(+) had no significant effect on mitochondrial 
activity as a proxy for viability (Figure 3.3C) or on cell proliferation (Figure 
3.3D). 
The negative enantiomer JQ1(-) had no significant effect on IL-1β-induced IL-
6 or CXCL8 release.  However, JQ1(-) increased cell mitochondrial activity as 
measured by MTT assay (EC50 of 327±1.3nM and Emax =122±13.5% (Table 
3.11).   
3.3.4.1.3 GSK2801 & SGC-CBP30 
GSK2801 no significant effect on either cell proliferation or inflammation whilst 
SGC-CBP30 had no significant effect on IL-1β-induced IL-6 or CXCL8 release 
(Figure 3.4 A & B).  SGC-CBP30 also had no effect on mitochondrial activity 
as a proxy for viability (Figure 3.4C) although it significantly decreased cell 
proliferation (IC50 of 21.0±1.1nM, Imax = 100±0%) (Figure 3.4D) (Table 3.11).   
3.3.4.2 Histone Methyl-transferase Inhibitors  
UNC0638, UNC0642, UNC1999, PFI-2 and GSK343 had no significant effects 
on the release of IL-1β-induced inflammatory mediators, cell proliferation or on 
mitochondrial activity as a proxy for viability (Table 3.11). 
3.3.4.3 Lysine Demethylases Inhibitors 
3.3.4.3.1 GSK-J1 
GSK-J1 significantly increased IL-1β-induced IL-6 release at its highest 
concentrations (EC50 = 108.8±1.3nM, Emax =638±228%, P<0.05).  These 
concentrations did not affect cell viability but significantly reduced cell 
proliferation (IC50 = 56.48±1.1nM, Imax = 100±0%)(Table 3.11).    
3.3.4.3.2 GSK-J4 + GSK-J5 
GSK-J4 had no effect on IL-1β-induced IL-6 or CXCL8 release.  However it 
potently suppressed cell proliferation (IC50 of 5.86±1.1nM, Imax = 100±0%, 
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P<0.05) and cell viability (IC50 = 22.35±1.1nM, Imax = 77.2±12.1%, P<0.05).  
The only effect of GSK-J5 was to enhance IL-1β-induced IL-6 release by up to 
31.4±58.9% with an EC50 of 1788±3.9nM (Table 3.11).   
 
Figure 3.2. Bromosporine concentration-response on IL-1β stimulated 
Beas2B Cells 
Concentration-dependent effect of bromosporine on IL-1β stimulated Beas2B 
cells.  Cells were pre-treated with bromosporine (0–4096nM) for 2 hours 
before being stimulated with IL-1β (1ng/ml) for 24 hours. Graphs show IL-1β-
induced IL-6 (A) and CXCL8 (B) release, MTT viability assay (C) and a BrdU 
cell proliferation assay (D). IL-6 and CXCL8 release are normalised to 
stimulated, MTT and Cell proliferation are normalised to unstimulated. Data 
are presented as mean ± SEM of n=4 independent experiments, *p<0.05 
compared to IL-1β stimulated cells with one way ANOVA and Dunn’s multiple 
comparison.  
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Figure 3.3. JQ1(+) concentration-response on IL-1β stimulated Beas2B 
Cells 
Concentration-dependent effect of JQ1(+) on IL-1β stimulated Beas2B cells.  
Cells were pre-treated with JQ1(+) (0-1024nM) for 2 hours before being 
stimulated with IL-1β (1ng/ml) for 24 hours.  Graphs show IL-1β-induced IL-6 
(A) and CXCL8 (B) release, MTT viability assay (C) and a BrdU cell 
proliferation assay (D). IL-6 and CXCL8 release are normalised to stimulated, 
MTT and Cell proliferation are normalised to unstimulated.  Data are 
presented as mean ± SEM of n=4 independent experiments, *p<0.05, 
**p<0.01 compared to IL-1β stimulated cells with one way ANOVA and Dunn’s 
multiple comparison. 
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Figure 3.4. SGC-CBP30 concentration-response on IL-1β stimulated 
Beas2B Cells 
Concentration-dependent effect of SGC-CBP30 on IL-1β stimulated Beas2B 
cells.  Cells were pre-treated with SGC-CBP30 (0-1024nM) for 2 hours before 
being stimulated with IL-1β (1ng/ml) for 24 hours.  Graphs show IL-1β-
induced IL-6 (A) and CXCL8 (B) release, MTT viability assay (C) and a BrdU 
cell proliferation assay (D). IL-6 and CXCL8 release are normalised to 
stimulated, MTT and Cell proliferation are normalised to unstimulated.  Data 
are presented as mean ± SEM of n=3 independent experiments, *p<0.05 
compared to IL-1β stimulated cells with one way ANOVA and Dunn’s multiple 
comparison. 
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Probe Target IL-1β  induced IL-6 Release IL-1β  induced CXCL8 Release Effect on proliferation Effect on MTT 
Bromosporine BRD4 + CBP 
IC50 = 61.2±1.2nM 
Imax = 93.4±2.1% 
IC50 = 74.9±1.3nM 
Imax = 98.7±0.5% 
IC50 = 335±1.7nM 
Imax = 89.1±9.6% 
NA 
JQ1(+) BrdT + Brd4 
IC50 = 152.9±1.4nM 
Imax = 92.6±4.1% 
IC50 = 50.7±1.6nM 
Imax = 86.9±8.1% 
NA NA 
JQ1(-) JQ1(+)Control NA NA 
EC50 = 327±1.3nM 
Emax = 122±13.5% 
NA 
SGC-CBP30 CBP/p300 NA NA 
IC50 = 21.0±1.1nM 
Imax = 100±0% 
NA 
UNC0638 G9a probe NA NA NA NA 
UNC0642 G9a/GLP Probe NA NA NA NA 
UNC1999 EZH2/1 Probe NA NA NA NA 
GSK343 EZH2 Probe NA NA NA NA 
GSK2801 BAZ2B/A NA NA NA NA 
GSK-J1 JMJD3 Probe 
EC50 = 108.8±1.3nM 
Emax = 634±228% 
IC50 = 26.87±10^25nM 
Imax = 26±50% 
IC50 = 56.48±1.1nM 
Imax = 100±0 
NA 
GSK-J4 J1 Pro-drug NA NA 
IC50 = 5.86±1.1nM 
Imax = 100±0% 
IC50 = 22.35±1.1nM 
Imax = 77.2±12.1% 
GSK-J5 GSK-4 Control 
EC50 = 1788±3.9nM 
Emax = 31.4±58.9% 
NA NA NA 
PFI-2 SETD7 Probe NA NA NA NA 
Table 3.11. Epigenetic probe concentration-response summary 
Summary table of epigenetic probe effects on IL-1β treated Beas2B cell function ± = SEM.   
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3.4 Discussion 
This chapter started by leveraging existing data sets from UBIOPRED 
epithelial brushings and airways biopsies to measure the differences in gene 
expression. The data showed there were significant changes in Histone 
Clusters between severe asthmatics and healthy patients. Proteomics of 
HBECS treated with FP significantly changed the expression of 13 proteins, 
however HDAC7 and SETD7 proteins with histone modifying properties had 
large decreases in mean log2 FC. To try to measure post-translational 
changes to histones after FP treatment global histone modification 
measurements were carried out in nHBECs, but no global changes were 
found.  Finally, to see if epigenome modifying proteins were able to control the 
inflammatory profile of epithelial cells, Beas2B cells were treated with a 
selection of probes. JQ1+, a Brd4 inhibitor was shown to reduce IL-6 and 
CXCL8 release and SGC-CBP30 the selective mimetic for CBP and p300 
transcription factors was shown to reduce epithelial proliferation without 
effecting viability. 
3.4.1 U-BIOPRED Brushing and Bronchial biopsy Data 
The U-BIOPRED data has been collected from a large cohort of stable 
patients with differing severity of disease (Shaw et al. 2015) with no 
exogenous activation.  This gives it great power to investigate changes in 
gene expression profiles particularly of those genes relating to histone 
modification and histones themselves.  
 
Bronchial brushings will collect mainly epithelial cells rather than the mixed 
cellular profile seen in bronchial biopsies which includes epithelial, smooth 
muscle, mucus and inflammatory cells along with cartilage and fibrocytes 
(Labont et al. 2008).  Bronchial brushings may be expected, therefore, to 
demonstrate greater numbers of significantly differentially expressed genes 
(DEGs) reflecting disease severity as the results are not contaminated or 
diluted by other cell types. Indeed, in this study we do see a greater number of 
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significant DEGS related to histones and histone modifications than we 
observed in the bronchial biopsies.  
 
There were changes in histone expression and the ability to collect cells and 
carry out experiments on isolated cells made the bronchial epithelium a good 
candidate for this study. The most commonly changed set of genes in 
bronchial brushings appears to be the Histone Cluster 1 including genes H1E, 
H2BK and H2BJ from a large cluster of histone encoding genes on 
chromosome 6 (Albig et al. 1997). However the fold changes were low so this 
data must be treated caustiously. Histone H1 has a role in maintaining higher 
order chromatin structure whilst H2a, H2b, H3 and H4 to bind to form 
nucleosomes (Marion & Roux 1980; Davey et al. 2002; Luger et al. 1997).  
These variants of the Histone H1 have differing affinities to DNA (De et al. 
2002), and have different purposes depending on the stage of development 
(Pan & Fan 2016). H1 isoforms can differentially inhibit DNA replication 
through an affinity for chromatin mediated by their modified carboxyl-terminal 
domains (Halmer & Gruss 1996; Sun et al. 2015). 
When comparing bronchial brushings of healthy subjects to severe asthmatics 
we see that H1E is downregulated whilst H2bk and H2bj are upregulated. 
H2bj is also increased in bronchial brushings of severe asthmatics compared 
to non-severe asthma implicating it has a role more exclusively in severe 
asthma. This may suggest that the chromatin structure in severe asthmatics is 
more open than in healthy subjects allowing for increased expression of 
inflammatory genes. 
H2bk is also increased in bronchial biopsies between healthy subjects and 
severe asthmatics but the change is smaller than that observed in the 
bronchial brushings.  Epithelial cells are the most common cell type collected 
in biopsies and this maybe the reason that there is a similar but reduced 
effect. 
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3.4.2 SILAC Analysis 
SILAC analysis data was used to explore the protein expression of histone 
modifying proteins in epithelial cells. The SILAC data was obtained using 
epithelial cells from healthy subjects only and does not have the fidelity to 
differentiate between post-translationally modified proteins, such as 
phosphorylation, methylation and acetylation of histones.  A limitation of this 
data when investigating epigenetic regulation is that we will only see 
increases/decreases in proteins which control the epigenetic process rather 
than the post-translational modifications of these proteins that regulate their 
activity.  It was important to take into account the amount of histone protein 
present as it may help to understand the subtypes present after certain 
treatments.  In addition, we only analysed the data at a single time-point (24 
hours) and a time-course study may have revealed other changes. 
 
Firstly, we observed a significant increase in Histone H1.5 protein after 
stimulation with IL-1β.  This protein is encoded by the HIST1H1B gene whose 
expression was not altered in bronchial brushings between asthmatics, 
irrespective of severity, and healthy volunteers.  This follows expectation as 
IL-1β is not known to be a key mediator in all asthmatics.  However, recent 
evidence indicates that asthmatics with a neutrophilic subtype of asthma have 
enhanced expression of IL-1β associated with increased inflammasome 
activity (Simpson et al. 2014).  Subsequent studies will be needed to 
determine any link with neutrophilic asthma.  In contrast, we observed a 
decrease in H1e mRNA expression in severe asthma bronchial brushings.  
The failure to see an effect of IL-1β on the expression of this protein may 
indicate the need an assay with higher sensitivity or for a different cell 
challenge such as IL-13 or IL-33, the need to perform additional time-course 
studies or that the altered transcription of these proteins is not reflected in 
differences in protein expression. 
 
When IL-1β stimulated cells were treated with FP no significant changes of 
histone or epigenetic regulating proteins were discerned. There was a very 
118 
 
 118 
high negative fold change for the genes encoding HDAC7, SMYD3, and 
SETD7, a histone deacetylase, and two H3K4 histone methyltransferase 
however without significance at these n numbers. Two genes involved in viral 
responses are also downregulated in CS treated cells; Ubiquitin-like protein 
ISG15 (Ea & Baltimore 2009; Yang et al. 2009) and Interferon-stimulated 
gene 20 kDa protein (Zhou et al. 2012).  
3.4.3 Global Histone Modifications 
To give higher fidelity to the pre-existing SILAC data with regards histone 
modifications after FP treatment an investigation into global histone 
modifications was carried out.  There was a small non-significant decrease in 
total H3 protein after FP treatment which reflects the non-significant decrease 
in histone proteins seen in the SILAC studies. There is also a contradiction 
between the histone modification data and the SILAC data where the SILAC 
data shows a log2 FC increase of 62 of Histone 3, the ELISA shows no 
change. Whether this is because of the low levels of collected histones in the 
ELISA or due to an error in reading of the protein in SILAC it is unclear. There 
is also no real positive control that the FP is having an effect in that the 
CXCL8 ELISA doesn’t show FP creating a significant decrease, just a trend 
downwards. 
3.4.4 Epigenetic Probes  
A selection of drugs which target various epigenetic mechanisms were tested 
to see the effect they had on proliferation and release of inflammatory 
markers. The bromodomain inhibitors bromosporine and JQ1(+) both inhibited 
IL-1β-induced IL-6 and CXCL8 release from Beas2B cells.  Bromosporine is a 
very broad spectrum bromodomain inhibitor and acts on BRD2, BRD3, BRD4, 
BRDT, TAF1 and CECR2 (Picaud et al. 2016) whereas JQ1(+) is more 
specific targeting Brd2, Brd3 and Brd4 with a 10 fold specificity over other 
BET proteins (Filippakopoulos et al. 2010). Despite the difference in specificity 
they seem to have similar efficacy in terms of inhibition indicating that BRD2, -
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3 and -4 are more critical for IL-1β-induced IL-6 and CXCL8 expression.  
Although demonstrating potent anti-inflammatory effects, these compounds 
may be too non-specific to use as a treatment in patients where other options 
are available.  
 
SGC-CBP30 is selective for the CBP/p300 transcription factors which also 
contain bromodomains but does not inhibit IL-1β-induced IL-6 or CXCL8 
release from epithelial cells.  However, it was able to halt epithelial cell 
proliferation.  Previous studies indicate that SGC-CBP30 modulates regulatory 
T-cells (Ghosh et al. 2016) and Th17 cells (Hammitzsch et al. 2015) by 
specifically inhibiting CBP/p300 which has a downstream effect on the FOXP3 
gene.  FOXP3+ T-cells promote epithelial proliferation (Mock et al. 2014) 
which is the opposite to the direct effect of SGC-CBP30 in epithelial cells 
reported here.  This may however, point to common endogenous agonist for 
CBP/p300 that has a role in epithelial cell proliferation which maybe important 
for asthma as epithelial cell proliferation contributes to airway remodelling 
(Cohen et al. 2007).  In vivo studies in mice may help to delineate whether the 
effects of SGC-CBP30 on epithelial cells or Treg cells are of greater 
importance in severe asthma. 
 
3.5 Conclusion and Next steps 
There was no change in expression of epigenome regulating proteins in the 
U-BIOPRED data in severely asthmatic patients, however there was changes 
of Histone Cluster 1 genes. This could suggest changes in affinity to histones 
to DNA and account for changes in expression.  
The expression of SETD7, SMYD3 and HDAC7 decreased following FP 
treatment, but not significantly, suggesting a power issue where an increase 
in n number could show these to be important. However there was no 
significant changes in the histones or the modifications that these proteins 
modify at the global level.  Longer time-course studies may reveal whether 
there is a functional consequence of these protein expression changes. 
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Some epigenetic probes did demonstrate changes to inflammatory protein 
release such as bromosporine and JQ1.  Proliferation of the bronchial 
epithelium was attenuated by SGC-CBP30 suggesting that there is a role for 
these proteins in inflammation and so potentially a role in asthmatic 
inflammation as well. 
The intention was to follow up these studies with a more accurate genome-
wide assessment of the differences in histone modifications, specifically H3K4 
me3 because of the change in expression of SETD7 and SMYD3, H3K27me3 
and H3K27ac because of their broader roles, in bronchial epithelial cells from 
severe and non-severe asthmatics to elucidate the detail rather than global 
changes.  This would have been carried out by Chromatin Immuno-
precipitation-Sequencing (ChIP-Seq) analysis combined with gene arrays to 
study the correlation between these modifications and gene expression. It 
would be important to follow these studies up in primary asthmatic cells, 
especially for the probes that showed an effect.  However, due to difficulties 
with recruitment of patients and issues concerning primary cell culture and the 
need from large numbers of cells it was considered not viable to perform this 
part of the study.  As there are a number of papers implicating CD8+ T-cells 
as playing a role in severe asthma and the relative ease of access of blood 
cells, I decided to analyse differences in gene expression profiles in these 
cells and the effect of epigenetic probes/mimics on CD8+ cell function and 
whether there were differences depending on asthma severity.  The 
remainder of the thesis describes these analyses. 
 
Histone molecules were shown to change expression in the U-BIOPRED 
datasets, however there was no significant change in the expression of other 
epigenome modifying proteins genes leaving me to reject this element of the 
hypotesis that bronchial brushings and biopsies would change expression of 
these proteins between Asthma disease states.  
 
There appeared to a no large significant changes in protein expression of 
epigenome modifiying proteins following glucocorticosteroid treatment of 
121 
 
 121 
nHBE cells in the SILAC study, though there was large fold changes of some 
genes of interest they were not significant, perhaps indicating a power issue. 
Currenty I have to reject the element of the hypothesis suggesting GCSs 
affect the expression of epigenetic tags/enzymes in proteomic examinations 
of bronchial epithelium. 
 
The effect of epigenetic probes bromosporine and JQ1 were able to affect 
release of inflammatory proteins from Bronchial Epithelial cell lines and may 
have the power to minimise asthmatic inflammation so this element of the 
hypothesis can be accepted. 
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Chapter 4: CD8+ T-Cell 
Transcriptome in 
Asthma 
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4.1 Chapter Introduction 
Although CD4+ T-cells are considered, canonically, to be a driving force in 
asthma it has been demonstrated that CD8+ T-cells also play a role. CD8+ T-
cells primarily target and destroy virus-infected cells and cancerous cells by 
recognising non-self antigens on cell membranes and when activated release 
oxidative and cytotoxic compounds (Jenne & Tschopp 1988), activate cell 
death pathways (Hildeman et al. 2003) within the infected cells, and 
encouraging the proliferation of other CD8+ T-cells (Whitmire et al. 2005). 
 
CD8+ T-cells show an increased production of IL-4 and IL-13 in the peripheral 
blood of asthmatics (Zhao et al. 2011; MacHura et al. 2010). These Th2 
cytokines promote asthmatic processes and CD8+ T-cells may continue to 
release these cytokines after migration to the lungs. CD8+ T-cells have also 
been shown to suppress IgE production in healthy volunteers but not in 
severe asthmatics indicating these cells fail to regulate allergic asthma (Lee et 
al. 1997). 
 
There is no difference between the number of circulating CD8+ T-cells or 
CD4+ T-cells in severe asthmatics, non-severe asthmatics or healthy subjects 
(Tsitsiou et al. 2012).  CD4+ T-cells from severe subjects only expressed 40 
significantly upregulated genes compared to cells from healthy asthmatics 
and no significantly downregulated genes.  In comparison, CD8+ T-cells 
showed 1359 upregulated genes and 207 downregulated genes in a similar 
comparison (Tsitsiou et al. 2012). These differences in CD8+ T-cell gene 
expression were not present between healthy volunteers and non-severe 
asthmatics, indicating that severity is strongly linked to these changes. 
Analysis by Tsitsou and colleagues demonstrated no clear abnormal 
pathways and the data may benefit from unbiased pathway analysis such as 
Weighted Gene Connectivity Network Analysis (WGCNA). 
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As described in Methods and Materials (Section 2.7.1.5), WGCNA is used to 
analyse large gene sets to find sets of genes whose changes in expression 
are linked and does not discriminate against small increases or decreases.  
For example, small FC that go either slightly up or slightly down a similar 
amount in each subject can imply a pathway(s) working together. These 
results can then be linked to a clinical measurement such as percent 
predicted of Forced expiratory volume in 1 second (FEV1 % predicted). 
 
4.2 Chapter Hypothesis and Aims 
WGCNA, in conjunction with standard bioinformatic pathways analysis, will 
reveal a greater description of the activated/repressed pathways in CD8+ T-
cells from severe and non-severe asthmatics.  Analysis of these changes in a 
new cohort of patients will validate the approach and show novel pathways 
specific for CD8+ T-cells in severe asthma. 
 
This hypothesis will be tested by examining whether: 
• Analysis of pre-existing PBMC’s transcriptomics in severe asthmatics , 
non-severe asthmatics and healthy patients show differentially 
expressed genes, 
• There is a difference between CD8+ T-cell gene expression profiles 
using FDR and FC in a new cohort of severe and non-severe 
asthmatics, 
• WGCNA analysis can find networks of genes that contribute to an 
altered function in CD8+ T-cells, and whether 
• These networks can be validated in a previous study cohort which 
showed a change in CD8+ T-cell expression in severe asthmatics. 
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4.3 Results 
4.3.1 Investigation of gene expression in peripheral blood 
mononuclear cell in the U-BIOPRED cohort 
 
The U-BIOPRED consortium collected and analysed circulating mononuclear 
cells from 246 non-smoking severe asthmatics (SAn), 77 non-severe, non-
smoking asthmatics (NSA) and 87 non-asthmatic healthy volunteers (NHV) 
using gene array, DEGs were identified by ANOVA, including covariates for 
RNA quality, gender, and clinical site. This data has been tabulated to show 
top FC and FDR (log2 FC >2, FDR p-value ≤ 0.05). 
 
The data shows no significant differences between NHV and NSA in this strict 
selection criteria however, the data shows five genes which fit this criterion 
when comparing SAn and NHV (Table 4.1) which include all three genes 
shown in SAn vs. NSA (Table 4.2). The three strongly differentially expressed 
genes (DEGs) in both comparisons were defensin alpha 4, olfactomedin 4 
and matrix metallopeptidase 8 (MMP8).  Defensin alpha 4 showed a 2.34 log2 
FC with a FDR of 3.38E-06 when comparing SAn to NHV and a 2.08 log2 FC 
(FDR = 3.70E-06) when comparing SAn and NSA. Olfactomedin 4 showed a 
2.34 log2 FC (FDR = 5.05E-05) when comparing SAn to NHV and a 2.06 log2 
FC (FDR = 0.0023) when comparing SAn and NSA. MMP8 showed a 2.13 
log2 FC (FDR = 4.98E-05) when comparing SAn to NHV and a 2.12 log2 FC 
(FDR = 6.46E-05) when comparing SAn and NSA. This data demonstrates 
that without some level of selection for peripheral blood mononuclear cells 
only limited changes are detectable.  
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Table 4.1. DEG in Peripheral Mononuclear Cells – Severe Asthmatics vs. Healthy Subjects 
Differentially expressed genes (DEGs) in peripheral mononuclear cells of severe asthmatics vs healthy subjects.  Genes which 
show a FDR P<0.05 and log2 FC of <2. FC – fold-change, FDR – adjusted p-value. 
 
 
Severe vs Non-Severe 
Asthma log2 FC 
Severe vs Non-Severe 
Asthma   Raw p-value 
Severe vs Non-Severe 
Asthma  FDR Gene Symbol Gene Title 
2.0751 9.73E-07 0.0005 DEFA4 Defensin Alpha 4 
2.0571 1.76E-05 0.0023 OLFM4 Olfactomedin 4 
2.1231 1.48E-08 6.46E-05 MMP8 Matrix Metallopeptidase 8 
Table 4.2. DEG in Peripheral Mononuclear Cells – Severe vs. Moderate Asthmatics 
Differentially expressed genes (DEGs) in peripheral mononuclear cells of severe non-smoking asthmatics vs non-severe 
asthmatics.  Genes which show a FDR P<0.05. log2 FC – fold-change, FDR – adjusted p-value. 
  
Severe Asthma vs 
Healthy log2 FC 
Severe Asthma vs 
Healthy Raw p-Value 
Severe Asthma vs 
Healthy FDR 
Gene 
Symbol Gene Title 
2.1454 8.21E-09 3.70E-06 LTF Lactotransferrin 
2.2586 6.10E-09 3.16E-06 CEACAM8 Carcinoembryonic Antigen Related Cell Adhesion Molecule 8 
2.3441 7.16E-09 3.38E-06 DEFA4 Defensin Alpha 4 
2.3071 4.51E-07 5.05E-05 OLFM4 Olfactomedin 4 
2.1334 6.81E-09 4.98E-05 MMP8 Matrix Metallopeptidase 8 
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4.3.2 CD8+ T-Cell Isolation and Gene Array 
4.3.2.1 Patient Demographics 
To study the differences in severe and non-severe asthmatics CD8+ T-cell 
gene expression and histone modifications patients described in Table 4.3  
were recruited to give blood. The demographics are slightly skewed towards 
females and subjects were similar in age. FEV1 % predicted is lower in severe 
patients but this was not significant (Difference 7.26%, p=0.63).  Furthermore, 
severe-asthmatics take more oral prednisolone (difference 5mg, p=0.080) and 
more inhaled steroids (FP equivalent mg difference 1800, p=0.066) than non-
severe asthmatics although again these did not reach significance.  The lack 
of significance may reflect the low number of patients studied in each group, 
an n=10 per group would show significance in Oral Corticosteroids with the 
current variance by Mann-Whitney Test.   
 
 Asthma severity   
 
Non-Severe Severe Difference p-value 
Sex (M:F) 2:3 1:6   
Age (Median, Range) 55 (39-68) 57 (40-69) 2 0.61 
FEV1 % predicted 
(Median, Range) 
81.11 
(71-89) 
73.85 
(32 - 112) 7.26 0.63 
FVC % predicted 
(Median, Range) 
90.05 
(78-95) 
95.65 
(67-120) 5.60 0.49 
FEV1/FVC 
(Median, Range) 
69.26 
(65-83) 
66.77 
(38-81) -2.49 0.43 
   
  
Oral Prednisolone 
(mg) (Median, Range) 0 (0-0) 5 (5-30) 5 0.080 
Inhaled FP equivalent 
(mg) (Median, Range) 
200 
(0-3200) 
2000 
(1000-3200) 1800 0.066 
Table 4.3. CD8+ T-cell patient demographics.  
FEV1 (Forced expiratory volume in 1 second), FVC (Forced Vital Capacity). p-
value calculated by Mann-Whitney Test  
128 
 
 128 
4.3.2.2 Flow Cytometry of CD8+ Enriched T-Cells. 
The efficacy of the enrichment of CD8+ T-cells from patient PBMCs using 
negative selection by magnetic beads (Section 2.6.4) was quantified using 
flow Cytometry (Section 2.7.1.7).  Using the gating strategy demonstrated in 
Figure 4.1 cells were 91.0±7.7% lymphocytes (mean±SD, Table 4.4) (Figure 
4.1A & B). Of these lymphocytes 65±11.5% (Table 4.4) were CD3+/CD8+ T-
cells with the gating selected based on visible populations (Figure 4.1C & D). 
This data shows a total of 59.1±12.5% (Table 4.4, samples excluded following 
PCA not shown) of all cells collected were CD3+/CD8+ T-cells. These cells 
were used for analysis of upregulated CD8+ T-cell pathways involved in 
severe asthma using gene array and ChIP-Seq.  
 
These enrichment scores are relatively poor because this FACS protocol was 
not correctly compensated to account for the interference between the FITC 
and the PE flurochrome. In previous studies using a FACS protocol with 
flurochromes which do not interfere and using the same isolation method as 
carried out above the purity of CD8+ T-cells was consistently around ~90%. 
An example of a correctly stained cells in a FACS plot is given in Figure 4.2. 
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Figure 4.1. FACS Gating Strategy for CD8+ T-cells.  
(A) shows gating for lymphocytes and monocytes pre-enrichment with (B) 
demonstrating the same gating post-enrichment. The cells from the 
Lymphocyte gate pre- (C) and post-enrichment (D). 
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Figure 4.2 FACS Gating Strategy for CD8+ T-cells from Tsitsiou, 2012 
(A) shows gating for lymphocytes and monocytes post-enrichment with (B) 
demonstrating the CD3/CD8 Stains. 
 
 
Severity Lymphocyte count (%/SD) 
CD3+/CD8+ Count 
(%/SD) 
Total CD3+/CD8+ 
Cells (%/SD) 
NS 1 95.9 82 78.6 
NS 2 93 56.4 52.5 
NS 3 93.2 78.9 73.5 
S 1 93 78 72.5 
S 2 94.3 61.2 57.7 
S 3 76.8 61.3 47.1 
S 4 79 56.7 44.8 
S 5 99.7 51 50.8 
S 6 93.8 59.1 55.4 
    All  91 / 7.7 65 / 11.47 59.1 / 12.47 
Non-Severe 94 / 1.6 72.4 / 13 68.2 / 8 
Severe  89.4 / 9.3 61.2 / 9.1 54.7 / 10 
 
Table 4.4. Enrichment of CD8+ T-cells  
Enrichment of CD8+ T-cells as counted by gating demonstrated in Figure 
4.1A and B for lymphocyte count and CD3+/CD8+ as demonstrated in Figure 
4.1C and D.  Data are shown for individual samples and for pooled data.  
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4.3.2.3 Gene Array 
RNA was extracted and reverse transcription and amplification was carried 
out as described in Methods Sections 2.7.1.1 to 2.7.1.4. The arrays were 
normalised using a robust multichip average method within Partek software.  
Figure 4.3  shows that the distribution of read intensity across all the arrays 
and between groups have been suitable normalised as the peaks overlay.  
 
Figure 4.3. Gene Array Read Frequency Plot for CD8+ T-cell  
Read frequency Plot for CD8+ T-cell blood samples run on gene array post-
normalisation. The data shows Non-Severe (Red, n = 3), the excluded Non-
Severe (Blue, n= 2) and Severe (Green, n = 6) comparing Frequency of reads 
of each value against each value read. 
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4.3.2.4 Principal Component Analysis 
Principal Component Analysis (PCA) is method to simplify multidimensional 
data to show its most variable elements in a few metrics and can be shown as 
a single three-dimensional image. Partek software takes all the variables 
(genes) and plots them against each other, ranks the genes by the amount 
they change and assembles the genes into groups of similar variability. The 3 
most variable groups are plotted by asthma severity on the PCA graph (Figure 
4.4). The top 3 PCA functions account for 53.2% of the gene variability. 
 
On the graph three outliers can be seen, while there was considerably fewer 
genes counted in two of them, it was decided to exclude all three as probable 
technical failures. This left array data from 6 SA and 3 NSA for further 
analysis. 
 
Once the data was selected Partek was used to draw up a list of genes 
showing high fold-change (FC), significant p-value and significant FDR value. 
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Figure 4.4. Gene Array Genes Detected and PCA 
Genes detected for CD8+ T-cell samples (A) by gene array and principal 
component analysis (B) plotting the same samples. Red shows non-severe 
asthmatic, Green shows severe asthmatic (one non-severe sample is 
obscured by a severe sample). Excluded outliers have red circles.  
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4.3.2.5 Differential Gene Expression 
There were 7 differentially expressed genes by FDR between severe and non-
severe asthmatics with a log2 FC of x>1.5 or x<-1.5. These genes are shown 
in Table 4.5. There are also some non-significant genes (by FDR) with high 
negative log2 FC which are shown in Table 4.6.  Genes in Table 4.7 are those 
with a high log2 FC.  These are paired with the gene ontology outputs from 
gProfiler to show related pathways derived from the literature.  The data 
shows significantly differentially expressed genes were associated with 
congenital disorder of glycosylation and immunodeficiency and the genes with 
high log2 FC included pathways such as response to bacteria. 
 
Gene Symbol log2 FC FDR p-value 
HIST1H1C -1.528 3.14E-02 
MAN2B2 1.790 3.81E-02 
SSB 1.573 4.01E-02 
GNB2L1 -1.655 4.28E-02 
LOC440280 1.702 4.32E-02 
TUBA1A 1.653 4.71E-02 
TAF15 2.130 4.73E-02 
Table 4.5. Significantly DEGs of CD8+ T-cells – NSA vs SA 
Differentially expressed genes (DEGs) of CD8+ T-cells from non-severe and 
severe asthmatics as calculated by Partek FDR p-value 0.05. FC>1.5, FC<-
1.5 FDR – false discovery rate, log2 FC – fold-change. 
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Gene Name log2 FC FDR p-value 
NDUFB8 -2.812 0.132 
GGA1 -2.652 0.350 
SFRS6 -2.632 0.180 
PSME4 -2.398 0.150 
LOC641814 -2.339 0.181 
LOC644250 -2.330 0.287 
CD81 -2.307 0.140 
SNHG3 -2.241 0.279 
LOC100130053 -2.237 0.222 
F2R -2.208 0.238 
LOC100132119 -2.116 0.120 
BLVRB -2.114 0.468 
ALG8 -2.107 0.409 
CNN2 -2.094 0.276 
LOC100129553 -2.077 0.303 
LOC651483 -2.057 0.104 
TRIM16L -2.048 0.254 
MX1 -2.047 0.247 
C14ORF85 -2.047 0.263 
LOC440027 -2.038 0.226 
LOC645899 -2.016 0.221 
Table 4.6.  Large negative FC DEGs of CD8+ T-cells – NSA vs SA 
Log2 fold-change (FC) <-2 differentially expressed genes of CD8+ T-cells from 
non-severe and severe asthmatics as calculated by Partek. FDR – false 
discovery rate adjusted p-value.  
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Column ID log2 FC FDR p-value  Column ID log2 FC FDR p-value 
DEFA1B 4.677 0.305  SNORD46 2.298 0.203 
MPO 4.213 0.258  SLC9A4 2.264 0.074 
JUN 4.129 0.085  C9ORF41 2.223 0.198 
ZFP36 3.639 0.078  MIR1974 2.200 0.339 
FAM177A1 3.122 0.155  SAT1 2.182 0.209 
DEFA3 3.084 0.465  C9ORF80 2.181 0.228 
DEFA1 3.061 0.466  STK36 2.161 0.133 
C6ORF48 2.979 0.316  C6ORF111 2.157 0.139 
CAMP 2.803 0.336  TAF15 2.131 0.047 
JUND 2.778 0.054  DAZAP2 2.122 0.092 
BMS1P5 2.726 0.254  RPL18 2.113 0.235 
DDIT4 2.694 0.085  ARHGAP21 2.107 0.197 
HDC 2.652 0.455  CDC2L2 2.093 0.141 
PRR14 2.577 0.075  HNRNPA3 2.084 0.302 
EGR1 2.553 0.403  ZNF91 2.057 0.127 
GCA 2.543 0.330  FOS 2.051 0.274 
DUSP1 2.483 0.145  PARP1 2.031 0.143 
CTSG 2.481 0.372  CBX5 2.020 0.087 
RSL24D1 2.392 0.107  OAZ1 2.010 0.075 
SDF2L1 2.378 0.071  SRRM2 2.006 0.075 
LASP1 2.001 0.096      
 
Table 4.7. Large Positive FC DEGs of CD8+ T-cells – NSA vs SA  
Log2 FC>2 differentially expressed genes (DEGs) of CD8+ T-cells from Non-
Severe and Severe asthmatics as calculated by Partek. FDR – false discovery 
rate adjusted p-value.  
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4.3.2.6 PCR Confirmation 
PCR was performed on several genes highlighted as being of interest by the 
gene array for confirmation of large positive fold change genes including those 
which represent key groups including anti-bacterial genes (MPO and 
DEFA1B), corticosteroid reactive genes (DUSP1) and one gene from the 
group involving mRNA stablility (ZFP36). There was a good correlation 
between the gene array data and the RT-qPCR data for almost all genes 
studied (Figure 4.5). The only gene which trended differently was MPO 
(Figure 4.5A&B).  DEFA1B (Figure 4.5C&D), ZFP36 (Figure 4.5E&F) and 
DUSP1 (Figure 4.5G&H) were all expressed similarly according to array and 
PCR data. 
 
4.3.2.7 Cross-Study Confirmation 
Comparing the data from the Tsitsiou 2012 paper, stored online at GEO 
(GSE31773), and the gene arrays performed here, there was a strong 
correlation in expression levels between genes such as HIST1H1C (Figure 
4.6A&B), ZFP36 (Figure 4.6C&D), DUSP1 (Figure 4.6E&F) & CD81 (Figure 
4.6G&H), but not GGA1(Figure 4.6H&I). 
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Figure 4.5. PCR/Gene Array Confirmation 
PCR results compared with gene array data for MPO (A & B), DEFA1B (C & 
D), ZFP36 (E & F) and DUSP1 (G & H). * = p<0.05, ** = p<0.01 by Mann-
Whitney Test.  GA – gene array. AUI = Arbitrary Units of Intensity 
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Figure 4.6. Gene Array/Tsitsiou Gene Array Comparison 
CD8+ T-cell gene array confirmation of non-severe and severe asthmatics from Tsitsiou Dataset (Bottom panel, ET) downloaded 
from GEO (GSE31773) compared to CD8+ T-cell data collected in this thesis (Top panel). HIST1 (A & B), ZFP36 (C & D), DUSP1 
(E & F) CD81 (G & H) and GGA1 (I & J). * = p<0.05, ** = p<0.01 by Mann-Whitney Test.  GA – gene array. AUI = Arbitrary Units of 
Intensity
Non-Severe Severe
6
7
8
9
10
11
AU
I
ZFP36 GA
**
Non-Severe Severe
6
7
8
9
10
11
AU
I
ZFP36 ET GA
****
Non-Severe Severe
6
7
8
9
10
AU
I
DUSP1 GA
*
Non-Severe Severe
7
8
9
10
11
AU
I
DUSP1 ET GA
Non-Severe Severe
5
6
7
8
9
10
AU
I
CD81 GA
Non-Severe Severe
7
8
9
10
11
12
AU
I
CD81 ET GA
**
Non-Severe Severe
0
5
10
15
AU
I
GGA1 GA
*
Non-Severe Severe
7
8
9
10
AU
I
GGA1 ET GA
****
Non-Severe Severe
6.0
6.5
7.0
7.5
AU
I
HIST1H1C GA
****
Non-Severe Severe
0
2
4
6
8
10
AU
I
HIST1 ET GA
***
A
B
C
D
E
F
G
H
I
J
140 
 
 140 
4.3.2.8 WGCNA 
WGCNA is an unbiased method used to find groups (modules) of significant 
genes which change together and correlate with clinical outcomes.  This 
analysis was performed using methods described by Zhang and colleagues 
(Zhang et al. 2005).  
 
Firstly, in a test to find outliers; the subjects were hierarchically clustered 
based on gene expression of genes with raw p-value < 0.05 as shown in 
Figure 4.7. The clustering does not distinguish the severity of disease and 
does not show any distinct outliers. There are three branches which break off 
to show two non-severe asthmatics in one branch. One branch just contains 
severe asthmatics, the other shows severe asthmatics with one non-severe 
asthmatic. The heat map in Figure 4.7 shows the intensity of clinical features 
which are measured including treatment, airway measurements and general 
clinical measurements which were used in the WGCNA analysis. 
 
To minimize noise from gene array data, the Pearson correlations created in 
the network analysis were raised to the power β otherwise known as the soft 
power value. The soft power value chooses an appropriate level of 
connectedness between the genes to find those moving together. To select 
the soft power value we use the Scale Free Topology criterion (Zhang et al. 
2005). Different values of β are plotted against Scale Free Topology criterion 
and used to select the soft power value to take forward as in Figure 4.8. 
Figure 4.8A shows the Scale Free Topology Model, which begins to saturate 
at a value of 12 so this was used as the soft power value for the Topological 
Overlap Matrix. Median (Figure 4.8B) and mean (Figure 4.8C) connectivity are 
non-zero and max connectivity (Figure 4.8D) is also appropriate.  
 
Following the soft threshold setting the data was applied to the Topological 
Overlap Matrix (TOM), modules were created and assigned a random colour 
name to aid referencing groups as demonstrated in Figure 4.9. 
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Figure 4.7. CD8+ T-cell Sample Gene Dendrogram and Trait Heatmap 
CD8+ T-cell sample dendrogram by hierarchical clustering of gene expression 
and trait heat map for severe (S) and non-severe asthmatics (NS).  The 
greater intensity in value is reflected by the darker red colour.  Grey colouring 
represents missing values.  
BMI = Body Mass Index, FP = Fluticasone Propionate, FEV1 = Forced 
Expiratory Volume after 1 second, FVC = Forced vital capacity RAST = 
radioallergosorbent test. 
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Figure 4.8. WGCNA Soft Power Selection Criteria 
Selected β or soft power value using free scale topology model fit (A), median 
connectivity (B), mean connectivity (C) and max connectivity (D). The plotted 
numbers show the average number of connections of each gene. 
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Figure 4.9. Gene dendrogram and module colours of WGCNA clusters 
 
The eigengenes were clustered using hierarchical clustering. As none were 
found to be similar no modules were merged (Figure 4.10).   
Finally, the correlation between module expression and patient traits was 
measured and shown in Figure 4.11. The green-yellow module shows high 
positive correlation to severity (r=0.95, p=7x10-06) whilst only showing a small 
correlation with limited significance to oral prednisolone usage (r=0.33, 
p=0.4).  This indicates that the green-yellow module can discriminate 
prednisolone usage from asthma severity (Table 4.8).  FEV1 % predicted was 
positively correlated with the light-green module (r=0.72, p=0.03) and strongly 
negatively correlated with the red (r=-0.86, P=0.002) and blue (-0.97, px10-07) 
modules.  The 47 genes from the green-yellow module (Table 4.8), the 43 
genes from the light-green module (Table 4.9), the 78 genes from the red 
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module (Table 4.10) and the 143 genes from the blue module (Table 4.11) 
were run in gProfiler to determine if there are any known relationships 
between these genes.  
gProfiler gene ontology analysis from the blue module showed nodes of high 
connectivity which included IL17A, ZNF24, BID, PDE9A, BOX12, KDM4D and 
EDN.  The green-yellow module’s gene ontology networks key nodes were 
TUBA1A, DST, DCTN1, VSX1, GNBL2, STK16 and ARMCX2.  The red 
module’s gene ontology network included KCNIP2, FGFR4 and IL10 as key 
nodes.  The light-green module’s gene ontology network showed WHSC1, 
PTPN13 and CPEB1 to be key nodes. 
Pathway analysis indicated that the Green-Yellow module was associated 
with a number of pathways including “Neuropathy, Distal Hereditary Motor 
Type VIIB”, “Perry Syndrome, Parkinsonism with Alveolar Hypoventilation and 
mental depression” and Adenine Phosphoribosyltransferase Deficency”.  In 
contrast, the gene lists within the light green, red and blue modules did not 
show significant associations with any currently defined pathways. 
  
145 
 
 145 
 
 
Figure 4.10. Clustering of module eigengenes 
Clustering of module eigengenes showing no similarity between groups and 
therefore no combining of modules. 
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Figure 4.11. WGCNA Module-trait Relationship  
Module-trait relationship (R-value, (p-value)). WGCNA modules are shown are shown by their colour. In the chart red shows high 
positive correlation and blue shows high negative correlation with white as no correlation. BMI = Body Mass Index, FP = 
Fluticasone Propionate, FEV1 = Forced Expiratory Volume after 1 second, FVC = Forced vital capacity, RAST = radioallergosorbent 
test.  
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ANKLE1	 GNB2L1	 NUP205	
APCDD1	 HIST1H1C	 OR13D1	
APOL2	 HOXA11AS	 PCDHB10	
APRT	 HS.565001	 RIMS2	
ARFGEF2	 HS.567088	 RUVBL1	
ARMCX2	 HSDL2	 SEC22C	
BAG4	 KIAA1160	 SLC23A2	
C1QTNF4	 LANCL1	 SLC35E2	
CBWD7	 LDB3	 SMYD3	
CNTROB	 LMCD1	 SSB	
CTAG1B	 LOC100128025	 STK16	
DCTN1	 LOC100130795	 SUCLG2	
DDX23	 LOC730083	 SVEP1	
DEPDC1	 LOC731479	 TAF15	
DGKK	 M6PRBP1	 TUBA1A	
DLGAP4	 MAN2B2	 UBE2V1	
DST	 MED27	 VSX1	
FAM90A5	 MGC70870	 ZFP2	
FGD6	 NFKBIZ	 ZNF654	
Table 4.8. Genes within the WGCNA Green-Yellow Module 
(57 genes) 
 
 
 
AIM1L GCK HS.580515 MSGN1 
AP4S1 GCNT3 HS.582211 MT1E 
BCR GGTLC1 KIAA0895L OR5K3 
C1QTNF9B HBG1 LOC100128918 PTPN13 
C2ORF42 HNF4A LOC100131693 PYCR1 
C3ORF35 HOXB7 LOC100131970 RAB7B 
CPEB1 HS.538525 LOC100134333 RS1 
CRTAP HS.556255 LOC100134414 TMEM184B 
DNAJC5B HS.562488 LOC729744 TMEM19 
FBN2 HS.576771 MANEA TTF2 
 HS.579070 MIR96 WHSC1 Table 4.9. Genes within the WGCNA Light-Green Module 
(43 genes) 
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ACSM3 FGFR4 IL18 MIR555 
ADAMTSL1 FOLR1 KCNIP2 NCCRP1 
AOC2 FSCB LCN6 OR1L1 
ARL16 GABPB2 LILRB1 OR5F1 
C10ORF31 GLRB LOC100008588 OR6C6 
C21ORF24 GRK1 LOC100130168 OR6Y1 
C21ORF55 HS.122053 LOC100130445 PCDHGA8 
CCBE1 HS.130178 LOC100132154 PDE4C 
CDKN2AIPNL HS.282556 LOC100132727 PDXDC2 
COQ7 HS.537603 LOC100133649 POU3F4 
CRCP HS.539981 LOC127099 PPA2 
CYLN2 HS.544884 LOC728857 PPT2 
DEFB106A HS.546089 LOC729090 RPL7L1 
DFNA5 HS.569711 LOC730281 SLC34A3 
EDN2 HS.570636 LPPR5 USP49 
EIF2AK4 HS.578850 LRP8 WDYHV1 
FBXO33 HSPC268 LRRC45 ZBTB10 
FCGR2B IL10 MGC16703 ZNF430 
   ZNF84 Table 4.10. Genes within the WGCNA  Red Module 
(78 genes) 
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ABCC13 COLQ HS.555115 LOC100132391 MTIF2 REPS2 
ABHD14B DBX1 HS.557218 LOC100132593 NDRG4 RREB1 
ACSM2B DHRS2 HS.562585 LOC100132839 NEUROG3 RRP7B 
ADAM11 EDG7 HS.564949 LOC100132891 NRF1 SCAND3 
ADC EDN1 HS.569985 LOC100133465 NUDCD3 SLC25A29 
ALG10B EGFL8 HS.573047 LOC100133893 OR10W1 SLC8A1 
ANKRD28 FAM101B HS.574784 LOC100133990 OR2T34 SMOC1 
AP1G1 FAM90A13 IGDCC4 LOC100134423 OR51I2 SNRNP40 
APOBEC3F FANCA IL17A LOC202134 OVOL2 SOX12 
ATXN7 FKBP9L IL1F7 LOC728969 PAEP ST8SIA5 
BID FLJ44124 IMAA LOC729756 PDE9A STARD13 
BOLL GLYBP JSRP1 LOC730066 PEX11A STK35 
C10ORF73 GNAI1 KDM4D LOC730159 PFTK2 TBXAS1 
C14ORF65 GP2 KIAA0895 LOC732215 PLGLB1 TLR10 
C1ORF158 GPR173 KRT18P17 LRRC37A4 PLSCR4 TNXA 
C5ORF42 H2BFWT KRT71 LRRC41 POLD2 TTC22 
C9ORF125 HIST1H3E LHX4 MGC57359 POMT1 ZBTB34 
C9ORF82 HS.124623 LIFR MIOS POU2AF1 ZDHHC11 
CARD8 HS.148844 LOC100128904 MIR1252 PPIL4 ZFP41 
CASC2 HS.511717 LOC100129489 MIR186 PSAT1 ZHX2 
CGB HS.537922 LOC100129758 MIR548Q PTBP2 ZIK1 
CLUAP1 HS.545028 LOC100129946 MIR592 RAB19 ZNF24 
CLUL1 HS.552087 LOC100130979 MT1IP RANBP6 ZNF280C 
CNN3 HS.552427 LOC100131530 MTERFD2 RAP2B  Table 4.11. Genes within the WGCNA Blue Module  
(143 genes) 
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4.3.2.9 WGCNA of Tsitsiou Data 
An identical analysis was performed on the Tsitsiou data comparing non-
severe and severe asthmatics. When clustering module eigenvalues some 
colours were merged as shown in Figure 4.12. There were fewer patient traits 
published in the Tsitsou paper giving a more limited module-trait relationship 
(Figure 4.13). However, the purple module (Figure 4.13) had a significant link 
to FEV1 % predicted (r=0.59, p=0.04) and an equally strong negative 
correlation for severity (r=-0.79, p = 0.001) and prednisolone usage (r=-0.77, 
p=0.002). The purple module contains 56 genes (Table 4.12) and gProfiler 
gene ontology shows that KDSR, QKI, MATR3, AIDA, P4HB, CANX, STAT1 
and MAP3K2 are key nodes. Pathways as suggested by gProfiler included the 
endomembrane system where 23 of the selected 46 genes gprofiler could 
identify were involved to some extent, vesicles, intracellular vesicles, 
cytoplasmic vesicles, pigment granule and melanosomes. 
 
 
Figure 4.12. WGCNA Cluster Dendrogram and Module Colours of 
Tsitsiou Data 
151 
 
 151 
Tsitsiou, 2012 Dataset downloaded from GEO (GSE31773) WGCNA gene 
dendrogram and module colours pre- and post-merger of modules. 
  
Figure 4.13. Tsitsiou Data Module-Trait Relationships 
Tsitsiou dataset downloaded from GEO (GSE31773).  Module-trait 
relationship (R-value, (p-value)). In the chart red shows high positive 
correlation and blue shows high negative correlation with white as no 
correlation.  
FEV1 = Forced Expiratory Volume after 1 second, FVC = Forced vital 
capacity, PC20 = provocative concentration of inhaled bronchodilator which 
causes FEV1 to fall by 20%. 
  
152 
 
 152 
 
LACTB ANKRD20A1 PTPN11 VDAC1 
ITGB1 ARF4 CLIP1 ZBED2 
ITGB1 VAMP3 MAP3K7 AIDA 
DNAJB9 ZFR MAP3K7 CES3 
CRTAP GDE1 SH3GL3 YIPF5 
METTL8 FAM20B VAMP3 NAA50 
QKI PCYOX1 IPO5 EXOC5 
MATR3 CLN5 VDAC1 TRIM4 
KDSR RAB1A DLAT NGRN 
CTD-2076M15.1 APLP2 H2AFY HIBADH 
RP1-142L7.9 ADH5 ADAM10 YIPF5 
P4HB CANX ITGA6 RSPRY1 
RAC1 SRI TOR1AIP1 GLDN 
BOD1L1 FRG1B STAT1 HIBADH 
Table 4.12. Genes within the Tsitsiou WGCNA Purple Module  
(56 genes) 
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4.4 Discussion 
This chapter has utilised data from the U-BIOPRED study looking at the 
geneomics of peripheral blood mononuclear cells, which contains T-cells and 
shows a decrease in CEACAM8 in severe asthmatics. CD8+ T-cells collected 
from severe and non-severe asthmatics shown that severe asthmatics have a 
significantly increased expression of TUBA1A and WGCNA shows there are 
groups of genes involved in cytoskeletal activity and vesicle budding. It is also 
interesting to note that there are high fold change, but not statistically 
significant changes in expression of anti-microbial genes in CD8+ T-cells 
which have also been shown in another similar data set, and this group of 
genes has also been selected by WGCNA to be important in severe asthma. 
This study has low power and there should be concerns about the purity of 
the cells as the FACS was incorrectly carried out, however the comparison to 
previous studies helps to demonstrate that the expression sets are similar and 
that a repeat of this study in a larger group may well help back up the results.  
4.4.1 U-BIOPRED Peripheral Mononuclear cells Gene 
Expression 
The DEG analysis from this blood PBMC study shows downregulation of the 
genes which encode defensin alpha 4 (Lehrer & Ganz 1992), MMP8 (Ugarte-
Gil et al. 2013) and lactoferrin (Farnaud & Evans 2003).  In addition, the 
expression of CEACAM8 was also down-regulated.  The protein CEACAM8 
regulates cell adhesion and activation of human eosinophils (Yoon et al. 
2007) and decreases Toll Like Receptor 2 (TLR2) triggered immune 
responses minimizing pro-inflammatory immune responses in the airway 
(Singer et al. 2014).  The decrease in CEACAM8 mRNA expression in severe 
asthmatics is one way in which severe asthmatics might have a more limited 
response to treatment, but the decrease in the antibacterial genes is most 
likely due to CS treatment.  It is of note that CEACAM8 mRNA expression was 
previously reported as up-regulated in CD4+ T-cells and CD8+ T-cells in 
severe asthmatics (Tsitsiou et al. 2012). The differences in gene expression 
seen here and with the Tsitsiou study may reflect the fact that U-BIOPRED 
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dataset was not deconvoluted to account for cell type differences that occur in 
the blood of asthmatic patients with different disease severity.  Future studies 
may analyse the expression of these genes to reflect the individual 
contribution of various peripheral blood cell types such as monocytes, 
neutrophils, T-cells and B-cells make. In further studies it would also be of 
interest to carry out proteomics to investigate if the gene expression carries 
through into protein production. 
 
4.4.2 CD8+ T-cell Gene Array Experimental Design 
By comparing severe and non-severe subsets we were able to suggest new 
aberrant pathways which could be further investigated in larger studies and 
may eventually be able to understand severe asthma. Previous cluster 
analysis focussed on clinical variables and a few biochemical or cellular 
measures have shown asthma to be highly heterogeneous (Moore et al. 
2010).   
 
The low number of patient samples used here (n=3 non-severe asthma and 
n=6 for severe asthma after exclusions for outliers) have given this study 
lower power. It would take an n=10 to differentiate the groups by dose of Oral 
Corticosteroids with the current variance and this seems like a good starting 
place for further studies.  It would be interesting to expand the groups to 
include differentiated cell subtypes from severe and non-severe asthmatics, 
but this would necessitate even larger patient numbers. Generally the PCR 
confirmed what was found in the gene array. The differences between the 
MPO PCR confirmation and the MPO gene array could be dues to differences 
between the sequences examined by PCR and the GA. A primer specifically 
matching the sequence on the gene array should have been used rather than 
a stock MPO primer from Qiagen which has a propriatory design and cannot 
be compared. 
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A number of genes were elucidated using WGCNA which were able to 
differentiate between the effects of the high dose of steroids that severe 
asthmatics take and the disease itself. The green-yellow module (Figure 4.11) 
which without being significantly linked to oral prednisolone (r=0.33, p=0.4) or 
inhaled FP equivalent (r=0.3, p=0.4) was strongly linked to severity (r=0.95, 
p=7e-06). This demonstrates that there are some genes which are 
differentially expressed in severe asthmatics independent of steroid usage.   
A limitation of the study was that no objective measure such as cortisol levels 
or plasma prednisolone metabolites were measured and so we cannot 
discount compliance being an issue.  As such, the differentiation between the 
groups may reflect a true subgroup or an effect of not using drugs.  However, 
these subjects have been treated at the Royal Brompton Hospital; Severe 
asthma clinic for many years, are not well controlled and have steroid side-
effects.  Another potential limitation of the study was the fact that we did not 
achieve 100% cell purity.  Flow Cytometry showed that 90% of cells were 
lymphocytes and 65% of these lymphocytes were CD3+/CD8+ cells.  The low 
purity could be a concern, as the FACS was incorrectly controlled and cannot 
be repeated, however a prior study using the same method showed ~90% 
purity in all samples (Tsitsiou et al. 2012). Alongside this, the same previous 
study had similar expression to this data. Despite this a repeat of this study 
with proper FACS analysis, protein expression studies and higher n-numbers 
would help to confirm or deny these next points. 
4.4.2.1 Cytoskeleton Genes 
The cytoskeleton plays a vital role in T-cell activation. After TCR activation f-
actin is polymerised and creates an ‘immunological synapse’. Inhibition of 
actin polymerisation in T-cells inhibits T-cell activation (Valitutti et al. 1995; 
Grakoui et al. 1999). 
 
Tubulin is part of the microtubule organising centre (MTOC) for cell-cell 
interactions between antigen presenting cells (APC) and T-cells (Kupfer & 
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Dennert 1984; Kupfer et al. 1987) which regulates the secretion of effector 
molecules and targeted receptor endocytosis (Sancho et al. 2002). 
Whilst interacting with the MTOC in APCs, the cytoskeleton and Golgi 
apparatus reorients beneath the contact site (Kuhné et al. 2003; Kuhn & 
Poenie 2002; Saito & Yokosuka 2006; Kupfer & Dennert 1984; Kupfer et al. 
1987),  In addition, microtubules direct IL-2, IL-4 and IL-5 stores to the surface 
of T-cells when they are associated with APCs. (Kupfer et al. 1991; Reichert 
et al. 2001). 
 
TUBA1A mRNA which codes for tubulin α, one of the two main components of 
tubulin, is significantly upregulated in severe asthmatics CD8+ T-cells. 
Conversely, several genes involved with actin filament support including 
CD81, CNN2, which encodes Calponin 2 and GGA1 which encodes golgi 
associated, gamma adapter ear containing ARF binding protein 1, were had 
high negative fold-change suggesting an imbalance between tubulin and actin 
filaments if this was found to be significant in future studies.   
 
CD81 is important for T-cell activation and myotubule maintenance (Charrin et 
al. 2013).  In T-cells CD81 forms a link with CD4 or CD8 (Imai et al. 1995) to 
provide a co-stimulatory signal with CD3 (Todd et al. 1996; Tachibana & 
Hemler 1999). It is also important for T-cell maturation in mice as when mice 
fetal thymus organ cultures were treated with CD81 antibodies they were 
prevented from differentiating from CD4-CD8- cells into CD4+ cells (Boismenu 
et al. 1996).  CD81 also inhibited αβ T-cell maturation while sparing γδ cells.  
CD81 matures double positive CD4+/CD8+ to single positive CD4+ or CD8+ 
(Cibotti et al. 1997).  CD81 deficient mice express normal numbers and 
subsets of T-cells but have diminished antibody responses to protein 
antigens. With a large increase in CD81 in T-cells you would expect a greater 
reaction to stimuli. CD81s role with the cytoskeleton is demonstrated most 
clearly in B cells were CD19 movement to cell depends upon CD81s presence  
where they form a complex with Leu13 to increase B cell activation (Levy 
2014).  
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Calponin 2 is a calcium binding protein which also binds actin, calmodulin, 
troponin C, and tropomyosin, and functions in the structural organization of 
actin filaments which in T-cells are vital for formation of lamellipodium 
structure which increases the interactive APC-T-cell binding surface area.  
Golgi-Associated, Gamma Adaptin Ear Containing, ARF Binding Protein 1 is 
important for Golgi traffic and therefore release of active proteins in promoting 
cell death.  In future studies it would be vital to investigate the proteomics to 
understand whether these proteins expression are upregulated similarly to the 
genes. 
4.4.2.2 RNA Modifying Genes and AP-1 
SSB and TAF15 genes were significantly increased more than 1.5-fold in 
severe asthmatics and represent the RNA Binding Motif Containing (RBM) 
family of genes (http://www.genenames.org/cgi-bin/genefamilies/set/725) 
which are linked by high homology. SSB and TAF15 have roles in microRNA 
functions, RNA protection and in regulation of post-transcriptional 
modifications of RNA. These modifications of RNA may play a part in the 
changed expression profile of severe asthma.  
 
SSB produces Sjogren syndrome antigen B otherwise known as ‘Lupus La 
protein’ which binds to UUUOH 3’ to prevent exonuclease digestion of the RNA 
which protects RNA from degradation (Stefano 1984).  
TAF15 encodes TATA-Box Binding Protein Associated Factor 15 which is one 
of many proteins that RNA polymerase II requires for gene transcription.  
 
The up-regulation and translation of RBM genes could well be linked to the 
non-significant but high fold-change up-regulation of the FOS, JUN & JUND 
genes.  Both Jun and JunD form a heterodimer with Fos to form AP-1 which 
has previously been reported to be implicated in relative steroid insensitivity in 
peripheral blood cells in patients with severe asthma (Lane et al. 1998).  
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AP-1 is a transcription factor which has been shown to regulate differentiation, 
proliferation and apoptosis of cells which is key to the T-cell receptor 
activation. T-cell receptor activation is context and state dependant in its 
effects and can be responsible for burst like clonal proliferation, memory cell 
differentiation, release of cytokines and cytotoxic molecules and to induce 
apoptosis (Wirth et al. 2010; Ahmed & Gray 1996; Kaech & Cui 2012).  
 
BACH2 is a transcriptional repressor which is recruited to enhancers and 
limits TCR-driven genes by attenuating the availability of AP-1 (Roychoudhuri 
et al. 2016) and promotes differentiation of Foxp3+ Treg cells to prevent lethal 
inflammation.  Furthermore, in TH1 cells AP-1 activation in conjunction with IL-
4 stimulation of the JAK-STAT pathway can activate further IL4 production in 
a feed-forward manner to induce TH2 differentiation following Gata3 
expression (Ouyang et al. 2000; Macián et al. 2000). Gata3 can then drive 
epigenetic changes at the TH2 cytokine cluster. 
4.4.2.3 Antimicrobial Properties of Cytotoxic T-cells 
Looking at the highest FC genes (Table 4.6) there is an insignificant trend that 
suggests that anti-bacterial genes are broadly up-regulated in severe 
asthmatics, particularly genes such as DEFA1B/A3/A1, CAMP, MPO and 
CTSG. Though there is a potential that these cells were contaminated with 
other cells in the enrichment stage of their extraction, the gene DEFA4 was 
also shown to be upregulated in this cell type in severe asthma in Tsitsiou et 
al. 2012. These genes code for the proteins neutrophil defensin 1 (and other 
defensins), which possess a membrane pore-forming antibacterial mechanism 
to puncture the bacterial cell membrane (Sahl et al. 2005); cathelicidin, an 
antimicrobial peptide with a similar mechanism of action to defensins 
(Kościuczuk et al. 2012); myeloperoxidase, a peroxidase enzyme which 
produces hypohalous acids which carry out antibacterial activity (Klebanoff et 
al. 1984) and cathepsin G, a serine protease (Thomas et al. 2014) and broad-
spectrum anti-bacterial protein able to target both gram positive and negative 
bacteria (Shafer et al. 1991)  
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These up-regulated antibacterial genes are linked by gene ontology analysis 
(Section 4.3.2.5) to “response to bacterium” and “disruption of cells of other 
organisms” pathways.  Although CD8+ aren’t commonly cited in the literature 
as defensin producing cells it is not an entirely novel finding. α-defensins were 
found in CD8+ T-cells of HIV infected patients, and it was suggested by the 
authors that it was due to both intrinsic production and uptake from co-
cultured cells (D’Agostino et al. 2009).  Proteomics, ELISAs or western blots 
would be able to show for sure whether this upregulation has been translated 
into protein. 
 
It is interesting that genes that may lead to an increased ability to mount a 
response to bacterial infections were found in cells from severe asthmatics, 
suggesting that asthmatics code for a more aggressive cytotoxic T-cell 
phenotype. It would be interesting to see if this is reflected in defensin release 
and cellular function as well as expression.  Although the role of cytotoxic T-
cells is not to respond to bacteria (except intracellular bacteria), CAMP, MPO 
and CTSG are all genes that can be used to respond to viral infections which 
may provide a link between the fact that CD8+ T-cells remain in the airways 
for longer following viral infection (Hogan et al. 2001) and that severe 
persistent asthma is associated with frequent bacterial and viral 
exacerbations. 
4.4.2.4 Miscellaneous Genes 
HIST1H1C (-1.528 log2 FC and corrected p-value 3.14E-02) is the most 
significantly changed gene and in a proteomics study was shown to be one of 
the most abundant proteins in mouse cytotoxic T-cells (Hukelmann et al. 
2016).  The role of Histone H1 proteins is to create higher order chromatin 
structures and condensing DNA into heterochromatin. This change could 
equally be a result of stage in the cell cycle or possibly epigenetic changes in 
levels of packing of the DNA. 
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Finally, dual specificity phosphatase 1 (DUSP1) has been purported to be a 
mediator for ICS and is induced by CS (Abraham & Clark 2006; Clark & Lasa 
2003; Clark 2003) and has been implicated in relative CS insensitivity. In this 
study it was found to have a high fold change, but non-significant increase, 
confirmed in larger stuies it would be interesting to see if severe asthmatics 
who weren’t currently taking Oral Corticosteroids also had dysregulated 
expression of this gene to rule out interference from  (Shah et al. 2016).  
 
4.4.3 WGCNA Analysis of CD8+ T-cell Data 
Using WGCNA with a selected input of genes with raw p-value <0.05 allows 
for a semi-unbiased selection of pathways associated with various clinical 
traits.  Employing a completely unbiased analysis (i.e. running all expressed 
genes) was considered too computationally intensive.  When analysing these 
data sets it is important to note that the WGCNA doesn’t take into 
consideration the direction of change of the genes in it’s output, just that the 
genes changed are related.  These results are discussed below. 
4.4.3.1 Green-Yellow Module 
The Green-Yellow module showed a high positive correlation to asthma 
severity (r=0.95, p=7x10-06) with only a small non-significant correlation with 
oral prednisolone usage (r=0.33, p=0.4).  This indicates that this group of 
genes are the ones most likely to be associated to FEV1 % predicted rather 
than the effects of oral prednisolone or ICS.  Using gene ontology, key nodes 
were found including the genes coding for tubulin α (TUBA1A), dystonin 
(DST), dynactin subunit 1 (DCTN1), guanine nucleotide-binding protein 
subunit beta-2-Like 1 (GNB2L1), serine/threonine kinase 16 (STK16), visual 
system homeobox 1 (VSX1) and armadillo repeat containing, X-linked 2 
(ARMCX1) from pathways including “Neuropathy, Distal Hereditary Motor 
Type VIIB”, “Perry Syndrome, Parkinsonism with Alveolour Hypoventilation 
and mental depression” and  Adenine Phosphoribosyltransferase Deficency”.   
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TUBA1A, DST, DCTN1 and STK16 are involved in cell motility and internal 
localisation. TUBA1A codes for one of the key proteins in tubulin formation 
(Sancho et al. 2002) and dystonin is required for anchoring intermediate 
filaments to the actin cytoskeleton and so is key for cell-cell adhesion junction 
plaques.  The three post-transcriptionally created isoforms of DCN have 
different roles: one is actin binding, one is localised to the nuclear envelope 
and one to the plasma membrane (Jefferson et al. 2006; Young et al. 2006).  
It was not possible in this study to distinguish which isoform was present from 
the gene array data.  Dynactin 1 is a subunit of dynactin which can activate 
ER-to-Golgi transport in a microtubule-independent manner and is involved in 
vesicle budding (Verissimo et al. 2015).  Serine/Threonine Kinase 16 has also 
been shown to be involved in vesicle budding (In et al. 2014).  GNB2L1 codes 
a protein that is required to allow membrane localisation by VANGL2 (Van 
Gogh-Like Protein 2) and inhibits Wnt activity (Li et al. 2011).  
 
The two other genes that were determined by this method have not previously 
been associated with asthma and may be novel mechanisms or candidate 
targets for novel severe asthma therapies.  VSX1 has a well described role in 
binding to red/green visual pigment in the eye and its protein family also 
contains deltaEF1. DeltaEF1 knock-out mice have skeletal and T-cell 
abnormalities with reduced CD4-CD8+ levels relative to CD4+CD8- cells 
(Higashi et al. 1997). ARMCX2 is involved in development and maintenance 
of tissue integrity through an unknown mechanism and its role in severe 
asthma should be examined. It has also been shown to be released in 
extracellular vesicles, from Colorectal cancer, mesenchymal stem cells and in 
urine, however its role is unknown (Hong et al. 2009; Fraser et al. 2013; Bruno 
et al. 2009). For both of these genes it would be interesting to investigate their 
changes in protein to see if this is simply a gene change or whether they may 
begin having a practical role. 
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4.4.3.2 Light-Green, Red and Blue Module 
The light green module was found to be positively correlated with a higher 
FEV1 % predicted. The Light-Green modules most highly linked genes show a 
wider variety of pathways that may work together including a paralog of 
EHMT1 (H3K9 methylase) and a probable histone-lysine N-methyltransferase 
(Stec et al. 1998), Wolf-Hirschhorn Syndrome Candidate 1 (WHSC1).  Protein 
tyrosine phosphatase, non-receptor type 13 (PTPN13) is another relatively 
unstudied gene although PTP family members tend to regulate cell growth, 
differentiation and mitotic cycle (Goebel-Goody et al. 2012; Paul & Lombroso 
2003; Denu & Dixon 1998; Zhang et al. 2010).  Finally cytoplasmic 
polyadenylation element binding protein 1 regulates mRNA translation and 3’ 
untranslated region and may play a role in cell proliferation (Sousa Martins et 
al. 2016).  This gene list did not provide any specific pathway based on the 
current literature and the role of these genes require further investigation and 
examination of expression in other chronic inflammatory diseases.  However, 
the role of H3K9 methylation in T-cell function and in severe asthma deserves 
further study. 
 
The Red and Blue modules are both inversely correlated with FEV1 % 
predicted and like the light green module have a more disparate selection of 
genes with no clear connection. The red modules key nodes contain KCNIP2 
a potassium voltage-gated channel interacting protein 2 which is a calcium 
regulator for potassium voltage-gated channels, FGFR4 (fibroblast growth 
receptor 4), a tyrosine-protein kinase that acts as cell-surface receptor for 
fibroblast growth factors (Loo et al. 2000) and IL-10 which has anti-
inflammatory effects by down regulating the expression of Th1 cytokines 
(Sher et al. 1991; Zhang et al. 2011). The blue module also contains a variety 
of genes including the proinflammatory cytokine IL17A, phosphodiesterase 
PDE9A, the sequence specific DNA binding transaction factor ZNF24, the 
lysine demethylase KDM4D and endothelin 1 without a clear link between 
their activation and often with contradictory functions.  For example, in the red 
module IL17 is pro-NF-κB whereas IL10 is inhibitory towards NF-κB.   
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4.4.4 Tsitsiou Purple Module 
The data from Tsitsiou 2012 showed a weak correlation of the purple module 
with FEV1 % predicted.  g:Profiler showed a strong link for many of the genes 
in vesicular transport and other intracellular transport proteins a few of these 
genes were SRI which codes Sorcin, which induces movement from the 
cytoplasm to sarcoplasmic reticulum in response to elevated calcium levels in 
muscle, RAC1 which codes for Ras-Related C3 Botulinum Toxin Substrate 1 
invovled in cytoskeletal reorganization, ADAM10 whose protein is involved 
intracellular adhesion, RAB1A which codes a GTPase which controls vesicle 
traffic to the Golgi apparatus and many others with related function. Though 
the genes were not identical to those found in the patients that had been 
collected specifically for this study, the key pathway is strongly linked. This 
demonstrates this phenotype is reproducible in other data sets and warrants 
further future work. 
 
4.5 Conclusion and next steps 
These gene arrays may show that CD8+ T-cells in severe asthma have 
changes in cytoskeleton activation compared to non-severe asthmatics. This 
is hinted at by gross decreases in CD81, calponin 2 and golgi adapter ear 
containing ARF binding protein 1 and significant increases in tubulin α 
alongside changes in the pathways of vesicle formation and internal cell 
localisation as shown by WGCNA.  The important genes include DST, DCTN1 
and GNB2L1, STK16 and VSX1. It is also possible that a new protein involved 
in vesicle formation has been elucidated, ARMCX2. Currently ARMCX2 has 
been associated in two cancer papers with a focus on Cisplatin resistance in 
ovarian cancer and having tumour suppressive roles in Fragile X syndrome 
patients (Zeller et al. 2012; Rosales-Reynoso et al. 2010), a change in protein 
expression of Armcx2 in the ECM of damaged liver tissue (Klaas et al. 2016) 
and a role in murine gonadal development (Smith et al. 2005) with out any 
clear suggestion of it’s mechanism. 
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Activation of T-cells invokes cytoskeleton mechanisms which bind virally 
infected or cancerous cells, bind to other T-cells when activated and are then 
required in order to release their cytotoxic payloads from vesicles. This may 
suggest that this canonically anti-viral, anti-cancerous cell type is involved in 
asthma in ways other than those previously understood, or that viral infections 
in severe asthmatics are dealt with in a different manner by CD8+ T-cells.  
Functional analysis of the anti-viral capacity of animals with restricted and 
inducible changes in the expression of these proteins will provide further 
information. 
 
There are also substantial FC increase in antibacterial genes in CD8+ T-cells 
and U-BIOPRED peripheral mono-nuclear cells in severe asthma.  These 
include up-regulation of defensins (DEFA4 and DEFA1B) and 
metalloproteases (MMP9 and MPO) and suggests an enhanced anti-bacterial 
response. The fact that this change is also seen in all mononucleocytes in a 
much bigger cohort suggests that this may not be simply a CD8+ T-cell 
response in severe asthmatics, or that it is such a big change in CD8+ T-cells 
that it is discernable through the noise of the other cell types.  Deconvolution 
of the U-BIOPRED data may give further evidence for abnormalities in the 
innate, and adaptive, immune systems in severe asthma.   
 
AP1 activation induces the release of defensin from epithelial cells (Wehkamp 
et al. 2004).  I have provided evidence of increased mRNA expression of the 
AP1 components FOS and JUN in these cells and it is possible that AP-1 
drives the increased expression of defensins that we see in CD8+ T-cells in 
severe asthma, however studies on protein will have to be carried out to 
confirm this. 
 
The big question to address is whether these changes are as a result of an 
overall asthmatic phenotype or whether these changes in CD8+ T-cells are 
driving a distinct asthmatic phenotype.  It is also unclear how the peripheral 
blood CD8+ cells interact with other cell types in the lungs and in the blood 
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and does this alter in severe asthma. Bronchoalveolar lavage would provide 
means to investigate this further with the possibility of using single cell –
omics.  
 
The results presented in this chapter provide some evidence that epigenetic 
changes may be important in severe asthma.  Differences in the expression of 
epigenetic modifying enzymes along with those of histone H1 indicate a link 
between these changes and epigenetic regulation of the expression of the 
DEGs reported here.  In the next two chapters the effect of epigenome 
modifying compounds will be tested on CD8+ T-cells and the level of 
coverage of histone modifications across the genome will be measured using 
ChIP-Seq.   
 
Though it is not possible to fully confirm the hypothesis with the low numbers 
of patients samples and even lower numbers after exclusions I was able to 
investigate the CD8+ T-cell and use the methodology to see suggestions of 
novel genes involved in the CD8+ T-cells using WGCNA. There were small 
numbers of significantly changed genes in the severe asthmatics compared to 
non-severe asthmatics and pathways for these genes were also validated in a 
previous study. PMBCs transcriptome from severe and non-severe asthmatics 
and healthy patients did show few differentially expressed genes. 
  
166 
 
 166 
Chapter 5: H3K27ac in 
Asthmatic CD8+ T-Cells  
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5.1 Chapter Introduction 
H3K27 tri-methylation (H3K27me3) has been shown to inhibit expression 
when found across the body of a gene, cause transcriptional pause when 
bound to transcriptional start sites (TSS) and it is associated with increased 
transcription when on the promoter region (Young et al. 2011). This profile 
was discovered using ChIP-Sequencing, a method to study the level of 
coverage of the genome with a particular protein. A conference abstract has 
reported that H3K27me3 demethylation is vital for activation of CD4+ T-cells 
(LaMere 2015).  This study indicated that the inhibitory effect of H3K29ac in 
the body of genes was abrogated when both naïve and memory T-cells were 
activated.  This variety of transcriptional control and its clear role in the 
activation of other T-cells makes it an ideal histone modification to study in 
relation to the modified transcriptome in CD8+ T-cells. 
 
The role of H3K27me3 in transcriptional pause suggests that it can mark 
bivalent genes which also contain pro-transcriptional histone modifications in 
the TSS. H3K27ac is a pro-transcriptional mark and has also been shown to 
be involved in the mechanism of transcriptional pause (Nimura & Kaneda 
2015). Increased HAT transferase activity is shown to in asthmatic biopsies of 
the lung and studies suggest that HAT:HDAC ratios are related to asthma 
severity (Ito et al. 2002; Su et al. 2008). H3K27ac is associated with enhancer 
regions of actively expressed genes (Creyghton et al. 2010). 
 
Analysis of the combination of H3K27me3 and H3K27ac marks would begin 
to give a picture of the CD8+ T-cell epigenome and how they regulate the 
DEGs that are seen in CD8+ T-cells between severe and non-severe 
asthmatics. 
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5.2 Chapter Hypothesis and Aims 
The difference between asthma severity and gene expression of select genes 
and pathways maybe linked to differences in H3K27me3 and H3K27ac in 
CD8+ T-cells.   
 
This chapter, therefore, set out to examine the following aims: 
 
• Perform an analysis of H3K27ac and H3K27me3 ChIP-Seq on the 
same samples as the gene expression data, 
• Create a dataset with both gene expression and percentage coverage 
of histone modifications to show the strength of the relationship 
between expression and H3K27ac and H3K27me3 in severe and non-
severe asthmatics. 
  
 
5.3 Results 
CD8+ T-cells were isolated at the same time and in the same manner as the 
previous chapter and from the same patients. Samples were snap frozen as 
the samples were taken over the course of 6 months so that the processing 
could be carried out at the same time to minimise batch effects. However the 
effects of snap freezing the cells may have had an effect on the on the 
stability of the DNA and is not part of the standard ChIP-Seq protocol where 
the DNA would be taken up to the point of being ready to be sequenced 
before storing.   
5.3.1 ChIP Quality Control 
H3K27ac ChIP was successfully carried out on 3 samples from those 
described in chapter 4: non-severe NS1, NS4 (excluded from the gene array 
analysis due to a poor gene count in the PCA), and Severe S6.  No inputs or 
H3K27me3 enrichment for the ChIP-seq were run due to failures to isolate 
adequate quantities of immunoprecipitated DNA. This may be due to a failure 
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of the ChIP, DNA amplification or isolation although the step at which this 
failure occurred cannot be elucidated. For example, there was no DNA 
present in the DNA Bioanalyser reads from the inputs, H3K27me3 as 
demonstrated in Figure 5.1A, and B shows a plot from a successful 
preparation. As previously mentioned this may have been due to the storage 
prior to processing.   
 
 
A      B 
 
Figure 5.1. DNA Bioanalyser read  
DNA Bioanalyser reads showing florescent units against base pair lengths. 
(A)Two peaks at 100 and 10380 are the ladder used to calibrate reads and 
(B) an idealised plot of the sample if properly processed should look like. 
 
Of the three samples run the number of reads that were completed was 
19,440,407, 14,603,369 and 4,421,840 for NS1, NS4 and S6 respectively. 
The low read count for S6 may have been the cause for the sparse peaks 
when viewing the data (Top row in Figure 5.3 - Figure 5.9). However, in 
general large peaks that were found in other libraries were also present in this 
data. As such, data from the severe reads can be relied on when a peak is 
shown, however the lack of a peak may not correlate to a genuine H3K27ac 
sparse region. As such, care must be taken when analysing this data.    
We are also able to use FastQC to show that there were some reads which 
sequenced through the index adapters for the genes (Table 5.1). 
These were removed by the pipeline.  The sequence length distribution 
(Figure 5.2) shows that read lengths were consistent at ~46bp across the 
reads. 
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Patient Sequence Count Percentage Possible Source 
Non-Severe 
4 
GGAAGAGCACACGT
CTGAACTCCAGTCAC
CCGTCCATCTCGTAT
GC 
559319 3.83 
TruSeq Adapter, 
Index 16  
(97% over 46bp) 
Severe 
6 
GGAAGAGCACACGT
CTGAACTCCAGTCAC
GTCCGCACATCTCGT
AT 
57007 1.29 
TruSeq Adapter, 
Index 18  
(97% over 36bp) 
 
Table 5.1. Overrepresented sequences in ChIP-Seq 
Overrepresented sequences from Non-Severe 4 and Severe 6 taken from 
FastQC report 
 
 
 
 
Figure 5.2. Sequence Length Distribution  
Sequence Length Distribution showing number of reads against sequence 
length of H3K27ac ChIP from NS1, NS4 and S8. Showing the average read of 
46BP. 
 
Non-Severe 1
Non-Severe 4
Severe 8 Sequence Length Distribution
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5.3.2 H3K27ac ChIP-Seq  
The only comparison of peak size free of potential error between severe and 
non-severe asthmatic subjects is that peaks higher in the severe asthmatics 
are genuinely higher than those of non-severe patients. Peaks higher in non-
severe asthmatics could simply be a result of a deficit in reads in the severe 
subject. Table 5.2 shows the peak value of genes of interest selected from 
Chapter 4. Of the 20 genes selected only three, CAMP, GGA1 and CD81 
were shown to be more highly enriched in H3K27ac in severe asthmatics 
compared to non-severe asthmatic subjects as demonstrated in their UCSC 
genome browser reads (CAMP, Figure 5.3; GGA1, Figure 5.4; CD81, Figure 
5.5). Of these three genes, the enrichment of H3K27ac was only similar to 
that in other cell types for GGA1.  
The H3K27ac peaks at the FOS (Figure 5.6), ZFP36, CNN2 and HIST1H1C’s 
(Figure 5.7) promoters was lower in severe asthmatics compared to NS 
asthmatics.  This may be a genuine effect but can’t be distinguished from an 
effect resulting from the lack of reads (Table 5.2). DEFA1 (Figure 5.8), JUND, 
NDUFB8, MAN2B2, TAF15, TUBA1A and TRIM16L all have absent H3K27ac 
promoter peaks in the severe patient.  In contrast, DUSP1, HDC, JUN, MPO, 
RBM39 (Figure 5.9) and MX1 all have equal sized H3K27ac promoter peaks 
between severe and non-severe patients. 
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Gene 
Peak Size at 
Promoter Comparison 
Gene 
Expression in 
Severe asthma 
DEG FDR 
p-value 
<0.05 S8 NS1 NS4 
CAMP 10 5 5 Higher Peak in Severe Upregulated 
 CD81 37 0 5 Higher Peak in Severe Downregulated 
 GGA1 50 40 36 Higher Peak in Severe Downregulated 
 FOS 74 163 116 Lower Peak in Severe Upregulated 
 ZFP36 10 35 35 Lower Peak in Severe Upregulated 
 CNN2 20 30 18 Lower Peak in Severe Downregulated 
 HIST1H1C 15 119 108 Lower Peak in Severe Downregulated * 
DEFA 0 7 5 Absent Severe Peak Upregulated 
 JUND 0 22 30 Absent Severe Peak Upregulated * 
NDUFB8 0 50 35 Absent Severe Peak Upregulated 
 MAN2B2 0 25 15 Absent Severe Peak Upregulated * 
TAF15 0 61 50 Absent Severe Peak Upregulated * 
TUBA1A 0 5 0 Absent Severe Peak Upregulated * 
TRIM16L 0 35 16 Absent Severe Peak Downregulated 
 DUSP1 35 35 35 Severe=Non-Severe Upregulated 
 HDC 30 30 30 Severe=Non-Severe Upregulated 
 JUN 46 30 45 Severe=Non-Severe Upregulated 
 MPO 10 23 10 Severe=Non-Severe Upregulated 
 RBM39 62 63 66 Severe=Non-Severe Upregulated * 
MX1 15 36 15 Severe=Non-Severe Downregulated 
  
Table 5.2. ChIP-Seq H3K27ac Promoter Peak Summary 
Summary of Promoter peaks sizes and their relation to gene expression of 
important genes to high-fold change genes and significantly changed genes. 
Numbers taken from UCSC genome browser.
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Figure 5.3. CAMP H3K27ac ChIP-Seq Peaks 
CAMP centred H3K27ac reads from CD8+ T-cells as shown in UCSC genome browser of individual patients; Severe Asthmatic 6 and 
Non-Severe Asthmatics 1 and 4 rated on a relative peak height. Beneath Non-Severe 1 is a plot showing H3K27ac peaks from 
previously reported studies and beneath that purported transcription factor binding sites. The peak of interest is aligned at the gene start 
site.  
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Figure 5.4. GGA1 H3K27ac ChIP-Seq Peaks  
GGA1 centred H3K27ac reads from CD8+ T-cells as shown in UCSC genome browser of individual patients; Severe Asthmatic 6 and 
Non-Severe Asthmatics 1 and 4 rated on a relative peak height. Beneath Non-Severe 1 is a plot showing H3K27ac peaks from 
previously reported studies and beneath that purported transcription factor binding sites. The peak of interest is aligned at the gene start 
site. 
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Figure 5.5. CD81 H3K27ac ChIP-Seq Peaks 
CD81 centred H3K27ac reads from CD8+ T-cells as shown in UCSC genome browser of individual patients; Severe Asthmatic 6 and 
Non-Severe Asthmatics 1 and 4 rated on a relative peak height. Beneath Non-Severe 1 is a plot showing H3K27ac peaks from 
previously reported studies and beneath that purported transcription factor binding sites. The peak of interest is aligned at the gene start 
site. 
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Figure 5.6. FOS H3K27ac ChIP-Seq Peaks 
FOS centred H3K27ac reads from CD8+ T-cells as shown in UCSC genome browser of individual patients; Severe Asthmatic 6 and Non-
Severe Asthmatics 1 and 4 rated on a relative peak height. Beneath Non-Severe 1 is a plot showing H3K27ac peaks from previously 
reported studies and beneath that purported transcription factor binding sites. The peak of interest is aligned at the gene start site. 
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Figure 5.7. HIST1H1C H3K27ac ChIP-Seq Peaks 
HIST1H1C centred H3K27ac reads from CD8+ T-cells as shown in UCSC genome browser of individual patients; Severe Asthmatic 6 
and Non-Severe Asthmatics 1 and 4 rated on a relative peak height. Beneath Non-Severe 1 is a plot showing H3K27ac peaks from 
previously reported studies and beneath that purported transcription factor binding sites. The peak of interest is aligned at the gene start 
site. 
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Figure 5.8. DEFA1 H3K27ac ChIP-Seq Peaks 
DEFA1, DEFA3 and DEFA1B centred H3K27ac reads from CD8+ T-cells as shown in UCSC genome browser of individual patients; 
Severe Asthmatic 6 and Non-Severe Asthmatics 1 and 4 rated on a relative peak height. Beneath Non-Severe 1 is a plot showing 
H3K27ac peaks from previously reported studies and beneath that purported transcription factor binding sites. The peak of interest is 
aligned at the gene start site. 
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Figure 5.9. RBM39 H3K27ac ChIP-Seq Peaks 
RMB39 centred H3K27ac reads from CD8+ T-cells as shown in UCSC genome browser of individual patients; Severe Asthmatic 6 and 
Non-Severe Asthmatics 1 and 4 rated on a relative peak height. Beneath Non-Severe 1 is a plot showing H3K27ac peaks from 
previously reported studies and beneath that purported transcription factor binding sites. The peak of interest is aligned at the gene start 
site.
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5.4 Discussion 
An increase in H3K27ac at the TSS normally associates with an increased 
expression of a gene (Creyghton et al. 2010) and this is demonstrated by 
CAMP (Figure 5.3).  CAMP gene expression is increased in severe asthma 
cells and the enrichment of the H3K27ac mark suggests that it is controlled by 
the expected mechanism of enhanced histone acetylation. However, both 
GGA1 (Figure 5.4) and CD81 (Figure 5.5) had an increased peak of H3K27ac 
but a reduced gene expression demonstrated by gene array.  This suggests 
that GGA1 and CD81 could be regulated by bivalent regions at the TSS which 
require both H3K27ac and H3K27me3 histone modifications, or other 
regulatory marks, to act in concert to enable gene expression to occur. 
 
The CAMP gene encodes the cathelicidin antimicrobial peptide whose 
activation, therefore, is likely to be controlled by histone acetylation status.  
This enrichment of H3K27ac could also account for the increased expression 
of the DEFA genes (Figure 5.8) which are contained in one locus.  However, 
the H3K27ac mark at the TSS has a gap in the severe asthma subject in this 
region.  It has been shown previously that β-defensins and cathelicidin are 
controlled by acetylation in epithelial cells during infection (Shin et al. 2010; 
Chakraborty et al. 2008).  Specific ChIP analysis may confirm whether this is 
the case here. 
HDC and MPO also show an equal enrichment at their promoters between the 
severe and non-severe patients, again the enrichment at the TSS in the 
severe asthmatic subject could have been underestimated by the ChIP-Seq.   
 
CNN2 and HIST1H1C (Figure 5.7) have lower H3K27ac peaks in the severe 
asthmatic cells and the expression of both these genes are downregulated.  
This result is expected although this data cannot be relied upon since both 
FOS and ZFP36, which also have reduced H3K27ac peaks, are up-regulated 
at the gene level in these cells.  
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5.5 Conclusion and next steps. 
This experiment needs to be repeated, not only is the n=1 in severe and n=2 
non-severe insufficient for drawing broader conclusions about severe asthma, 
the read count is also far too low. The lack of H3K27me3 data prevented the 
elucidation of the role of this mark in the regulation of gene expression in 
human primary CD8+ T-cell and the location of bivalent genes.  Ideally, a 
repeat experiment should be performed using much greater subject numbers 
that would allow analysis of subtypes of the disease.  Greater cell numbers 
will provide more RNA and cDNA for analysis and allow the use of input DNA 
to assess the level of enrichment more accurately. 
  
If all patients had been correctly analysed the data set would have allowed the 
relationship between the expression of every gene and its associated histone 
acetylation and tri-methylation score to be assessed.  This would have 
enabled me to determine on a global genetic scale, the genes which are 
differentially regulated between severe and non-severe asthmatics by 
alterations in histone modifications. 
 
Although the levels of acetylation and methylation were not adequately 
measured using ChIP-seq, in the next chapter I use epigenetic mimics to help 
understand the mechanisms that control gene and protein expression in CD8+ 
T-cells.   
 
It was not possible to address the hypothesis for this chapter due to the low n-
numbers due to poor processing protocols. In future attempts samples should 
be processed before storing. It may be sensible to compare single patients to 
their expression rather than the averages across the cells as a general 
merthodology if enough patients work efficiently with both ChIP-Seq and Gene 
Array. 
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Chapter 6: The Role of 
CBP and p300 in CD8+ 
T-cells of Severe 
Asthmatics 
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6.1 Chapter Introduction 
MIP1α/CCL3 is a marker of CD8+ T-cell activation and is strongly chemotactic 
for eosinophils and macrophages suggesting a role in both Th1 and Th2 
phenotypes (Cocchi et al. 1995; Oliveira et al. 2002; Reichel et al. 2009). 
Median levels of MIP1α have been shown to be increased in asthmatic 
sputum (Daldegan et al. 2005).  
 
Th2 type inflammatory inhibition has been associated with Brd-linked 
acetylation (Pinz et al. 2015). This suggests that BET mimics/probes such as 
bromosporine, JQ1 or SGC-CBP30 may be able to reduce inflammation in 
CD8+ T-cells as has been demonstrated with JQ1 in LPS- and IL-1β-induced 
inflammation in mouse macrophages and human epithelial cells respectively 
(Filippakopoulos et al. 2010; Khan et al. 2014). 
Histone methylation is associated with CD4+ T-cell differentiation and H3K4 
tri-methylation is found in Th2 cells at the IL4/IL13 locus demonstrating an 
activating property (Wei et al. 2009). This indicates that using methylated 
lysine mimics such as GSK-J1 and GSK-J4 may also limit Tc2 cell activation. 
There are many methylases which influence T-cell transcriptional activation, 
both positively and negatively. For example G9a, which targets H3K9 
methylation, inhibits the release of VEGF which modulates basement 
membrane remodelling, EZH2 catalyses H3K27 trimethylation and can block 
production of IL-4 and IL-13 whilst  SETD7, which specifically targets H3K4, 
modulates gene activation at NF-κB binding sites (Barsyte-Lovejoy et al. 
2014; Wang et al. 2001; Rai et al. 2010; Yamashita et al. 2006; Tumes et al. 
2013). Mimics such as UNC0642, GSK343, and PFI-2 block G9a, EZH2/1 and 
SETD7 actions respectively. 
 
6.2 Chapter Hypothesis and Aims 
CD8+ T-cells from severe asthmatics will have a novel mechanism of control 
to activate release of inflammatory cytokines that can be investigated by using  
epigenetic probes/mimics. The probes will have differing effects on the 
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function of CD8+ T-cells and bronchial epithelial cells. To investigate this 
hypothesis I will: 
• Measure the inhibitory effects of epigenetic mimics on Dynabead 
induced release of MIP1α from CD8+ T-cells of severe asthmatics and  
• Investigate the mechanism of action of mimics which reduce 
inflammation by carrying out ChIP and PCRs of key genes.  
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6.3 Results 
6.3.1 Primary human CD8+ T-Cells 
6.3.1.1 Effect of epigenetic probes/mimics on dynabead-induced MIP1α 
release from CD8+ T-cells isolated from severe asthmatics 
Cells from two patients (Subject 1 and 2, Table 6.1) were used for most of the 
screening experiments but a third subject (Subject 3, Table 6.1) was also 
used for the SGC-CBP30 studies to enable the use of statistics. The doses 
and activators were selected using a TALL-104 model cell line.  The severe 
asthmatics were as defined in Section 2.6.1.  Two of three patients had been 
on a course of oral prednisolone in the previous year and all were on >800mg 
inhaled FP or equivalent and were atopic (Table 6.1).  
 
Most compounds (Figure 6.1: UNC0638 (B), UNC0642 (C), JQ1(-) (E), 
Bromosporine (F), GSK-J1 (G), GSK-J4 (H), UNC1999 (I), GSK-343 (J)) had 
no apperent effect on the dynabead-stimulated release of MIP1α from severe 
asthmatic cells.  JQ1(+) had a variable concentration-dependant response 
(Figure 6.1D) reaching a maximal effect at 320nM of 30.6±20.4 inhibition.  If 
the n-number had been increased it is likely that it would have been a 
significant increase.  
SGC-CBP30 significantly inhibited MIP1α release at the highest dose from 
stimulated CD8+ T-cells with a maximal response at 1600nM which reduced 
MIP1α output to 10.1±6.2% of the maximal release with an IC50 = 210nM. MTT 
showed no significant decrease in mitchondiral activity suggesting acceptable 
viability. 
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#	 Age	 Atopy	 Severity	 Prednisolone	(mgs)	
ICS	(FP	
equivalent,	
mgs)	
FEV1	
(L)	
FEV1	
%	Pred	
FVC	
(L)	
FEV1
:FVC	
1	 31	 +	 Severe	 20mg	 1000	 3.3	 104	 3.8	 84	
2	 48	 +	 Severe	 2	courses	in	past	year	 800	 2.67	 95	 3.35	 90	
3	 29	 +	 Severe	 0	 800	 2.67	 82	 3.6	 75	
 
Table 6.1. Patients Demographics for CD8+ T-cells used for compound 
screening 
Demographics of severe asthma volunteers whose peripheral CD8+ T-cells 
were used to screen compounds. Cells from patient 1 were used for all 
epigenetic mimics, cells from patient 2 were used for all studies except those 
for GSK-J5 and UNC1215. Patient 3 was only used for studies using SGC-
CBP30. ICS = inhaled corticosteroid, FP = fluticasone propionate, FEV1 = 
forced expiratory flow in 1 second, FVC = forced vital capacity, % pred = 
percent predicted. 
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Figure 6.1. Concentration-Response to Epigenetic Probes of Dynabead-
Stimulated Severe Asthamtic CD8+ T-cells 
Concentration response of SGC-CBP30 (A), UNC0638 (B), UNC0642 (C), 
JQ1(+) (D), JQ1(-) (E), bromosporine (F), GSK-J1 (G) GSK-J4 (H), UNC1999 
(I), GSK343 (J) and UNC1215(K) 24 hours post stimulation of peripheral 
blood CD8+ T-cells (2x105/ml) with dynabeads (2x105 beads/ml). n=2 (except 
A which has n=3). * = p<0.05 Freidman’s test (ANOVA non-parametric 
matched pairs) MTT showed no decrease in viability. 
 
6.3.2 RT-qPCR  
In separate experiments, CD8+ T-cells from two severe asthmatics (Table 
6.2) were stimulated with dynabeads in the presence and absence of SGC-
CBP30 and PCR analysis was performed on FOXP3, TUBA1A, JUND, 
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DEFA1B, CD81, MIP1α and IFNγ mRNAs. TUBA1A, JUND, DEFA1B, CD81 
were selected based on their changes in the severe asthma patients from 
Chapter 4. FOXP3 was selected as it is T-cell differentiation control gene 
which is regulated by CBP/p300, MIP1α on account that its protein output is 
inhibited by SCG-CBP30 and IFNγ as a marker for Tc1 type activation.  
JUND (Figure 6.2B) expression was decreased after stimulation (ΔCT, 3.06 ± 
4.33 x106 v’s 2.58 ± 3.6 x105) and further attenuated with SGC-CBP30 pre-
treatment (1.06 ±1.48 x104). The expression of FOXP3 (Error! Reference 
source not found.A), IFNγ (Error! Reference source not found.C), CD81 
(Error! Reference source not found.D) and MIP1α (Error! Reference 
source not found.E) mRNAs all decreased with dynabeads but were 
unaffected by treatment with SGC-CBP30 (FOXP3 ΔCt, unstimulated = 4.17 ± 
5.90 x1015, dynabeads = 5.64 ± 7.96 x108, dynabeads/SGC-CBP30 = 2.18 
x108± 3.07 x106; CD81 ΔCt, unstimulated = 2.88 ± 4.07 x108, dynabeads = 
5.01 ± 8.39 x106, dynabeads/SGC-CBP30 = 5.38 ± 7.61 x106; MIP1α ΔCt, 
unstimulated = 2.41 ± 1.58 x1010, dynabeads = 2.23 ± 1.4x108, 
dynabeads/SGC-CBP30 = 2.30 ± 2.04 x108; IFNγ ΔCt, unstimulated = 9.02 ± 
4.38 x1010, dynabeads = 6.86 ± 7.55 x106, dynabeads/SGC-CBP30 = 6.08 ± 
6.74 x106).  
TUBA1A mRNA expression increased after dynabeads stimulation (ΔCt, 1.14 
± 1.61 x10-3 v’s 8.67 ± 0.12 x10-2) and further increased 10-fold with SGC-
CBP30 (ΔCt, 0.11 ± 0.15).  
Finally, DEFA1B expression increased post-dynabead stimulation (ΔCt, 9.54 ± 
13.50 v’s 13.93 ± 19.70) which was reversed by pre-treatment with SGC-
CBP30 (ΔCt, 3.55 ± 5.028). 
 
Age	 Atopy	 Severity	 Prednisolone	(mgs)	
FP	(mg)	
Equivalent	
FEV1	
(L)	
FEV1	%	
predicted	 FVC	
FEV1:	
FVC	
47	 +	 Severe	 0	 1000	 2.87	 72.5	 3.92	 68	
68	 -	 Severe	 0	 500	 2.03	 83	 2.7	 87	
 
Table 6.2. Patient Demographics CD8+ T-cells used for SGC-CBP30 RT-
qPCR screening 
189 
 
 189 
Demographics of severe asthmatics whose peripheral CD8+ T-cells were 
stimulated with dynabeads in the presence and absence of SGC-CBP30 and 
analysed using RT-qPCR. 
 
  
Figure 6.2. RT-qPCR analysis of gene expression in CD8+ T-cells from 
Severe asthmatics after SGC-CBP30 and Dynabeads treatment  
Gene expression by RT-qPCR of FOXP3 (A), JUND (B), IFNγ (C), CD81 (D), 
CCL3 (E), DEFA1A (F) and TUBA1A (G) from Severe Asthmatics’ (Table 6.2) 
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Peripheral CD8+ T-cells after two hours stimulation with 2x105/ml dynabeads 
and pre-treated for one hour with 400nM SGC-CBP30. n=2. 
 
6.3.3 CREB Binding Protein ChIP 
CD8+ T-cells were isolated from 2 severe asthmatics (Table 6.3), stimulated 
with dynabeads in the presence and absence of SGC-CBP30 with the same 
number of cells in each well for each patient. CBP immunoprecipitation 
followed by PCR analysis of FOXP3 (Figure 6.3), IFNγ (Figure 6.4) and MIP1α 
(Figure 6.5) promoters was performed to investigate whether CBP was 
associated with regulatory regions of these key genes.  CBP binding to the 
FOXP3 promoter was markedly decreased by dynabead stimulation in both 
subjects (Fold Enrichment (FE), the Input:Output ratio, 1.079 to 0.145 in 
severe subject 1 and 5.540 to 0.062 in severe subject 2).  The effect of 
CBP30, however, was variable with a further decrease in severe subject 1 (FE 
= 0.008) and an increase in severe subject 2 (FE = 1.050).  
IFNγ showed minimal CBP enrichment after dynabead stimulation (3.84x10-3 
v’s 9.38x10-3) in severe subject 1 but this binding was completely ablated in 
the presence of CBP30.  No Ct score was observed from the PCR run for 
dynabeads/CBP30. In severe subject 2, CBP promoter binding at the IFNγ 
promoter decreased after dynabeads (FE, 0.345 v’s 1.45x10-3) and further 
decreased in the presence of dynabeads/CBP30 (FE, 2.1x10-5).  CBP binding 
to the MIP1α promoter of severe asthma subject 1 showed limited change 
between unstimulated and dynabeads-stimulated samples (FE, 7.57x10-3 v’s 
8.89x10-4) in severe subject 1 but showed no binding after dynabeads/CBP30 
exposure with no detectable Ct score from the PCR run.  In contrast, CBP 
MIP1α promoter binding in severe subject 2 decreased after dynabeads 
stimulation (FE, 0.135 v’s 1.07x10-3) and a slight increase in CBP binding with 
CBP30 (2.889x10-3). 
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#	 Age	Atopy	 Severity	 Prednisalone	(mgs)	
FP	(mg)	
Equivilent	
FEV1	
(L)	
FEV1	%	
predicted	 FVC	
FEV1:	
FVC	
Severe	1	 56	 -	 Severe	 0	(3	courses	a	year)	 500	 2.56	 78	 3	 79	
Severe	2	 29	 +	 Severe	 0	 1000	 2.25	 69	 3.55	 63	
Table 6.3. Patient Demographics for SGC-CBP30 treated CD8+ T-cells 
used for CBP ChIP  
Demographics of subjects whose peripheral CD8+ T-cells were stimulated 
with dynabeads (2x105/ml) in the presence and absence of SGC-CBP30 
(400nM) and CBP binding analysed using PCR after 2 hours of stimulation. 
 
  
 
Figure 6.3. CBP Binding to the FOXP3 Gene after SGC-CBP30 treatment 
CBP Binding to the FOXP3 gene promoter in peripheral blood CD8+ cells 
from 2 severe asthmatic subjects (Table 6.3) 2 hours after stimulation with 
dynabeads (2x105/ml) and pre-treated for one hour with 400nM SGC-CBP30.  
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Figure 6.4. CBP Binding to the IFNγ  Gene after SGC-CBP30 treatment 
CBP Binding to the IFNγ gene promoter in peripheral blood CD8+ cells from 2 
severe asthmatic subjects (Table 6.3) 2 hours hours after stimulation with 
dynabeads (2x105/ml) and pre-treated for one hour with 400nM SGC-CBP30. 
Severe 1’s SGC-CBP30 treatment did not cross threshold in PCR. 
 
 
 
Figure 6.5. CBP Binding to the CCL3 Gene after SGC-CBP30 treatment 
CBP Binding to the MIP1α gene promoter in peripheral blood CD8+ cells from 
2 severe asthamtic subjects (Table 6.3) 2 hours hours after stimulation with 
dynabeads (2x105/ml) and pre-treated for one hour with 400nM SGC-CBP30. 
Severe 1’s dynabead stimulation alone did not cross threshold in PCR. 
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6.4 Discussion 
SGC-CBP30, the p300/CBP specific bromodomain inhibitor (Hay et al. 2014), 
reduced anti-CD3/CD28-stimulated MIP1α release in a concentration-
dependant manner in CD8+ T-cells (Error! Reference source not found. & 
Figure 6.1). This demonstrates the potential to expand the power of this study 
by recruiting more patients. If these findings were to remain valid there may 
be potential for the therapeutic use of compounds with similar targets since 
reducing the inflammatory response of CD8+ T-cells in the asthmatic airways 
could reduce bronchoconstriction and airway remodelling, particularly post-
infection (Hogan et al. 2001). 
 
The MIP1α gene expression showed a small decrease following dynabeads 
stimulation, but no difference between SGC-CBP30 stimulation with 
dynabeads and dynabeads alone. Considering the data in other cell types it 
was surprising that CBP30 did not decrease anti-CD3/CD28 dynabead-
induced MIP1α mRNA expression (Figure 6.2E) and it is unclear from the 
current ChIP analysis (n=2) whether CBP protein binding to the MIP1α 
promoter is affected by the CBP30 mimic. Increasing the number of subjects 
studied will begin to clarify these issues.  One possible alternative explanation 
is that p300/CBP has a role in MIP1α translation and/or release from vesicles 
rather than on gene expression per se.  
 
p300, which is closely linked to CBP in both homology and function, has a role 
in macrophage autophagy and directly acetylates several core proteins 
including microtubule-association protein 1A/1B light chain (LC3) (Lee & 
Finkel 2009). p300 inhibition has also been shown to increase the activity of 
acetyl transferase α-tubulin N-acetyl transferase 1 (αTAT1) which hyper-
acetylates tubulin (Mackeh et al. 2014). This could suggest a role for 
CBP/p300 in microtubule release of vesicles containing MIP1α rather than 
direct transcriptional roles. It will be important to look at other proteins 
released by CD8+ T-cells to investigate whether there is inhibition of the 
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release of other inflammatory cytokines and cell puncturing apparatus such as 
IFNγ. The expression of Ifng expression was suppressed after dynabead 
stimulation (Figure 6.2B) and was unchanged after CBP30 stimulation. It has 
been shown previously that CBP30 has no effect on IFNγ in Th17 cells 
(Hammitzsch et al. 2015) and so it would be interesting to see its level of 
release in these CD8 T-cells and in other T-cell subtypes.  JQ1+ has a similar 
effect to CBP30 on release of MIP1α if after increasing the n-number of these 
studies it maintained this effect it would be interesting to see the mechanism 
of action that it was able to carry this out by. 
 
As there was a change in the release of MIP1α and high serum MIP1α has 
been linked to decreased FOXP3 stability, I explored the possibility that 
FOXP3 instability is associated with a reduction of its expression. This data 
demonstrated that FOXP3 was downregulated when stimulated with 
dynabeads suggesting that it could be cell activation which reduces FOXP3 
expression. This would be sensible as activation of Tc cells will reduce the 
Treg function of these cells which is under FOXP3 control.  
 
TUBA1A mRNA expression (Figure 6.2E) increases after stimulation of CD8 
cells by dynabeads whereas the expression of CD81 (Figure 6.2D) decreases 
and CBP30 has no effect on the expression of either. The dynabead 
stimulation has enhanced a set of traits that were previously shown in severe 
asthma compared to non-severe asthma (Section 4.4.2.1). Dynabeads also 
demonstrated an enhancement of the previously demonstrated severe 
asthma phenotype with DEFA1A expression similar in Section 4.4.2.3. 
DEFA1A is the only mRNA investigated whose expression was increased 
following dynabead stimulation and was decreased, but not significantly, with 
SGC-CBP30.  This suggests that CBP30 could counter the differential 
expression of this gene as reported in CD8+ cells from severe asthmatics as 
studied in Chapter 4.  It will be important to determine the global effects of this 
mimic on gene expression profiles from severe asthma cells to obtain a full 
understanding of potential benefits and side-effects of CBP30. 
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The increase in tubulin mRNA expression could suggests a move towards the 
CD8+ cells adopting more cell-cell adhesion characteristics if this manifested 
in protein expression. An increase in cell-cell adhesion could be observed 
under the microscope following dynabead stimulation (Figure 6.6 
   
Figure 6.6. Micrograph of CD8+ T-cell Clustering around Dynabeads 
CD8+ T-cells (clear) bind to each other and associate with dynabeads (dark) 
(x400, no stain). 
 
The expression of JUND, which has been previously reported to have a role in 
steroid insensitivity (Lane et al. 1998), was downregulated after dynabead 
stimulation and further down-regulated by CBP30.  This is in contrast to the 
elevated expression of JUND seen by Lane and colleagues examining total 
PBMCs but further studies will need to be conducted to determine whether 
there is differential expression in patients with different asthma severity.  The 
suppression of JUND by CBP30 suggests that it may be effective in 
subjects/cells where it is overexpressed.  
 
6.5 Conclusion and next steps 
Dynabead activation of CD8+ T-cells has differential effects on the genes 
studied here.  They enhance or inhibit the expression of DEFA1A, CD81 and 
TUBA1A in similar ways to that seen in the cells from severe asthma subjects 
in the previous chapter.  
 
This preliminary data, using low n-numbers, demonstrates that CBP30 limited 
the release of MIP1α without affecting the total expression of MIP1α/CCL3 
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mRNA. p300 has a role in acetylation of tubulin and microtubule acetylation, 
which has been mostly studied in autophagy (Lee & Finkel 2009).  This effect 
of p300, rather than an effect on acetylated histone interactions with basal 
transcription factors, may account for the suppression of the release of 
MIP1α-containing vesicles.  
 
It is possible that the mechanism involved in the release of MIP1α is 
specifically different from the cytokine release of the the bronchial epithelium 
as in chapter 3. SGC-CBP30 is able to have a significant effect on MIP1α 
release at high doses, where as this did not happen in bronchial epithelium 
suggesting a cell type specific effect of this compound. SGC-CBP30 did have 
a dose responsive effect and higher n-numbers may have shown this to be 
significant at much lower doses. JQ1+ seemed to also have a similar effect 
which may be possible to ascertain if the n-number was increased, however 
this may work by a different mechanism as it also had this effect on the 
epithelium.   
I was unable to elucidate the specifics of the mechanism which inhibited the 
release of MIP1α, as the n-numbers were so low, however it is possible that 
the effects of SGC-CBP30 operate via a non-mRNA route, perhaps an effect 
on Tubulin acetylation. To further study this it could be possible to co-
immunoprecipitate CBP and Tubulin to demonstrate an association once the 
n-numbers were increased to confirm that this infact the case. 
 	 	
197 
 
 197 
Chapter 7: Discussion 
  
198 
 
 198 
7.1 General Discussion 
Using a combination of differential gene expression analysis from published 
U-BIOPRED data on bronchial brushing cells, proteomics analysis by SILAC 
of FP actions on healthy human airway epithlelial cells and pharmacologic 
analysis of epigenetic mimics, I was able to demonstrate small mRNA 
changes in histone H1 and H2B expression in severe asthma and that the 
BET mimic JQ1 was able to suppress IL8 release without affecting cell 
proliferation or viability in eptithelail cells.  In contrast, SGC-CBP30, that 
targets CBP/p300, prevented epithelial cell proliferation without affecting 
inflammation.  Interestingly, CITED2 mRNA, which encodes CBP/p300 
interacting protein, was overexpressed in bronchial biopsies but not airway 
structural cells of severe asthmatics.  In peripheral blood CD8+ T-cells SGC-
CBP30 was able to suppress the release of the inflammatory mediator MIP1α 
which was also affected by JQ1, but not bromosporin without affecting CCR3 
mRNA levels.  Gene expression analysis of CD8+ T-cells from severe 
asthmatics and non-severe asthmatics suggested the importance of RNA 
modifying genes, the pro-inflammatory AP-1 complex and antimicrobial 
genes.  Using WGCNA it was possible to identify a module that was 
associated with asthma severity (as determined by FEV1 % predicted) but 
independent of steroid use.  This module contained genes linked to alterations 
in histone methylation and with intracellular organelle movement such as 
TUBA1A.  Other modules were related to FEV1 % predicted which contained 
interesting genes such as IL-10, IL-17 as well as others with little known 
interactive function.  Further higher power analysis may define the pathways 
involved in selective CD8+ gene expression linked to asthma severity which 
may provide novel pathways for drug discovery. 
 
7.1.1 Bronchial Epithelial Epigenome Exploration 
The hypothesis that epigenetic status and global transcriptome of the 
bronchial epithelium in severe asthma could help to discover novel pathways 
was first tested by using pre-existing expression and proteomic data sets.  
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The U-BIOPRED bronchial brushings showed significant differences in the 
gene expression of histone cluster 1, H1E and H2BK between severe 
asthmatic subjects and healthy controls which was not observed in 
mild/moderate asthmatics (Section 3.3.1.1).  These histones have differing 
affinities for DNA (Halmer & Gruss 1996; Sun et al. 2015) and are involved in 
the regulation of gene expression.  The data suggests that the differing affinity 
may affect the global response to perturbation by exogenous stimuli that 
occurs in cells from severe asthmatics. No changes in the gene expression of 
histone modifying enzymes were shown, but this does not mean that their 
activity or protein expression was unchanged as they could be regulated at 
the post-translational level, for example phosphorylation of HDAC7 alters its 
nucleocytoplasmic shuttling properties (Gao et al. 2006). 
The effects of the anti-inflammatory asthma treatment fluticasone propionate 
(FP) was also studied in primary human bronchial epithelial cells.  FP effects 
on changes in the incorporation of amino acids, reflecting de novo protein 
synthesis, was measured by SILAC and downstream proteomic analysis by 
mass spectroscopy was performed. The low power SILAC data hinted at the 
idea that FP decreased the amount of HDAC7 and of SETD7 and SMYD3, 
two H3K4 methyltransferases, in cells from healthy non-asthmatic subjects.  
HDACs are associated with modulating inflammatory gene expression and 
other cellular functions (Elsharkawy et al. 2010; Ashburner et al. 2001) and 
HDAC2 is involved in mediating CS responsiveness (Barnes et al. 2004).   
 
HDAC7 is been shown to be involved in the trans differentiation of Pre-B Cells 
into macrophages and suppresses functions of macrophages including 
immune and inflammatory responses (Barneda-Zahonero et al. 2013), as FP 
reduces HDAC7 there is potential for it to be a mechanism of FP to reduce 
inflammation. 
 
The role of H3K4 methylases in regulating the inflammatory response and its 
control by CS is currently unclear, however an increase in the expression of 
these specific enzymes may suggest that altered methylation may be 
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important in CS function.  H3K4 methylation is implicated in the control of 
gene expression (Vijayanand et al. 2012) and may therefore be a key target of 
CS (Jangani et al. 2014).   
 
To investigate changes in bronchial epithelial histone modifications a multiplex 
ELISA of a variety of histone modifications was carried out.  This 
demonstrated that there were no global changes in levels of most histone 
modifications at baseline and that FP had no effect on whole cell acetylation 
status.  This may reflect the fact that acetylation effects regulated by FP are 
selective for responsive genes or that these modifications in healthy patients 
are relatively stable with high levels of redundancy. This redundancy is 
demonstrated by the siRNA depletion of HATs in drosophila cells, which has 
no effect and that the acetylome is probably more fixed than transient (Imhof 
et al. 2015).  
 
The next step which should have been followed was a full histone modification 
map of H3K4 methylation, H3K27ac and H3K27me3 and expression studies 
in the same bronchial epithelial samples.  This would have enabled me to 
differentiate the effects of FP on specific histone marks in a gene- and 
promoter/enhancer-specific manner.  These gene-specific effects on histone 
status are more likely to reflect FP actions than alterations in global 
methylation.  This approach may also have defined differences in the cellular 
methylome between severe and non-severe asthmatics and the extent to 
which these modifications controlled the changes in gene expression 
identified in the U-BIOPRED samples.  The data from U-BIOPRED has 
identified differences in gene expression between patients and is large 
enough that patient/sample sub-setting is viable.  
It would have been an ideal opportunity to explore differences in histone 
modifications in a large set of severe asthmatic subjects using ChIP-seq 
analysis.  However, the pace of sample collection and cell culture issues 
resulted in this approach not being viable to complete over the course of this 
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PhD.  Future studied should prioritise this type of analysis to improve our 
understanding of the bronchial epithelium’s relationship with severe asthma. 
 
Of the many selective epigenome mimics used to analyse cell function, two 
broad spectrum bromodomain readers inhibited the release of CXCL8 and IL-
6 - bromosporine and JQ1(+).  JQ1(+)s anti-inflammatory effects have been 
demonstrated in other cell types (Magistri et al. 2016; Meng et al. 2014). The 
more specific BET inhibitor, CBP30/p300, had no effect on the release of 
inflammatory mediators from bronchial epithelial cells measured in this study, 
but did have an effect on proliferation which is relevant to their mechanism of 
action which will be discussed later. 
 
7.1.2 CD8+ T-cell transcriptome 
Exploring the CD8+ T-cell transcriptome in severe asthma was fruitful in 
determining genes and more importantly novel pathways linked with severe 
asthma.  
 
This thesis highlighted the differential expression of a group of RNA modifying 
proteins, namely SSB and TAF15.  TAF15 modifies the transcription of RNA 
and SSB inhibits exonuclease digestion of RNA. This could give them the 
ability to increase the life span of RNAs which are differentially expressed in 
these cells.  Further study of these proteins may shed light on the cause of 
the differential expression of the other genes and ncRNAs seen in these cells 
in severe asthma.   
Fos, Jun & JunD which are components of the inflammation- and proliferation-
linked transcription factor AP-1 were all highly increased in severe asthmatic 
CD8+ T-cells.  This suggests that these cells are highly activated which is 
also indicated by the enhanced expression of another group of upregulated 
antimicrobial genes DEFA1B/A3/A1, CAMP, MPO and CTSG.  Why these 
genes should be activated to defend against infectious agents in stable 
subjects with severe disease is interesting and may reflect a sub-clinical effect 
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of microbiome or virome dysregulation.  It would be interesting to measure the 
release and internal storage of these proteins to investigate whether this is 
simply a change in mRNA expression or whether there is translation occurring 
to enact this phenotype.  Future studies should investigate the basal and 
dynabead-stimulated release of analytes from CD8+ T-cells from healthy, 
non-severe and severe asthmatics using unbiased proteomics or SomaLogic 
analysis to confirm this transcriptomic profile at the protein level.  
 
Interestingly when the PMBC transcriptome in the U-BIOPRED dataset was 
analysed, the expression of DEFA4, LTF, MMP8 and CEACAM8, genes 
representing anti-microbial proteins, were found to be decreased in severe 
asthmatics. This decrease in global expression of anti-microbial genes 
suggests that the increase observed in isolated CD8+ T-cells is selective and 
is in direct contrast to what other cells in the blood are producing.  This may 
reflect a selective recruitment of these cells to the airways from the blood 
compartment in severe asthma.  In this respect, it would be extremely useful 
to examine the expression of anti-microbial genes from isolated or 
microdissected CD8+ T-cells from airway biopsies to determine whether the 
same activation profile is occurring in the airways.  However, this may be 
technically difficult as CD8+ counts are low in bronchial biopsies. 
 
The combination of WGNCA, an unbiased pathway discovery method, and 
gene ontology, based on existing publications, was a useful way to find key 
genes driving CD8+ dysfunction in a semi-biased fashion.  The light-green 
module positively correlated to asthma severity and the gene ontology 
identified EHMT1, a H3K9 methylase, and another histone-lysine N-
methyltransferase, WHSC1 as being important in severe asthmatic CD8+ T-
cells.  Although the EHMT1/2 inhibitor (UNC0642) had no effect on the 
differentially expressed release of MIP1α from severe asthmatic CD8+ T-cell it 
is important to examine the effect of this inhibitor on whole cell transcriptomics 
or on the release of a wider range of analytes using SomaLogics for example.  
This emphasises the fact that although gene ontology is critical for drawing 
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out differentially regulated pathways it cannot usually select a single gene 
target.  Whether there are specific local changes in histone methylation status 
in CD8+ T-cell could be investigated by ChIP-Seq.   
 
WGCNA analysis also identified 2 modules, Red and Blue that were 
associated with FEV1 % predicted.  These modules highlighted several genes 
including IL17A, ZNF24, BID, PDE9A, BOX12, KDM4D, EDN, KCNIP2, 
FGFR4 and IL10.  Their functional interaction in CD8+ cells requires further 
elucidation. 
 
Many genes are determined as differentially expressed in disease and health 
but they are often ignored, as their functions are unclear or unknown.  These 
genes are often ignored during analysis in favour of genes which have greater 
currently available literature.  These unknown genes are termed the 
“ignorome” (Pandey et al. 2014) and it is increasingly recognised as a critical 
problem.  In neuroscience, the top 5% of genes are discussed in 70% of the 
relevant literature whereas 20% of the genes discovered have no associated 
literature whatsoever.  Often, the only relationship between the number of 
publications relating to a specific gene is its date of discovery, where older 
genes are more highly published (Pandey et al. 2014).  A similar study has 
been carried out in mouse asthma models using meta-analysis of data from 
well phenotyped models with gene arrays carried out on similar platforms 
(Riba et al. 2016).  The mouse asthma ignorome contained many protein 
coding genes which are highly differentially expressed in mouse asthma 
models, but have no published function or relationship with the models. 
Though the large increases of data which further existing work, the 
demonstration of the ignoromes of asthma will provide novel areas of 
investigation in future work.  
 
The WGCNA analysis of the Tsitsiou data (Tsitsiou et al. 2012) produced 
many fewer modules despite using the same algorithm.  In addition, they 
showed a weak correlation with FEV1 % predicted unlike the Red and Blue 
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modules obtained in the current dataset.  There were however strong links 
between the modules suggesting intracellular trafficking is a key process in 
defineing the asthmatics CD8+ T-cells phenotype 
The low sample sizes and heterogeneous nature of asthma will always be a 
problem when compared to the scale of the U-BIOPRED data.  The size of the 
U-BIOPRED dataset enables subsetting which is essential for the 
identification of biomarkers that are essential for the initial steps to enable the 
concept of personalised medicine and the identification of highly selected 
treatments for identified patients to be realised.  In addition, the detailed 
demographic details available in the U-BIOPRED dataset enables better 
discrimination of the WGCNA modules between the studies. 
 
7.1.3 CD8+ T-cell Histone Acetylation and Methylation 
The study to compare histone acetylation and methylation and to link this to 
gene expression profiles was inconclusive due to technical issues with sample 
preparation.  Performing H3K27ac and H3K27me3 ChIP-Seq on the same 
samples as the gene expression data would have been the most important 
element of the current thesis. Linking gene expression with histone 
modification marks across the genome would have clarified the roles and 
importance of these modifications.  These important experiments should be 
repeated.  
 
7.1.4 Role of Vesicle creation and budding in Severe Asthma 
CD8+ T-cells 
Intracellular localisation is vital for the T-cell activation including APC-T-cell 
signalling, the directional release of cytotoxic proteins by relocation of golgi 
apparatus and for directional cytokine release (Kuhné et al. 2003; Kuhn & 
Poenie 2002; Saito & Yokosuka 2006; Kupfer & Dennert 1984; Kupfer et al. 
1987; Kupfer et al. 1991; Reichert et al. 2001).  The expression of tubulin, 
which is vital for cell linking and intracellular movement of vesicles was 
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increased in CD8+ T-cells in severe asthma (Kupfer & Dennert 1984; Kupfer 
et al. 1987).  This increased expression suggests a potential over activation of 
these processes.  However, the expression of other genes such as those for 
CNN2 involved in cell-cell binding, GGA1 involved in linking the Golgi 
apparatus to vesicles by intermediate filaments and CD81, important for T-cell 
activation and myotubule maintenance  had a non-significant decrease in fold 
change (Charrin et al. 2013; Hines et al. 2014; Hirst et al. 2000).  This 
dissonance suggests that this pathway is highly modulated in severe asthma 
and potentially plays a key role in disease – selective modulation of the 
expression of these proteins along with the analysis of protein expression is 
critical to define the functional effect of these gene expression changes.  
Alongside this classical expression analysis, the WGCNA yellow-green 
module, which differentiated disease and oral steroid use, showed that 
TUBA1A, the tubulin gene, along with DST, DCTN1, VSX1, GNBL2, STK16 
and ARMCX2 which are also linked with this pathway, were differentially 
regulated as a group.   
 
The interrelationship of these genes is shown in Error! Reference source 
not found. DST, which codes for dystonin, anchors intermediate filaments to 
hemidesmosomes, the linkers which bind to the extracellular matrix, collagen 
and DNCT1 (Koster et al. 2003; Liu et al. 2003).  DCTN1 codes for a subunit 
of dynein, a protein whose role is to move vesicles along microtubules which 
are made of tubulin (Kiyomitsu & Cheeseman 2012). GNBL2 encodes RACK1 
which regulates integrin-mediated adhesion, protrusion and chemotactic cell 
migration, which are all key processes in cell-cell interaction and release of 
cytotoxic proteins (Cox et al. 2003). STK16 codes for a serine threonine 
kinase which regulates, alongside MAL2, the creation of robust lysosomes 
and sorting of soluble cargo in the trans-Golgi network.   
However, VSX1 and ARMCX2, do not have a clear role in these pathways.  
VSX1’s has been reported to regulate the development of the eye and 
ARMCX2 is found in extracellular vesicles but its precise function has not 
been elucidated.  Further experiments to determine the role of these 2 
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proteins in CD8+ T-cell function in severe asthma are necessary and doing 
this could be a step in the right direction in terms of overcoming the ignorome 
(Hong et al. 2009; Fraser et al. 2013; Bruno et al. 2009).  
 
 
Figure 7.1. Intracellular and extracellular traffic of CD8+ T-cells. 
This diagram has a focus on genes found in gene array to be significantly 
changed in Severe Asthma (Increased in orange, decreased in blue) and from 
the Green-Yellow Module (Green). 
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The changes in the expression of genes which have roles in the activity of the 
cytoskeleton and intracellular trafficking can be seen in two independent data 
sets when analysed with WGCNA with respect to FEV1 % predicted and 
therefore it would be immensely beneficial to study these proteins in healthy 
and severely asthmatic CD8+ T-cells, firstly using proteomics to gauge 
whether the production of these proteins correlates to baseline mRNA 
measurements and whether they are altered with cell activation.  In addition, 
elucidating the sub-cellular localisation of ARMCX2 using confocal microscopy 
might aid the understanding of its function.  This approach will also enable the 
determination of tubulin expression changes and in functionality in relation to 
microtubule formation in CD8+ T-cells from severe asthmatics. 
 
The importance of tubulin in CD8+ T-cell function was suggested by 
p300/CBP inhibitor, SGC-CBP30 inhibited the release of MIP1α, but may not 
have been acting specifically on transcription.  This may indicate a role for 
tubulin acetylation.  SGC-CBP30 had no effect on MIP1α mRNA but 
decreased its release from cells.  The relationship between the p300/CBP and 
tubulin could be studied using a co-immunoprecipitation between CBP and 
tubulin, measuring the acetylation status of tubulin and measuring tubulin-
alphaTAT1 acetylase activity which is shown to be upregulated when CBP is 
inhibited and is able to change tubulin binding to other proteins (Mackeh et al. 
2014; Howes et al. 2014). 
 
In the first results chapter, SGC-CBP30 caused inhibition of proliferation but 
not viability of HBECs from healthy subjects.  Although not investigated, this 
effect may also reflect an action of SGC-CBP30 on tubulin acetylation as this 
is essential for nuclear division (Morrissette & Sibley 2002).  
 
It will also be important to study the mechanisms by which SGC-CBP30 
attenuates the release of other analytes/inflammatory mediators to determine 
whether the specificity of SGC-CBP30 is broad or very selective.  This can be 
done by running SILAC on both cell media and on the cells themselves. 
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Alternatively SomaLogic analysis of >1300 mediators may be performed.  
Correlation with the effect of SGC-CBP30 on gene expression profiling using 
next generation sequencing or gene arrays will aid determination of whether 
tubulin acetylation is the most important target of SGC-CBP30.  Studies of 
whether MIP1α-containing vesicles are produced and remain intracellular in 
response to CBP/p300 inhibition will also be important. 
 
This thesis stated that epigenetic mechanisms play a key role in regulating 
epithelial and CD8+ T-cell function in the severe asthma phenotype, though 
this may still be the case it will require further investigation. It has, however, 
taken what was thought to be an epigenetic modifying compound (SGC-
CBP30) and suggested that it has another role in severe asthmatic CD8+ T-
cell activation pathway involved in the release of MIP1α. 
 
Pathways associated with intracellular transport and of antimicrobial 
responses are substantially changed in the CD8+ T-cells of severe asthmatics 
and should be extended to analysis of the proteome. Alongside this, the over 
expression of genes which encode for antimicrobial proteins could have 
deleterious effect if translated and released in the lungs potentially causing 
lung remodelling and untreatable hypersensitivity that is present in severe 
asthma. 
 
7.2 Conclusion and future studies 
To answer my hypothesis I would suggest that there are some some targets 
for which epigenetic modifying compounds such as SGC-CBP30 and JQ1+ 
which are able to modulate bronchial epithelial and CD8+ T-cell release of 
cytokines and proliferation which may be relevant to the underlying disease of 
severe asthma.  
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In this thesis there has been a lower power than hoped and the efficacy of the 
experiments haven’t all provided useful results in the positive or negative and 
as such I can’t answer the question of whether histone modifcations play a 
key role in regulating epithelial and CD8+ T-cell dysfunction in the severe 
asthma phenotype. However, the methodology of WGCNA has demonstrated 
the potential to further investigate the disease, with the possibility of being a 
method that will help targeted exploration of the ignorome and may have 
presented novel genes from antibacterial products to vesicle budding and 
release that with further investigation could be shown to be important in CD8+ 
T-cell function in severe asthma. 
 
In the future some of these attemped experiments in Bronchial Epithelium and 
CD8+ T-cells with ChIP-Seq and gene array should be repeated, with a 
clearer plan on how patient recruitment could be improved, and with the 
knowledge acquired during this PhD to carry out these experiments in a 
manner that will yield more substantial results. 
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